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Abstract
In this dissertation, we develop novel techniques that allow for the regression analysis of data
emerging from group testing processes and set the groundwork for graphic processing units (GPU)
enabled implementations. Group testing primarily occurs in clinical laboratories, where it is used to
quickly and cheaply diagnose patients. Typically, group testing tests a pooled specimen–several specimens combined into one sample–instead of testing individual specimens one-by-one. This method
reduces costs by using fewer tests when the disease prevalence is low. Due to recent advances in
diagnostic technology, group testing protocols were extended to incorporate multiplex assays, which
are diagnostic tests that, unlike their predecessors, test for multiple infectious agents simultaneously.
The diseases that a multiplex assay screen typically share co-infection risks. The positive correlation
stemming from co-infection risks creates a more challenging modeling framework. In this work, we
develop a Bayesian regression methodology that can analyze multiplex testing outcomes collected as
part of any group testing protocol. The model can maintain marginal interpretability for regression
parameters and, when the assay accuracies are unknown, we can simultaneously estimate regression parameters with the test’s sensitivity (true positive rate) and specificity (true negative rate).
Based on a carefully constructed data augmentation strategy, we derive a Markov chain Monte Carlo
(MCMC) posterior sampling algorithm that can be used to complete model fitting. We demonstrate
our methodology via numerical simulations and by using it to analyze chlamydia and gonorrhea,
which are sexually transmitted infections, data collected as part of Iowa’s public health laboratory’s
testing efforts. This regression framework’s drawback is the computational intensity of the proposed
steps in the MCMC algorithm. Due to computational costs, this algorithm does not scale well to
the high-volume clinical laboratory settings where group testing is commonly employed. We need
to accelerate the proposed algorithms to provide for faster modeling fitting and prediction. The
devised MCMC algorithm has several independent steps (e.g., sampling the latent disease status of
ii

each patient), or matrix operations. These sections of the algorithm are well-suited to be accelerated with parallel processing. Parallel processing is a software task that was historically used on
large-scale computer clusters, but GPUs perform similar computations. To solve the scaling issue
with our MCMC algorithms, we explore the GPU as a remedy. We discuss the necessary GPU techniques to take the first steps toward fitting group testing regression models with GPUs. Specifically,
we explore stochastic gradient and coordinate descent algorithm implementation with independent
steps and matrix operations. Finally, we provide an example MCMC implementation on a GPU to
demonstrate potential acceleration.
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Chapter 1

Introduction
Group testing, also known as pooled testing, is a common technique used in clinical laboratories to screen for infectious diseases. In this setting, group testing proceeds to test pooled
specimens, which are formed from physically combining specimens from each individual instead of
testing each specimen one-by-one. Robert Dorfman [3] was the first to demonstrate the benefits of
group testing which was motivated by the syphilitic screening efforts of the Second World War. In
the 1940s, the U.S. Public Health Service and Selective Service drafted millions of men for the war.
As part of a health screening, a blood draw was performed on each person to help identify those
with syphilis, a bacterial infection. Each blood draw was tested for a syphilitic antigen, in other
words, every draftee was tested to find every person with an immune response to the infection. In
1942, economists Robert Dorfman and David Rosenblatt attended an impromptu discussion on the
wastefulness of performing the test millions of times to find a few syphilitic men [4]. As a result of
those discussions, Robert Dorfman [3] authored the seminal paper that introduced group testing.
In this work, Dorfman [3] proposed the following two-stage group testing procedure called Dorfman
testing (DT). Suppose there are n specimens to be tested. Following Dorfman’s procedure, a portion
of each specimen is combined to form a pooled sample. In the first stage, the pooled sample is tested.
If the test result is negative, then the individuals are classified as negative and we have classified n
individuals with one test. If the test result is positive, we proceed to the second stage in which we
retest each specimen one-by-one with the individuals diagnosed based on their individual level test
result. It is easy to see that in low prevalence settings, this two-stage procedure has the potential
to reduce testing costs.
1

Owing to the reduction in testing costs, group testing has been widely adopted across
many different types of applications. The largest application is testing blood donations [5]. The
American Red Cross [6], Canadian Blood Services [7], Japanese Red Cross [8], and German Red
Cross [9] use a variation of DT with mini-pools of size 16, 24, 50, and 96, respectively, to screen
blood donations for hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency
virus type-1 (HIV-1). Group testing has been used to screen for a host of other infectious diseases
such as chlamydia and gonorrhea [10], human immunodeficiency virus [11], influenza viruses [12],
SARS-CoV-2 [13], West Nile virus [14], and Zika virus [15]. Group testing has also been used in
a variety of other application areas, to include detecting rare mutations [16], chromatography in
analytic chemistry [17], prevalence estimation for insect disease vectors [18], genomics studies [19],
water quality studies [20], detecting disease-causing bacteria in sheep [21] and salmonella on chicken
eggs [22], among others.
Group testing research typically focuses on addressing either the identification or estimation
problem. The identification problem involves the task of identifying the disease status of the screened
individuals, while the estimation problem is concerned with estimating either the disease’s population
characteristics; e.g., disease prevalence or regression functions [5] [23]. As part of the identification
problem testing algorithms are developed to minimize the number of tests performed when classifying
individuals. While DT can reduce costs, there are a wide variety of group testing algorithms that
can be employed. Generally, there are two types of algorithms hierarchical and non-hierarchical.
Hierarchical algorithms have the property that tests conducted in the previous stages are known
before the next stage of testing is performed and each subject is tested, either in a pool or individually,
at most, once per stage. DT is an example of a two-stage hierarchical procedure. In contrast, array
testing, originally used in genomics research [19] (see Phatarfod and Sudbury [24]), is an example
of a non-hierarchical algorithm. Two-stage array testing is non-hierarchical because individuals are
assigned to a rectangular grid in the first stage and, based on this assignment, row and column pools
are formed and tested. Therefore, each individual is tested in two overlapping pools, regardless
of the other pool’s outcome. In the next stage, individual testing resolves potential positives; for
further details see Kim, Hudgens, Dreyfuss, Westreich, and Pilcher [25].
Many hierarchical and non-hierarchical algorithms have been proposed, and a primary focus
in the development of these schema is to characterize their performance. Early algorithms assume
perfect testing and a homogeneous population, i.e., every subject has the same infection risk. Many
2

authors developed new algorithms that further reduced testing costs under these conditions. Sterrett
[26] proposed that if a master pool tests positive, then the positive pool would be resolved by
randomly selecting and retesting subjects from the pool individually until the first positive was found,
at which point the remaining subjects would be repooled and tested. This process would be repeated
until all individuals were classified. Sobel and Groll [27] developed a recursive splitting algorithm that
successively splits positive pools into smaller subgroups until all the individual’s statuses are resolved.
However, most tests for infectious diseases are not perfect and these inaccuracies are accounted for
by introducing testing errors. False-positive and false-negative errors occur when a test declares a
diagnosed status that is different than an individual’s true status. As part of evaluating a diagnostic
tests’ performance, these errors are described by the assay accuracies probabilities, sensitivity and
specificity, known as the true positive rate and true negative rate, respectively. In the presence
of imperfect testing, Kim, Hudgens, Dreyfuss, Westreich, and Pilcher [25] describe the operating
characteristics of S-stage hierarchical group testing procedures as well as two and three stage array
testing.
All of the aforementioned works still assume a homogeneous population, but realistically, we
can to assume that individuals have different disease risks. Hwang [28] was the first to acknowledge
and exploit this heterogeneity. The paper develops a dynamic programming algorithm to classify
individuals with different probabilities of disease and was the first step in informative group testing. Informative group testing leverages individual patient information to optimize a group testing
procedure. For example, Lewis, Lockary, and Kobic [29] describe the Idaho Bureau of Laboratories’ stratified specimen pooling scheme where the reason for visiting a health care provider, such
as routine pregnancy screening, exposure to Chlamydia trachomatis (CT) or Neisseria gonorrhoeae
(NG), symptomatic, and STD screening, determines the use of group or individual testing. Bilder,
Tebbs, and Chen [30] devise an informative group testing algorithm that modifies Sterrett’s [26]
strategy so that subject specific probabilities under imperfect testing conditions guides retesting.
Similarly, McMahan, Tebbs, and Bilder [31] modify DT by guiding pool construction via individual
level probabilities. Both of these procedures need a priori knowledge of the individual’s infection
probabilities, which are generally unknown. Thus, to implement informative techniques, we need an
estimation of these probabilities.
Much of the estimation work in group testing focuses on developing techniques that can
aggregate pool testing outcomes to estimate a disease’s prevalence within a population. Thomp3

son [18] first explored the estimation problem and derived a maximum likelihood estimator of the
prevalence based on MPT outcomes and provided the asymptotic distribution. Hughes-Oliver and
Swallow [32] proposed a two-stage adaptive estimation strategy to estimate the prevalence where
the pool size in the second stage is set to minimize the mean square error of the prevalence estimator. Thompson [18] and Hughes-Oliver [32] estimate the prevalence based on data from master pool
testing only and fail to account for imperfect testing. Sobel and Elashof [33] propose a maximum
likelihood estimator that accounts for retesting. Chen and Swallow [34] evaluate the robustness of a
prevalence estimator using testing and retesting errors. More recently, Bilder and Tebbs [35] develop
an empirical Bayes estimator for the prevalence with credible intervals. The aforementioned works
are all limited to estimating only population level prevalence.
Apart from estimating population prevalence, recent work has allowed for the incorporation of covariate information in the estimation of regression functions based on group testing data.
Estimating regression models relate patients’ covariates to their infection status. The first to use
regression modeling in group testing was Farrington [22]. The paper proposes estimating a generalized linear model using a complementary log-log link function based on testing outcomes takes from
master pools that were formed homogenously with respect to covariate information. Vansteelandt,
Goetghebeur, and Verstraeten [36] extended Farrington’s [22] work by allowing for imperfect testing,
general link function, and any composition of covariates within the pool. Using regression analysis
on group testing data is not limited to parametric models, Delaigle and Meister [37] developed a nonparametric regression model with imperfect testing for equal pool sizes while Delaingle, Hall, and
Wishart [38] extend this approach to allow unequal pool sizes. However, all of the aforementioned
regression works are capable of analyzing data arising from master pool testing. Xie [39] was the
first to incorporate retesting information to estimate a regression model. This author developed an
expectation-maximization algorithm to estimate regression parameters with imperfect testing and
covariates. Zhang, Bilder, and Tebbs [40] expand on Xie’s [39] work by looking at other common
algorithms and demonstrate that better estimation efficiency can be obtained if resting information
is included. These works assume that the assay’s sensitivity and specificity are known and designed
for specific group testing algorithms. McMahan, Tebbs, Hanson, and Bilder [41] create a Bayesian
regression framework that allows for general link functions and can analyze data from any group
testing scheme with imperfect testing. Liu, McMahan, Tebbs, Gallagher, and Bilder [42] build upon
the Bayesian framework to allow for a generalized additive regression framework to alleviate model
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misspecification from strict linear covariate relations while Joyner, McMahan, Tebbs, and Bilder [43]
incorporate random effects and variable selection.
The previously mentioned group testing literature uses an assay that screens for a single
trait. Recent medical diagnostic developments introduced multiplex assays that test for multiple
diseases simultaneously, which can facilitate completing a test panel comprised of a set of related
tests. For example, a STD multiplex assay simultaneously screens patients for the bacteria CT
and NG using nucleic acid amplification [1]. The SHL at the University of Iowa, Idaho Bureau of
Laboratories [29] and Nebraska Public Health Laboratory [44] use this technique. A multiplex assay
screens blood donations for three STDs: HBV, HCV, and HIV-1 [45] [46]. More considerations are
needed for multiplex assays. First, since related diseases form the test panel, the test outcomes
are potentially correlated as shown by Zhang, Bilder, and Tebbs [44] for CT and NG. Second, the
testing accuracies may differ for each disease. Finally, group testing procedures must be reassessed
when there are multiple traits.
In the context of multiplex assays, group testing algorithms are modified to account for
multiple diseases. For example, the SHL uses an adaptation of Dorfman’s group testing algorithm to
test for CT and NG. The modification is to always perform multiplex assays at each stage and retest
if any test is positive because it is simpler and more cost-effective [47]. Tebbs, McMahan, and Bilder
[47] were the first to characterize the performance of group testing on multiple infections. Later,
Hou, Tebbs, Bilder, and McMahan [48] generalize the work for higher-stage hierarchical algorithms.
Hou, Tebbs, Wang, McMahan, and Bilder [49] propose non-hierarchical algorithms utilizing twodimensional arrays and derive its operating characteristics. These works include imperfect testing
and retesting information but early work in the estimation problem did not. Hughes-Oliver and
Rosenberger [50] generalized Hughes-Oliver and Swallow’s [32] earlier work for a two-stage adaptive
group testing procedure designed for multiple diseases. The adaptation gives an optimal design for
the estimation of the prevalence of three diseases in Ethiopian women: HIV, chlamydia, and syphilis.
However, they assume perfect testing and master pool testing only. Tebbs, McMahan, and Bilder [47]
expand on the work of Hughes-Oliver and Rosenberger [50] to propose an expectation-maximization
algorithm to estimate disease prevalence with imperfect testing and retesting information.
Since the test outcomes from multiplex assays are not independent, estimating the regression
function is difficult. Zhang, Bilder and Tebbs [44] generalize the work of Xie [39] and Vansteelandt
et al. [51] by using a expectation-solution algorithm to estimate a regression model for master
5

pool testing data for multiple diseases. Later, Lin, Wang, and Zheng [52] propose a generalized
expectation-maximization algorithm for the regression analysis of data arising from a two-stage
group testing protocol using a multiplex assay. Estimating regression functions have two primary
benefits. First, as part of surveillance studies, estimating the regression function allows us to identify
risk factors that relate to infection status. Thus, we can identify parts of the population that are
at higher risk for disease. Second, by leveraging estimated regression functions to differentiate
individuals based on risk, informative group testing techniques can be employed to reduce the cost
of testing. For multiplex assays, Bilder, Tebbs, and McMahan [53] show substantial cost savings by
designing an optimal hierarchical S-stage procedure with individual probabilities of infection. Bilder,
Tebbs, and McMahan [54] propose the first non-hierarchical algorithm for informative multiplex
array group testing. Previous multiplex assay regression works by Zhang, Bilder and Tebbs [44]
and Lin, Wang, and Zheng [52] are limited to group testing algorithms for master pool testing and
two-stage group testing, respectively.
In the following chapter, we develop a Bayesian regression framework to simultaneously
estimate covariate effects, correlation structure, and assay accuracies using data from any group
testing scheme arising from a discriminating multiplex assay. Our work is an extension of the
Bayesian regression framework of McMahan, Tebbs, Hanson, and Bilder [41] to that allows for the
joint analysis of multiple diseases. We develop implementations of our approach under both the
multivariate probit and logistic models following the data augmentation strategies by Albert and
Chib [55] and O’Brien and Dunson [56], respectively. These implementations maintain their marginal
interpretability this allows inference of marginal effects rather than conditional effects. Moreover,
we develop easy to implement Markov chain Monte Carlo (MCMC) algorithm that can estimate
the proposed model. A benefit of using a Bayesian methodology is we can incorporate expert
knowledge to inform model fitting such as the assay’s clinical data for sensitivity and specificity
estimations. We explore the finite sample properties of our proposed approach through simulation
studies and by applying it to STD data collected by the SHL in Iowa. A drawback of our Bayesian
implementation is the amount of time required to compute enough samples for large data sets like
the ones that naturally arise from the high volume settings where group testing is utilized. For
example, in our application we have 13,862 female test results which are easily analyzed by our
algorithm. Although, when considering the test results for the United States our implementation
would be unteable. National test results would be at least an order of magnitude larger than the
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national infection rates for CT and NG, which where the most reported notifiable disease in 2019
with more than 1.8 million and 616,392 infections, respectively, according to a 2021 report [57].
With a low prevalence rate the number of tests needed for analysis can be an order of magnitude
larger. Our MCMC methodology does not scale efficiently to these infection rates.
To overcome the computational barriers limiting the scaling of our Bayesian implementation a common approach is to employ parallel processing. Parallel processing involves computing
independent steps simultaneously rather than sequentially for time savings. Historically, this was
accomplished on multiple CPUs in mainframes and supercomputers. More recently graphics processing unit (GPU) have been used for parallelized tasks. GPUs were not always for the task of
general-purpose computing. In 2001, Larsen and McAllister demonstrate matrix-matrix multiplications with 8-bit fix point precision [58] opening the door for GPUs in general-purpose computing.
There are several early applications such as finite element simulations [59], physics-based simulations [60], visually simulating ice crystal growth [61], and accelerating neural networks [62]. An
important milestone occurred in 2003, GPUs switched from 8-bit integer color to 32-bit floating
point that allows for a large range of matrix operations [63]. However, these operations were slower
than their CPU counterparts. In 2005, Galoppo, Govindaraju, Henson, and Manocha demonstrated
LU decomposition was faster on a GPU than a CPU [64]. By 2006, these advancements allowed people to contribute their GPUs for Folding@home, one of the largest distributed computing projects
that simulates protein folding [65]. All the early applications for GPUs had their drawbacks. Many
developers found designing and writing programs for GPUs difficult with numerous limitations and
workarounds using functions designed for video game development. The leading GPU designer,
NVIDIA, released their CUDA toolkit to address the need for an accessible framework [66]. The
toolkit is used by Terenin, Dong, and Draper [67] to demonstrate the effectiveness and speedups of
using a GPU for MCMC methods.
To lay the foundations for adapting a group testing MCMC algorithm for GPU acceleration,
we introduce GPU computing and run several test cases to demonstrate its effectiveness. We provide
a basic introduction to programming GPUs with NVIDIA CUDA, a common development library.
Following our introduction to GPUs, we implement two optimization routines using the hardware:
stochastic gradient descent and stochastic coordinate descent. These two methods are commonly
used in machine learning and statistics to minimize an objective function. They are particularly
useful in large data problems as they effectively solve the problem in small steps. The methods are
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stochastic because of the randomization of taking a sample from the available data or a parameter
to update. The difference between stochastic gradient descent and coordinate descent is how the
parameters are updated. Stochastic gradient descent updates all of the parameters simultaneously
based on a gradient vector computed using a randomly selected subset of the data. In contrast,
stochastic coordinate descent updates a randomly selected parameter based on the entire data set.
In our exploration, we gain techniques to parallelize independent processes and matrix operations.
We apply those lessons to accelerate a MCMC algorithm. We demonstrate the algorithm for the
Horseshoe probit regression model also shown by Terenin, Dong, and Draper [67].
This dissertation is organized as follows: In Chapter 2, we discuss our Bayesian regression
model, show its finite sample properties by several simulations and demonstrate its application with
Iowa’s CT and NG data. In Chapter 3, we give an introduction meant for a beginner with no prior
knowledge to familiarize with the terminology and set up of a simple GPU program. In Chapter 4,
we implement two descent algorithms on a CPU and GPU for comparison in complexity. In Chapter
5, we recreate Terenin, Dong, and Draper’s work [67] to show how randomization, sampling, and
MCMC methods are implemented on a GPU. Finally, in Chapter 6, we discuss future work.
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Chapter 2

Bayesian Regression for Group
Testing
Group testing is the process of combining specimens (e.g., urine, blood, etc.) from different
individuals into a pool, and testing the pool for disease or infection. Group testing was introduced
by Dorfman [3] to screen draftees for syphilis in the Second World War as a cost-savings measure
to reduce the number of tests performed. This type of testing is guided by testing schemes or
protocols that determine how testing proceeds algorithmically. Typically, the pooled specimen is
tested first. If the result of the pooled specimen is negative, then all individuals in the pool are
declared negative and only one test is used to classify all the members. If the pooled specimen
test is positive, then the members of the pool are retested in subset pools to eventually determine
the positive individuals. Since Dorfman introduced group testing, it has become a popular method
to screen large populations for diseases. The main advantage of group testing is the cost savings,
especially in high-volume settings. Group testing has proven effective in screening for sexually
transmitted diseases including chlamydia and gonorrhea [47], and screening blood donations for
infectious diseases [5] by blood banks (e.g., the German Red Cross [9], Japanese Red Cross [8],
Canadian Blood Services [7] and the American Red Cross [6]) for hepatitis B virus (HBV), hepatitis
C virus (HCV) and human immunodeficiency virus type-1 (HIV-1).
While group testing can result in cost savings for classifying every individual, imperfect testing and dependencies between pools make group testing more complicated for estimation. Imperfect
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testing or testing errors mean that the true disease status of an individual is never known; only the
diagnosed status of the individual at the time of testing is known. Moreover, in most group testing
protocols, many individuals are in multiple, possibly overlapping, pools. Pools sharing common
individuals no longer are independent. With imperfect testing, we cannot sidestep the dependencies
by assigning the true disease statuses to every individual and we cannot use regression models that
need independent outcomes. Instead, we have the diagnosed status of individuals through a set
of dependent tests. These issues complicate data analysis for estimation. For example, the most
basic group testing protocol is master pool testing. In master pool testing, all subjects are divided
into separate pools which are subsequently tested, with no testing being performed beyond this first
stage. If the pool is positive, then at least one member may be infected as imperfect testing means
a positive outcome could arise from a pool with no individual who has the disease. Moreover, the
number of likely positive individuals in the pool is unknown. With all these drawbacks, master pool
testing can be used to estimate population prevalence or a regression function. Farrington [22] was
the first to propose estimating the prevalence with a generalized linear model using a complementary
log-log link function. His work was restricted to perfect testing on master pools with the additional
limitation that the individual’s covariates were identical for each master pool. It is not reasonable in
a low volume clinical setting to have groups of patients with the same covariates. Moreover, most all
tests are imperfect. Tests have a less than perfect true positive rate (sensitivity) and true negative
rate (specificity) known as the assay’s accuracy probabilities. Motivated by HIV surveillance data,
work by Vansteelandt, Goetghebeur, and Verstraeten [36] allow for estimation with a general link
function and any set of covariates for each pool. They included imperfect testing and reflecting the
realities of HIV’s three layers of tests. However, they continued to only consider master pool test
results. For parametric extensions, Chen, Tebbs, and Bilder [68] add random effects, and research
by McMahan, Tebbs, and Bilder [69] account for biomarker distributions. For non-parametric regression, Delaigle and Meister [37] introduce testing errors and any individual covariates but use
only equal-sized master pooled specimen test results. Later, Delaingle, Hall, and Wishart [38] extended this non-parametric approach to allow for unequal pool sizes. The primary goal of group
testing algorithms is to diagnosis individuals; however, all of the previously mentioned regression
methods are designed to analyze data arising from master pool testing. In contrast, most group
testing protocols resolve postive master pools in an effort to diagnose each individual. For example, see Kim, Hudgens, Dreyfuss, Westreich, and Pilcher [25], Kim and Hudgens [70], Sterrett [26],
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Sobel and Groll [27], Sobel and Elashof [33], Hughes-Oliver and Swallow [32], Gastwirth and Johnson [71], Bilder, Tebbs, and Chen [30], and McMahan, Tebbs, and Bilder [31]. These algorithms
guide retesting subsets of individuals after a positive pool result to find the positive individuals or
for quality control. Xie [39] was the first to incorporate retesting information for estimation via an
expectation-maximization algorithm that estimates an individual’s probability of disease by viewing
their true disease status as a latent variable. The algorithm accounted for different testing errors
for the pool test and confirmation test. Zhang, Bilder, and Tebbs [40] provide further analysis of
the methodology. However, like most all other regression methods in group testing, it assumes the
assay errors were known. McMahan, Tebbs, Hanson, and Bilder [41] take a Bayesian approach that
allows for unknown testing error and any group testing protocol. Recent statistical research by Liu,
McMahan, Tebbs, Gallagher, and Bilder [42] extends the Bayesian approach to allow for generalized
additive models. All of the previously mentioned works are designed to analyze data arising from a
group testing protocol that uses a diagnostic test that screens for a single disease.
Recently, advances in medical diagnostic equipment have given rise to multiplex assays that
test for multiple diseases simultaneously. Equipment manufacturers brought the Aptima Combo
2 Assay for chlamydia and gonorrhea in 2001 and the cobas TaqScreen MPX Test [45] for HIV,
HBV, and HCV in 2009. The Aptima Combo 2 is in use at the State Hygienic Laboratory (SHL) at
the University of Iowa [41], the Idaho Bureau of Laboratories [29] and the Nebraska Public Health
Laboratory (NPHL) [44]. The cobas TaqScreen MPTX Test is used to screen blood donations [9].
Group testing algorithms are used for the multiplex assays at SHL according to Tebbs, McMahan,
and Bilder [47]. Multiplex assays generate even more complex data structures due to the correlation
of the outcomes. For example, risks for one STD can be risks for another STD. For descriptions and
properties of multiplex assay group testing schemes see Hughes-Oliver and Rosenberger [50], Tebbs,
McMahan, and Bilder [47], Hou, Tebbs, Bilder, and McMahan [48], Hou, Tebbs, Wang, McMahan,
and Bilder [49] and Bilder, Tebbs, and McMahan [54]. Warasi, Tebbs, McMahan, and Bilder [72]
develop a Bayesian framework to estimate the prevalence of multiple diseases with unknown assay
probabilities from multiplex assays. However, every patient has the same probability of infection
per disease. Building off of the methods of Xie [39], recent works incorporate data from multiplex
assays in the regression models of Zhang, Bilder, and Tebbs [44] and Lin, Wang, and Zheng [52].
The work of Zhang, Bilder, and Tebbs [44] develops an expectation-solution algorithm for multiple
diseases but they are restricted to master pool testing. The work of Lin, Wang, and Zheng [52]
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develop a generalized expectation-maximization for a copula-based multivariate binary regression
that analyses data limited to a two-stage hierarchical testing scheme.
To provide a general regression framework, we develop a Bayesian regression model that
can be used to analyze group testing data arising from any group testing protocol that utilizes a
multiplex assay. Our work generalizes the single disease work of McMahan, Tebbs, Hanson, and
Bilder [41] to analyze data from multiplex assays. Our Bayesian regression framework allows us to
analyze data from any group testing protocol that uses a discriminating multiplex assay. We can
estimate regression models that describe the risk of having all the diseases simultaneously while
specifically accounting for the correlation structure between diseases. The regression functions that
we estimate, maintain their marginal interpretability. When the assay accuracies are unknown, we
are able to estimate them simultaneously with the regression coefficients. With deliberate choices for
data augmentation stategies, we implement easy to compute Markov chain Monte Carlo (MCMC)
sampling algorithms that allow for model fitting. Because we use Bayesian methodologies, we can
use expert knowledge to guide model fitting. We provide two implementations of the model that
utilizes the data augmentation strategies for multivariate probit regression as described by Albert
and Chib [55] and multivariate logistic regression by O’Brien and Dunson [56]. We explore the finite
sample properties of our proposed estimation framework through simulation studies and further
illustrate its performance by applying it to chlamydia and gonorrhea test data collected by the SHL
in Iowa.
The remaining sections of this chapter are as follows: Section 2.1 provides the preliminary
information for the regression model and the modeling assumptions. In Section 2.2, we outline
the prior model specification and the development of the full conditional distributions. Section
2.3 provides the results of a simulation study that demonstrates the effectiveness of our approach.
Section 2.4 presents an analysis of chlamydia and gonorrhea testing data collected in Iowa and
concludes with a summary discussion. Additional tables, figures and results are in Appendix B.

2.1

Model Development
Suppose that N individuals are screened for D infectious diseases by a group testing protocol.

e i = (Yei1 , . . . , YeiD )0 be the vector of true disease statuses of the ith patient such that Yeid = 1,
Let Y
if the ith patient’s true status is positive for the dth disease and Yeid = 0 otherwise. We assume
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the availability of a collection of risk factors and demographic information that we denote as xid =
0
(1, xid1 , xid2 , . . . , xidQd )0 for the ith patient and dth disease. Let Xi = ⊕D
d=1 xid be the block diagonal

matrix for the ith patient with x0id for the dth block. We relate the predictor variables Xi to the
e i through the following general linear model, P (Y
e i |Xi , β, R) = H(X0 β, R) where
response variable Y
i
H is a known inverse link function, β = (β 1 , . . . , β D )0 be the vector of regression coefficients and R is
a correlation term. We restrict R to be a symmetric matrix where ρrs is the r, s entry and 1 is along
the diagonal. We later examine the multivariate probit and multivariate logistic link functions and for
convenience, we denote the linear predictors as µi = (µi1 , . . . , µiD )0 = (x0i1 β 1 , . . . , x0iD β D )0 = Xi β.
We also assume an individual’s infection status is conditionally independent across individuals given
e i |Xi ⊥ Y
e j |Xj for j 6= i. If the true disease statuses Y
e i where known then we
the covariates, i.e. Y
could easily estimate the model parameters. However, the true disease statuses are unobservable in
most group testing settings.
We are proposing a general framework that can analyze test data arising from any group
testing algorithm that uses a discriminating assay. There are many different types of group testing
protocols such as Dorfman testing [3], S-stage hierarchical testing, [25], array testing [24], 3-stage
array testing [25], three dimensional array testing [70], quality control retesting [71] [16], Sterrett’s
[26] strategy, Sobel and Groll’s [27] recursive splitting and many others [30] [31]. Many of these
protocols require individuals to be tested in multiple and possibly overlapping pools, individually or
as part of confirmatory retests. In order to handle all these algorithms and more, we introduce the
index set Pj to track pool membership. This index set identifies the individuals who contributed to
the jth pool for j = 1, . . . , M where M is the total number of tests performed. The true disease
status of the pool is determined by the individuals assigned to it. In particular, if any individual is
e j = (Zej1 , . . . , ZejD )0
positive for the dth disease, then the pool is positive for the dth disease. We let Z
be the vector of true pool disease statuses for the jth pool where Zejd = 1 if the jth pool has any
ejd = 1(P
e
member with disease d and Zejd = 0 otherwise. Thus, we have Z
i∈Pj Yid > 0) where 1(·)
is the usual indicator function. In the trivial case with |Pj | = 1 and Pj = {i}, the pool has a single
e i, Z
e j are unobservable as a result of imperfect testing.
individual. Much like Y
With a true pool status and pool test results, we can relate the two by testing errors. That
is, we allow for imperfect testing which results in false-positive errors and false-negative errors. We
denote the testing outcomes taken on the jth pool as Zj = (Zj1 , . . . , ZjD )0 where Zjd = 1 if the jth
pool tests positive for disease d and Zjd = 0 otherwise. Let the true positive rate or sensitivity for the
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ejd = 1) and the true negative rate or specificity be defined
jth pool be defined as Sej :d = P (Zjd = 1|Z
as Spj :d = P (Zjd = 0|Zejd = 0). In order to develop our model, we assume independence of testing
e 1, . . . , Y
e N ⊥ Zk |Y
e 1, . . . , Y
eN
between diseases conditionally on the true disease status, that is Zj |Y
for all j 6= k. This is a common assumption in group testing [73]. We also assume that the
e j does not depend on the covariates. Now we have the links between
conditional distribution of Zj |Z
the testing outcomes and the covariates. Furthermore, it is natural to sometimes believe sensitivities
are specificities are known and other times they are not and need to be estimated.
The sensitivity and specificity for each disease are provided by the manufacturer of the test
that we use as a fixed value or to inform priors. For example, the manufacturer of the Aptima
Combo 2 assay for CT and NG used by the SHL provides the assay’s sensitivity and specificity for
each disease, specimen type (swab or urine), and gender. In short, the assay’s performance can vary
not just between diseases but also based on the testing configuration. Additionally, the pool size may
affect the assay’s performance in the group testing context. Most tests rely on detecting biomarkers
such as an antigen, snippets of genetic material, or chemical compounds. Typically, assays give a
diagnosis based on elevated levels of a biomarker. If the biomarker exceeds a prespecified diagnostic
threshold, then we classify the specimen to be positive and otherwise we classify the specimen to be
negative. For example, after being exposed to a virus, a patient may test negative for a few days
until the virus replicates to a detectable concentration. When specimens are pooled together, if a
pool contains a positive specimen, then its signal could be diluted by the negative specimens, thus
limiting the assays ability to correctly classify the pool. To prevent this, the diagnostic threshold can
in some instances be recalibrated [74]. This recalibration step leads to the assumption by Kim et.
al. [25] that the sensitivity and specificity are the same for all pool sizes. However, in our regression
methodology we want the flexibility to acknowledge differences in the assay sensitivity and specificity
that might exist as a function of the pool size, disease, specimen type, gender, etc. For practical
purposes, we add the restriction that each pool is exactly one specimen type e.g. urine or swab.
We develop the notation for sensitivity and specificity to accommodate multiple test configurations. Let Se(l):d and Sp(l):d denote the sensitivity and specificity associated with the lth
assay test configuration for disease d for l = 1, . . . , L. Denote Se = (Se(1):1 , . . . , Se(L):D )0 and Sp =
(Sp(1):1 , . . . , Sp(L):D )0 . Let M(l) = {j : the lth test configuration was used to test the jth pool}
that is M(l) tracks which tests use the lth test configuration. That is Sej :d = Se0j :d = Se(l):d and
Spj :d = Sp0j :d = Sp(l):d when j, j 0 ∈ M(l). For generality, we consider three specific ways of handling
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the inclusion of testing accuracies. First, we consider the setting where the sensitivities and specificities are known. In our example Iowa data set we would have eight sets of known sensitivities and
specificities provided by the manufacturer corresponding to the different combinations of disease,
specimen and gender but do not vary by pool size. Second, we consider sensitivities and specificities
configuration exactly the same as in the previous setting except they are unknown and have to be
estimated. Third, it would be reasonable to assume the performance of the test is going to be the
same when testing pools of a common size. That is sensitivity and specificity would be the same
within pool size but vary across pool sizes. The SHL uses Dorfman testing with masterpools of size
four. Therefore in our example we estimate sixteen sets of sensitivities and sixteen specificities for
the previous combinations of diseases, specimen, and gender plus the additional two pool sizes. We
have the additional consideration that a partial ordering of sensitivities and specificities exist for the
group size within test configurations for disease, specimen, and gender to account for the dilution
effects. Suppose pools j and k have different sizes with |Pj | < |Pk |. If we assume there is a partial
order, then we assume that the larger sample has smaller sensitivity and larger specificity. Thus we
have Sej :d > Sek :d and Spj :d < Spk :d for all d. We consider one test being used and its performance
differs based on its test configuration. Generalizing to multiple assays is trivial within the notation
and framework we develop but for purposes of brevity we omit it.
Under the aforementioned assumptions, we may write the conditional distribution of the
observed data as

P (Z|X, β, R) =

X

e (Y|X,
e
P (Z|Y)P
β, R).

(2.1)

e
Y∈Y

e = (Y
e 1, . . . , Y
e N ) and Y is all the possible true
where Z = (Z1 , . . . , ZM )0 , X = (X1 , . . . , Xn )0 , Y
e In the expression above, we have that
disease statuses of Y.

e =y
e) =
P (Z = z|Y

M Y
D
Y

P (Zjd = zjd |Zejd = zejd )

j=1 d=1
M Y
D n
Y
z o1−ezjd
1−zjd ozejd n 1−zjd
z
Spj :d 1 − Spj :d jd
=
Sejjd:d 1 − Sej :d
j=1 d=1

=

L
D n
Y
Y Y
1−zjd ozejd n 1−zjd
z o1−ezjd
zjd
Sp(l):d 1 − Sp(l):d jd
,
Se(l):d
1 − Se(l):d
l=1 j∈M(l) d=1

(2.2)
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where zejd = I(

P

i∈Pj

yeid > 0). Equation 2.2 gives the probability of group testing outcomes given

the latent true disease status of the pools and the testing errors for the L assays. Additionally in
the expression above, we have:

e
P (Y|X,
β, R) =

N
Y

e i |Xi , β, R) =
P (Y

i=1

N
Y

H(X0i β, R)

(2.3)

i=1

where H is a known inverse link function which is linked to the specification of our multivariate
generalized linear model. In what follows, we consider specifications under the multivariate logit
and probit link functions. It is important to note, in the development the model described in
equation 2.1 we make three primary assumptions. First, we assume an individual’s infection status
e i |Xi ⊥ Y
e j |Xj for j 6= i.
is conditionally independent across individuals given the covariates, i.e. Y
Second, we assume independence of testing between diseases conditionally on the true disease status,
e 1, . . . , Y
e N ⊥ Zk |Y
e 1, . . . , Y
e N for all j 6= k. Lastly, we assume that the conditional
that is Zj |Y
e j does not depend on the covariates.
distribution of Zj |Z

2.1.1

Model Fitting Strategies
It is important to note that to evaluate 2.1 it requires us to compute 2N D possible prob-

abilities numerous times. It would be infeasible to compute every term, multiple times for a high
volume setting with N large. Instead, we consider a two stage data augmentation process to circumvent direct numerical evaluation of 2.1 to facilitate the development of an posterior sampling
algorithm. To reduce the complexity of the multiple fitting strategies that we outline, the posterior
sampling techniques for the regression coefficients, and the correlation matrix are developed under
the assumption that the testing errors are known and fixed. This assumption is relaxed in Section
2.2.3. The first of these data augmentation steps introduces the individual’s true disease statuses as
latent random variables. This leads to the following joint distribution:

e
e (Y|X,
e
P (Z, Y|X,
β, R) = P (Z|Y)P
β, R).

(2.4)

The second step introduces a series of latent variables that allows for the decomposition of the link
e i , is derived from a
function. We augment the likelihood so that the vector of binary indicator, Y
vector of continuous variables, Ti . Suppose we have a vector of latent variables Ti = (Ti1 , . . . , TiD )0
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with Yeid = 1(Tid > 0) and Ti has distribution fTi (ti |Xi , β, R). This gives the following conditional
distribution:

e
P (Z, Y|X,
β, R) =

L
D n
Y
Y Y
1−zjd ozejd n 1−zjd
z o1−ezjd
zjd
Se(l):d
1 − Se(l):d
Sp(l):d 1 − Sp(l):d jd
l=1 j∈M(l) d=1

×

(N Z
Y

fTi (ti |Xi , β, R)

i=1

D
Y

1(tid > 0) 1(tid ≤ 0)
y
eid

)
1−e
yid

dti

.

(2.5)

d=1

In what follows, we consider two specifications of fTi (ti |Xi , β, R) that are two of the most common
link functions: probit and logistic. To decompose the probit link function, we follow Albert and
Chib [55]. We use the strategy of Dunson and O’Brien [56] to decompose the logistic link function.
Under the probit model, fTi (ti |Xi , β, R) = ND (ti |µi , R) where µi = X0i β. An important
feature of this model is it retains the marginal intepretability of the regression coefficients. In the
following, we demonstrate the marginal distribution is the univariate probit model. We define the
set Aid as (0, ∞) when yeid = 1 and (−∞, 0] when yeid = 0. Without loss of generality, we show this
for the first true disease status.
X

P (Yei1 = yei1 |µi1 ) =

P (Yei1 , . . . , YeiD |µi , R)

y
eid :d6=1

X Z

=

y
eij :j6=d

Z
=
Ai1

Z
=

Ai1

Z
NTi (ti |µi , R)dti
AiD

Z Z
NTi1 (ti1 |µi1 , 1)NTi(−1) |Ti1 =ti1 (ti(−1) |ti1 , µi , R)dti
Z Z

Nti1 (ti1 |µi1 , 1)dti1
NTi(−1) |ti1 (ti(−1) |ti1 , µi(−1) , R)dti(−1)
R R

R R

Ai1

= Φ(x0i β 1 )yei1 {1 − Φ(x0i β 1 )}

1−e
yi1

.

(2.6)

This leads to the conclusion that the regression coefficients are interpreted the same as in univariate
probit model.
For our second implementation, we use the augmentation strategy for the multivariate logistic density function outlined by O’Brien and Dunson [56]. O’Brien and Dunson’s [56] gives the
distribution as the following:

fTi (ti |Xi , β, R) = TD,ν {gν (ti1 − µi1 ), . . . , gν (tiD − µiD ); 0, R}
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×

D
Y

L(tid ; µid )/T1,ν {gν (tid − µid ); 0, 1}

(2.7)

d=1

where gν (·) = Fν−1 {F (·)} using the notation Fν to represent the c.d.f. of the student-t distribution,
F to represent the c.d.f. of the logistic distribution, L represents the p.d.f. of the logistic distribution
and TD,ν (µi , R) be the multivariate t distribution with ν degrees of freedom, mean µi = X0i β and
correlation matrix R. The distribution’s derivation is not provided here but is shown in O’Brien
and Dunson [56]. Briefly, 2.7 is derived by transforming the logistic random variable Td into a
uniform density, then connects both characteristics by the copula method using the multivariate t
distribution. It can be shown that this distribution also provides the desired properties: the marginal
distribution is the univariate logistic density and the correlation matrix has ones along the diagonal
by construction.
When we introduce the ti as missing data our data model is the following:

e T|X, β, R) =
P (Z, Y,

D n
L
Y
Y Y
z o1−ezjd
1−zjd ozejd n 1−zjd
zjd
Se(l):d
1 − Se(l):d
Sp(l):d 1 − Sp(l):d jd
l=1 j∈M(l) d=1

×

(N
Y
i=1

fTi (ti |Xi , β, R)

D
Y

1(tid > 0) 1(tid ≤ 0)
y
eid

)
1−e
yid

.

(2.8)

d=1

The decomposition of the probit link function into the multivariate normal distribution leads to a
normal full conditional for the regression coefficients under a normal prior and leads to straightforward posterior sampling. This would also be desirable under the multivariate logistic model. O’Brien
and Dunson [56] demonstrate that this is achieved using importance sampling to approximate the
logistic distribution with the multivariate t distribution which can be decomposed into a mixture of
a gamma distribution and multivariate normal distribution which is shown in Section 2.2.
The choice of priors has the potential to significantly impact the model in the Bayesian
framework. For the regression part, our choice of priors follows from similar choices by O’Brien and
Dunson [56]. These are made with computational ease in mind. We choose a conditional conjugate
prior for β to be normal with mean 0 and covariance structure of Σ0 . It is important to note that
Σ0 could be chosen to assert minimal influence on the posterior analysis by choosing it such that
the prior is diffuse. This can be achieved by allowing the variances to be large. Additionally, we
select a uniform prior for ρrs over the support [−1, 1].
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2.2

Posterior Sampling
We describe the posterior sampling for β, and R when the assay accuracy probabilities Se(l):d

and Sp(l):d are known and fixed. We develop a MCMC posterior sampling algorithm that consists
of Gibbs steps and Metropolis-Hasting steps for each correlation term. To outline the development
e i , Ti , β, and
of the posterior sampling algorithm, we compute full conditional distributions for Y
R. Since Tid and Yeid have a straightforward relationship, it becomes hard to sample one without
the other. For both our implementations, we are able to sample Yeid without Tid by integrating
Tid out. Note that we are sampling Yeid and Tid and not their vector forms. We found it easier to
sample each true disease status per individual rather than simultaneously sampling all true diseases
statuses simultaneously per individual using a slice-sampler. This decomposition allows us to draw
from a Bernoulli distribution and a truncated normal distribution for Yeid and Tid respectively. For
R, we updated each entry by a random walk Metropolis-Hastings step. Simultaneously updating
the matrix faces difficulties arising from the restriction on the diagonal of the correlation matrix. In
what follows, we outline the probit model in Section 2.2.1 and the logistic model in Section 2.2.2.
We incorporate the testing errors in Section 2.2.3.

2.2.1

Probit Model
The full hierarchy of the proposed probit model is
Yeid = 1(Tid > 0)

i = 1, . . . , N, d = 1, . . . , D,

ti ∼ ND (Xi β, R)

i = 1, . . . , N,

β ∼ NQ (0, Σ0 ),
ρrs ∼ U nif orm(−1, 1)

(r, s) ∈ [D] × [D] 3 r < s.

(2.9)

Under the aforementioned prior specifications and the data augmentation steps, we have the full
conditional of the individual’s continuous latent true disease status is given by

Tid |Ti(−d) , T(−i) , yei , β, R, Z ∼




T N (Tid ; µ̃id , Σ̃id , 0, ∞),

if yeid = 1,



T N (Tid ; µ̃id , Σ̃id , −∞, 0), if yeid = 0,
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(2.10)

where

µ̃id = µid − Rd,(−d) (R(−d),(−d) )−1 (ti(−d) − µi(−d) )

(2.11)

Σ̃id = Rd,d − Rd,(−d) (R(−d),(−d) )−1 R(−d),d .

(2.12)

While the individual’s latent true disease status is

yeid |e
yi(−d) , ye(−i) , Se , Sp , β, R, T, Z ∼ Bernoulli [gid (1)/ {gid (0) + gid (1)}]

(2.13)

with

gid (x) =


Y 


Z

1−Zjd

Sejjd
:d S ej :d

1(x+P ye(−i)d >0) 

1−Z

Zjd

Spj :d jd S pj :d


1−1(x+P ye(−i)d >0) 

x
p1−x
id0 (1 − pid0 )



j∈Ai

(2.14)
where x ∈ {0, 1}, pid,eyid =

R

N (tid ; µ̃id , Σ̃id )1(tid > 0)yeid 1(tid ≤ 0)1−eyid , S ej :d = 1 − Sej :d , S pj :d =

1 − Spj :d , and Ai = {j : i ∈ Pj }. In other words, Ai tracks which pools the ith patient is a member.
Then the full conditional for the regression coefficients may be sampled simultaneously by

β|R, T, Z ∼ NQ (µ̃, Σ̃).

(2.15)

n
nP
o−1
o
PN
N
0
−1
0
−1
where Σ̃ = Σ−1
Xi
and µ̃ = Σ̃
Ti . Lastly, the correlation
0 +
i=1 Xi (R)
i=1 Xi (R)
parameters are individually sampled using Metropolis-Hastings steps. For each Metropolis-Hastings
step, we draw a candidate sample from a uniform random walk on the interval [ρrs − δ, ρrs + δ] where
we use reflection to contain the candidate in the interval (−1, 1). With the candidate and original
value, we easily compute the acceptance value for the Metropolis-Hastings step used to accept
or reject the candidate value. The full symbolic representation of the entire posterior sampling
algorithm is also given in Appendix A.
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2.2.2

Logistic Model
The full hierarchy of the proposed logit model is
Yeid = 1(Tid > 0)

i = 1, . . . , N, d = 1, . . . , D,

ti ∼ fTi (ti |Xi , β, R)

i = 1, . . . , N,

β ∼ NQ (0, Σ0 ),
ρrs ∼ U nif orm(−1, 1)

(r, s) ∈ [D] × [D] 3 r < s.

(2.16)

where fTi (ti |Xi , β, R) is as in 2.7. In order to compute full conditional posteriors, we face difficulties
with the distribution of the multivariate logistic density. We cannot decompose the density in the
same manner as the multivariate probit density. Thus we are unable to sample the distribution.
Instead, we use importance sampling to sample a similar distribution. We adjust our estimations of
the similar distribution using importance weights to recovery estimations of the original distribution.
For example, suppose the random variable X with probability density f is a difficult distribution to sample from and the random variable Y with probability density g is an easy distribution
to sample from. Normally, we estimate Ef [h(X)] by drawing X1 , . . . , Xn and computing the apP
proximation Ef [h(X)] ≈ 1/n i h(Xi ). However, we can only draw Y1 , . . . , Yn . Therefore, we use
the following relationship:
Z
Ef [h(X)] =

Z
h(x)f (x)dx =



f (x)
f (Y )
h(x)
g(x)dx = Eg h(Y )
.
g(x)
g(Y )

We can estimate the right hand side with the relation Eg [h(Y )f (Y )/g(Y )] ≈ 1/n

P

i

(2.17)

h(Yi )f (Yi )/g(Yi ).

Where the terms wi = f (Yi )/g(Yi ) are called the importance weights. The performance of importance sampling is improved by selecting a distribution that is similar to the original.
The multivariate logistic density is similar to the multivariate t distribution. Hence, we
substitute the multivariate logistic density for the multivariate t distribution, TD,ν (ti |µi , R), and use
importance sampling for estimation. The multivariate t distribution is ideal because it has heavier
tails and we can optimize the multivariate t distribution to be close to the multivariate logistic
distribution. Following O’Brien and Dunson [56], we choose the optimal value to be ν = ν̃ = 7.3 and
replace fTi (ti |Xi , β, R) with TD,ν̃ (Xβ, σ̃ 2 R) where σ̃ 2 = π 2 (ν̃ − 2)/3ν̃. With importance sampling,
we denote the target or original posterior density P and the posterior density of from which we draw
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samples as P ∗ . The following is our sample posterior density:

e T) ∝
P ∗ (Se , Sp , X, β, R|Z, Y,

L
D n
oejd n
o1−ezjd
Y
Y Y
1−zjd z
zjd
1−z
zjd
S e(l):d
Sp(l):djd S p(l):d
Se(l):d
l=1 j∈M(l) d=1

×

N
Y

TD,ν̃ (Ti |Xi , β, R)NQ (β; 0, Σ0 )

i=1

Y

U (ρrs ; −1, 1) (2.18)

r<s∈[D]×[D]

where S e(l):d = 1 − Se(l):d , S p(l):d = 1 − Sp(l):d . The corresponding importance weights are given by

w∝
=

e T)
P (Se , Sp , X, β, R|Z, Y,
∗
e T)
P (Se , Sp , X, β, R|Z, Y,
N
Y

fTi (Ti ; Xi β, R)
.
T
(Ti ; Xi β, σ̃ 2 R)
i=1 D,ν̃

(2.19)

To find the conditional distribution for P ∗ , we add another latent variable φi for the ith subject
to sample from the multivariate t distribution. We have Ti |β 1 , R ∼ TD,ν̃ (µi , σ̃ 2 R) is equivalent to
the hierarchical model Ti |β, R, φi ∼ ND (µi , σ̃ 2 φ−1
i R) and φi ∼ Γ(ν̃/2, ν̃/2). Most other notation
≈

is shared with the probit model with the exception of Σid = Rd,d − Rd,(−d) (R(−d),(−d) )−1 R(−d),d
σ̃ 2 /φi . Thus we get the similar full conditional distributions:

Tid |Ti(−d) , T(−i) , yei , β, R, φ, Z ∼


≈


T N (Tid ; µ̃id , Σid , 0, ∞),

if yeid = 1,

(2.20)

≈


T N (Tid ; µ̃id , Σid , −∞, 0), if yeid = 0.

While the individual’s latent true disease status is

yeid |e
yi(−d) , ye(−i) , Se , Sp , β, R, φ, T, Z ∼ Bernoulli [gid (1)/ {gid (0) + gid (1)}]

(2.21)

with

gid (x) =


Y 


Z

1−Zjd

Sejjd
:d S ej :d

1(x+P ye(−i)d >0) 

1−Z

Zjd

Spj :d jd S pj :d


1−1(x+P ye(−i)d >0) 

1−x

p0 id0 (1 − p0 id0 )x



j∈Ai

(2.22)
where p0 id,eyid =

R

≈

N (tid ; µ̃id , Σid )1(tid > 0)yeid 1(tid ≤ 0)1−eyid .
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Then the full conditional for the regression coefficients may be sampled simultaneously by

≈

≈

β|R, φ, T, Z ∼ NQ (µ, Σ).

(2.23)

where
≈

(
Σ−1
0

Σ=

+ σ̃

−2

N
X

)−1
φi X0i (R)−1 Xi

(2.24)

i=1
≈

≈

(

µ = Σ σ̃

−2

N
X

)
φi X0i (R)−1 Ti

.

(2.25)

i=1

While the full conditional of the gamma mixture is sampled individually as




φi |β, R, T, Z ∼ Γ (ν̃ + 2)/2, ν̃ + σ̃ −2 (Ti − µi )0 (R)−1 (Ti − µi ) /2 .

(2.26)

Again, the correlation parameters are individually sampled using Metropolis-Hastings steps. For
each Metropolis-Hastings step, we draw a candidate sample from a uniform random walk on the
interval [ρrs − δ, ρrs + δ] where we use reflection to contain the candidate in the interval (−1, 1).
With the candidate and original value, we easily compute the acceptance value for the MetropolisHastings step used to accept or reject the candidate value. The full symbolic representation of the
entire posterior sampling algorithm is also given in Appendix A.

2.2.3

Unknown Testing Errors
We now relax the assumption that testing errors are known and fixed. The sensitivity and

specificity of the model can be varied. Furthermore, the approach outlined in this section is general
and applied to both the logistic and probit models. Priors can be informed with the use of previous
studies [1] that seek to estimate the sensitivity and specificity. As part of validation of the assay
the manufacturer typically performs clinical trials for each combination of disease, specimen type,
and gender. For each test configuration, patients of known disease status are individually tested
using the assay. With the patients true disease status, each of the assay’s testing outcomes to be
categorized as true positive (T Pl,d ), false positive (F Pl,d ), true negative (T Nl,d ) and false negative
(F Nl,d ). Thus allowing for the estimation of sensitivity and specificity for each test configuration.
The T Pl,d , F Pl,d , T Nl,d , and F Nl,d from validation studies can be used to inform our assay accuracy
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priors.
We chose a beta distribution as a prior for both sensitivity and specificity. Many works in
group testing such as Warasi et al. [72], McMahan et al. [41], Joyner et al. [43], etc. use a beta
distribution prior for assay accuracies. We chose a beta distribution as a prior for sensitivity and
specificity as we can switch from an informative prior to an uninformative prior that is uniform on
(0, 1). In this dissertation, we develop two variations to estimating assay accuracies.
One approach would be to estimate an independent sensitivity and specificity for every test
configuration. In the following, we use a beta prior for every Se(l):d and Sp(l):d which leads to the
following prior for the set of sensitivities and specificities:

P (Se )P (Sp ) =

L
Y

f (Se(l):d ; T Pl,d , F Nl,d , 0, 1)f (Sp(l):d ; T Nl,d , F Pl,d , 0, 1)

(2.27)

l=1

where f (x; α, β, a, b) is the truncated beta prior distribution and the limits a = 0, b = 1 recover the
beta distribution. Note when α = β = 1, it follows the uniform distribution, an uninformative prior.
Another approach is to link test configurations to others where they only differ by pool size. For
example, test configuration l and l0 may have the same gender, and specimen type but represent
individual testing and group testing. We consider dilution effects with an additional constraint
on Se(l):d and Sp(l):d . Without the data for an informed prior, this constraint is used to partially
inform the sensitivity and specificity. In larger pools, we expect a decrease in the sensitivity and an
increase in specificity. It is natural to enforce the ordering Se(l):d > Se(l0 ):d and Sp(l):d < Sp(l0 ):d for
|Pl | < |Pl0 | by type. The ordering is a way to incorporated the dilution effect and bleed information
across the different testing configurations as they relate to pool size. In the Iowa example, we have
the stratum for CT, swab specimen and female with pools of size one and four. In this case, we may
write the prior distribution of sensitivities for the two pools as the following:

P (Se ) = f (Se(1):1 ; T P1,1 , F N1,1 , Se(2):1 , 1)f (Se(2):1 ; T P2,1 , F N2,1 , 0, 1).

(2.28)

In order to generalize, we see the following is equivalent:

P (Se ) ∝ fSe(1):1 |Se(2):1 (Se(1):1 ; T P1,1 , F N1,1 , 0, 1|Se(1):1 > Se(2):1 )fSe(2):1 (Se(2):1 ; T P2,1 , F N2,1 , 0, 1)
∝ f (Se(1):1 ; T P1,1 , F N1,1 , 0, 1)f (Se(2):1 ; T P2,1 , F N2,1 , 0, 1)1(Se(1):1 > Se(2):1 ).
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(2.29)

We add in an indicator function to represent the partial orderings within each test configuration.
S
Let P be the partition of the testing configurations [L] such that V ∈P V = [L] and for l, l0 ∈ V
then test configuration l and l0 differ only by size. That is for every V ∈ P , V represents the subset
of test configurations where the stratum is the same except they vary in pool size. Then we have
the following distributions:

P (Se ) ∝

Y Y

Y Y

1(Se(l0 ):d > Se(l):d ),

(2.30)

1(Sp(l0 ):d < Sp(l):d ).

(2.31)

l0 ∈V :|Pl0 |<|Pl |

V ∈P l∈V

P (Sp ) ∝

Y

f (Se(l):d ; T Pl,d , F Nl,d , 0, 1)

Y

f (Sp(l):d ; T Nl,d , F Pl,d , 0, 1)

l0 ∈V :|Pl0 |<|Pl |

V ∈P l∈V

The difference between assay accuracies with out ordering in Eqn. 2.27 and the product of assay
accuracies with ordering in Eqn 2.30 and Eqn. 2.31 is the addition of indicator functions. We refer
to the two approaches as no ordering and ordering, respectively.
With the beta distributions as a prior for the sensitivity and specificity, we compute the
full conditional distribution under both approaches. The full conditional distribution when the test
configurations are independent with no ordering are as follows:

Se(l):d ∼ f


 X


Sp(l):d ∼ f


 X


Zjd zejd + T Pl,d ,

j∈M(l)

X

(1 − Zjd )e
zjd + F Nl,d , 0, 1

j∈M(l)

(1 − Zjd )(1 − zejd ) + T Nl,d ,

j∈M(l)

X
j∈M(l)

Zjd (1 − zejd ) + F Pl,d , 0, 1







(2.32)

(2.33)



When test configurations share information through ordering, we have the full conditional distribution as follows:

Se(l):d ∼ f


 X


Sp(l):d ∼ f


 X


j∈M(l)

j∈M(l)

X

Zjd zejd + T Pl,d ,

j∈M(l)

(1 − Zjd )e
zjd + F Nl,d , Ae(l):d , Be(l):d




,



(2.34)


X
(1 − Zjd )(1 − zejd ) + T Nl,d ,
Zjd (1 − zejd ) + F Pl,d , Ap(l):d , Bp(l):d ,

j∈M(l)

(2.35)

25

where if V ∈ P is the subset of the partition containing l and l0 then

Ae(l):d =

Be(l):d =

Ap(l):d =

Bp(l):d =




0,

if @ l0 s.t. |Pl0 | > |Pl |,



max{Se(l0 ):d | |Pl0 | > |Pl |}, otherwise.



1,
if @ l0 s.t. |Pl0 | < |Pl |,


min{Se(l0 ):d | |Pl0 | < |Pl |}, otherwise.



0,
if @ l0 s.t. |Pl0 | < |Pl |,


max{Sp(l0 ):d | |Pl0 | < |Pl |}, otherwise.



1,
if @ l0 s.t. |Pl0 | > |Pl |,

(2.36)

(2.37)

(2.38)

(2.39)



min{Sp(l0 ):d | |Pl0 | > |Pl |}, otherwise.
(2.40)

The full symbolic representation of the posterior sampling algorithm for Se(l):d and Sp(l):d is also
given in Appendix A

2.3

Simulation
We use the following population models to evaluate our estimation methodology:

probit: Ti = (Ti1 , Ti2 ) ∼ N2 (Xi β, R)
e i = (1(Ti1 > 0), 1(Ti2 > 0))0
Y

(2.41)

logistic: Ei = (Ei1 , Ei2 ) ∼ N2 (0, R)
ν ν 
,
γi ∼ Γ
2 2
√
Tid = x0i β + logit (Fν (Eid / γi ))
e i = (1(Ti1 > 0), 1(Ti2 > 0))0
Y

(2.42)

where Xi β = (x0i β 1 , x0i β 2 )0 with xi = (1, xi1 , xi2 )0 , ρ12 = 0.3, and Fν (·) is the student-t cumulative
distribution function with ν = 7.3 degrees of freedom. In addition, xi1 ∼ N (0, 1) and xi2 ∼
Bernoulli(0.5). With the two population models, we choose (β 1 , β 2 ) = (−2.1, 0.5, 0.5, −1.7, 0.5, 0.5)
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for the probit model and (β 1 , β 2 ) = (−3.3, 0.5, 0.5, −2.55, 0.5, 0.5) for the logistic model. These
parameters give the population prevalence of about 5% and 10% for disease 1 and 2 respectively.
These models generate the true disease status and covariates for every simulated patient. We
e i , Xi )} for i = 1, . . . , N once for every comparison and repeat this 500 times.
generate {(Y
In these simulations, we study four testing scenarios: individual testing (IT), master pool
testing (MPT), Dorfman’s testing (DF), and two-stage array testing (AT). With IT, we perform
a multiplex assay for both diseases on every patient. The simplest form of group testing is MPT.
We arrange patients into separate pools of fixed size, four, and only perform the tests on the pools.
We choose pool sizes of four to reflect the typical pool size used in our application set. In this
case, the patient groups are disjoint, i.e., no patient can be in two groups. Moreover, we test for
two diseases in each pool. For DT, we arrange all patients in disjoint sets of four and test their
pooled results for two diseases similar to MPT. We retest all members of pools with any positive
results, individually, for both diseases. Pools with negative test results for both diseases do not need
retests because individuals in the pool are considered negative. For AT, we partition the patients
into subgroups of sixteen. The subgroup is arranged in a square four by four array and the columns
and rows are pooled. We follow the procedure outlined by Kim et. al. [25] for testing. Imperfect
P
testing is used for each scenario. We generate the true pool status Zejd = 1( i∈Pj Yeid > 0) simulate
ejd = 0 ∼ Bernoulli(1 − Sp(l):d ) with
the test response by Zj |Zejd = 1 ∼ Bernoulli(Se(l):d ) and Zj |Z
Se(1):1 = 0.94, Se(2):1 = 0.90, Se(1):2 = 0.98, Se(2):2 = 0.96 and Sp(1):1 = 0.93, Sp(2):1 = 0.95,
Sp(1):2 = 0.97, Sp(2):2 = 0.98.
For each population model, probit and logistic, we examine the performance of the model
under three cases for IT, MPT, DT, and AT. In the first case, we assume that assay accuracies are
known and the correlation between diseases, ρ12 , is unknown. In the second case, we change the
assumption that the assay accuracies are unknown and are estimated separately. In the third case,
we assume the unknown assay accuracies have an ordering. In each of the cases, we simultaneously
estimate the unknown parameters. Our simulation results for the probit population model for the
cases are found in Tables B.1, B.2, and B.3 in Appendix B. The logistic population model results
for the six cases are found in Tables B.4, B.5, and B.6.
For the simulation results, we use N = 5008 individuals so that every testing schema was
complete without remainder pools. We chose priors with minimal information and diffuse. For the
regression parameters β, we use the multivariate normal prior with mean 0 and correlation matrix
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Σ0 = 100I6 . For the correlation parameter, we use a uniform prior on the interval [−1, 1]. For the
sensitivity and specificity, we used independent beta priors, b(1, 1). For each case, we generate a
population and permute the individuals before each testing protocol. We perform 100, 000 posterior
draws, retain every tenth draw, and discard the first half as burn-in. This leaves us with 5, 000
posterior samples for each parameter.
We run K = 500 simulations. For each simulation, we compute the posterior mean and
standard deviation using the posterior samples. We find the average of K posterior mean estimates
of the bias, the standard deviation of the posterior mean estimates (SSD), and the average of the
posterior standard deviation estimates (ESE). In addition, we calculate the 95% equal-tailed credible
interval (ETI) for every parameter in the simulation with α = 0.05. We verify if the true parameter
is within the interval. The mean number of times the parameter is within the credible interval is
the empirical coverage probability (CP95).
Table B.1 shows the simulation results when assay accuracies are unknown but the regression
coefficients and the correlation term are simultaneously estimated for the probit population and
model. We observe that MPT is the worst performing with roughly double the bias, ESE, and SSD
as the best performing AT at the cost of approximately a third of the number of tests used. Notably
with the exception of the bias in the first disease intercept term and the correlation parameter. In
general, the bias, ESE, and SSD decrease in the order MPT, IT, DT, and AT with a few exceptions.
Another notable observation is that for IT, DT, and AT the bias for the regression coefficients are
the same sign as the true values.
We ran a simulation where assay accuracies are simultaneously estimated for the probit
model. Our results are recorded in Table B.2. The regression coefficient estimations decrease for DT
and AT and increase for IT and MPT over the previous study where assay accuracies are known.
This causes a significant reduction in the coverage probabilities for the regression coefficients for
MPT. The correlation parameter estimations increases significantly for IT and MPT where as the
bias doubles with an increase in SSD and ESE for DT and AT from the first simulation. The
estimations for sensitivity and specificity are poor for IT and MPT but are accurate for DT and AT.
AT again has the lowest biases, SSD, and ESE for the assay accuracies with only two exceptions.
Our third simulation examines DT and AT with and without ordering the assay accuracies. The
estimations are found in Table B.3. We find that SSD and ESE values can be slightly reduced with
ordering implemented but the biases only improve on one intercept term and the larger valued assay
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accuracies.
The forth, fifth and sixth simulations are similar for the previous three simulations except
that we use the logistic population and logistic model. The results in Table B.4 and Table B.5
are when the assay accuracies are known and unknown, respectively. The analysis is similar to the
probit model with a similar prevalence and number of tests performed. Table B.6 shows the results
for when the assay accuracies are unknown and ordered. The results show that the majority of SSD
and ESE estimates improve with ordering and the bias under ordering is only better for the higher
valued accuracies.
There are a few themes from the simulation results from both populations. The first theme
is that AT requires around eight percent more tests than DT in our simulation setup but while AT
demonstrate at least a 23% decrease in the number of tests performed compared to IT. The second
theme is that IT and MPT struggle to estimate sensitivity and specificity with flat priors. Both IT
and MPT provide reasonable regression coefficient estimates when the assay probabilities are known.
The third theme is that enforcing an ordering on the assay accuracies shows only a trade off effect
between bias and variance. Lastly, DT and AT demonstrate lower bias, SSD, and ESE parameter
estimations with reasonable coverage probabilities over IT and MPT.

2.4

Data Application
Iowa’s SHL is the state’s public health and environmental laboratory. It provides services for

disease detection, environmental monitoring, newborn and maternal screening, drinking water testing, and bioterrorism and chemical terrorism response and readiness. For STD screenings, medical
providers collect samples from patients and the specimen are sent to the SHL facilities for testing.
For chlamydia and gonorrhea screening, all urine samples are tested individually and specimens
collected on swabs from females are tested using DT with the dual assay for retesting according to
Tebbs, McMahan, and Bilder [47]. The testing protocol based on gender and specimen type is also
common in Idaho according to Lewis, Lockary, and Kobic [29]. The stratification helps separate
high prevalence populations from low prevalence populations such as men who get tested due to
STD symptoms versus regular screenings for females during pregnancy. In this section, we examine
clinical results for the 2014 Iowa clinical data for females. Included in the data set are results from
individually testing urine samples and both individual and pool testing swab specimens. Our anal-
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ysis of the data is presented in two tables: β estimation in Table B.9, ρ, sensitivity and specificity
estimations are in Table B.10.
The data contains 13,862 female’s test results for classification with individual covariates.
The test results are composed of 4,316 individual urine specimens, 2,272 swab specimen master pools
of size 4, 13 swab specimen master pools of size 3, 1 swab specimen master pool of size 2, and 417
individual swab specimens. We include nine patient covariates for modeling: one continuous and
eight categorical. The continuous variable is the patient’s age in years. The coefficient for age is
βd,1 for d = 1, 2. A density graph by specimen type can be found in Figure B.2. The majority of
patient ages are found in teens to late thirties with the swab specimen type age distribution rightshifted compared to the urine specimen type age distribution. We reduce the categorical variable
for race into three categories white (W), black (B), and other as black and white were the two
majority classes. We one-hot encoded the category such that the class for other is the baseline and
the majority classes were denoted by the indicators βd,2 for W and βd,3 for B for d = 1, 2. The
rest of the categorical variables do not need one-hot encoding as they have two classes. The other
indicators are patient-reported risks and symptoms for new sexual partner in the last 90 days (RNP,
βd,4 ), multiple partners in the last 90 days (RMP, βd,5 , sexual contact with a STD-positive partner
(RC, βd,6 ), symptoms of infection (S, βd,7 ), specimen type swab (1) or urine (0) (ST, βd,8 ), signs of
cervicitis (SC, βd,9 ) and signs of pelvic inflammatory disease (SP, βd,10 ) for d = 1, 2. We provide
descriptive statistics for the categorical covariates in Table B.7. We simultaneously estimate both
the urine and swab samples using both the probit model and the logistic model. With the correlation
term, sensitivities, specificities, and regression coefficients, we estimate 43 parameters.
To combine the testing types into one large dataset, we have separate parameters for the
testing error of each type of specimen in the model. Moreover, we make informed estimates of
sensitivity and specificity for each tuple of disease, test type, and group size. Hologic’s performance
data, used to establish their assay probabilities, provides the necessary counts to inform the priors
on each sensitivity and specificity per disease and test type combination. We provide the data for
female swab and urine specimens in Table B.8. Since there is no data based on group size, all
the varying group sizes have the same prior. Additionally, we explore enforcing an ordering on
the sensitivity and specificity based on group size and specimen type. For example, we have five
assay types l = 1, 2, 3, 4 for the four group sizes of swab specimens and l = 5 for individual urine
specimens. If ordering is in effect, we have the partial order of Se(1),d ≥ Se(2),d ≥ Se(3),d ≥ Se(4),d ,
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and Sp(1),d ≤ Sp(2),d ≤ Sp(3),d ≤ Sp(4),d for d = 1, 2. We chose the same priors from our simulations
for the correlation parameter and the regression coefficients. We generated 100, 000 posterior draws
and burned the first half and saved every tenth draw. This left us with 5, 000 posterior draws for
each parameter. We computed the posterior mean, sample standard deviation of posterior draws,
95% highest posterior density interval (HPDI), and 95% equal-tailed interval. We find that the
direction of the regression coefficients is in line with McMahan, Tebbs, Hanson, and Bilder [41].
From our estimations, We did not observe the dilution effect in sensitivity when sensitivity was
not partially ordered. Also we note that for the probit model ST is not significantly different from
zero for chlamydia with ordering but ST is with ordering. For the probit model, RMP was not
significantly different from zero for the disease gonorrhea with ordering but RMP is significant for
no ordering. For the logit model, we found that S and SC where not significantly different from zero
for gonorrhea without ordering but are with ordering enforced.
We have proposed a Bayesian regression model to estimate generalized linear models with
data from most group testing protocols for multiplex assays. Our implementation has the property
that the marginal distributions following the probit and logit link functions. This property allows us
to have estimate interpretable regression coefficients. There are some natural extensions of this work
that may be of interests. One could include variable selection strategies for model reduction steps.
The correlation between infections could conditionally depend on covariates. Non-linear relations
could be present in the covariates. Additionally extensions to handle non-discriminating testing
procedures could be of interest.
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Chapter 3

GPU acceleration with NVIDIA
CUDA
Graphic processing units (GPU) are supplemental hardware to CPUs that are used for
graphics rendering. To achieve real-time graphics, GPUs are designed for highly parallelized tasks.
Graphics rendering involves intricate model meshes which are composed of millions of triangles,
shaders to paint the textures, color and lights on each triangle and matrix transformations applied to every pixel and vertex of the model to move it in space. While the demand for graphics
performance fuels the GPU market, other numerically intensive tasks take advantage of the high
throughput numerical operations. NVIDIA is a market leader in GPUs and supports general purpose computing on graphics processing units (GPGPU) with NVIDIA’s CUDA (Compute Unified
Device Architecture) Software Development Kit (SDK). We use the NVIDIA CUDA SDK for all of
our GPU accelerated programs. This chapter is dedicated to introducing the SDK and hardware
architecture. In Section 3.1, we address the programmer’s model or an abstraction of the hardware.
The programmer’s model will cover the types of memory on the GPU as well as the thousands of
computational cores or CUDA cores on the GPU. In Section 3.2 and 3.3, we setup a development
environment and learn how to compile and execute code. In Section 3.4 and Section 3.5 we provide
basic examples to springboard into our next project.
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3.1

Programmer’s Model
While we discuss GPU acceleration in this chapter, a GPU is not always needed. There

are several metrics to evaluate needing a GPU. The first consideration is the size of the task.
Sometimes tasks are too small or simple causing the overhead costs of using and programming a
GPU to outweigh the benefits. On the other end of the spectrum, really large tasks sometimes do
not warrant using a GPU. Large tasks spend time sending messages between computers and waiting
on those communications. The cost of communication can drown out the benefits of using GPUs as
well as add unnecessary complexity. After all these considerations, many tasks benefit from GPU
acceleration.
The current GPU architecture has changed dramatically in the last couple of years [75]
[76] [77]. NVIDIA GPU’s hardware is composed of a medley of dedicated circuitry. CUDA cores
are next to tensor cores and ray-tracing cores as well as traditional texture units. The general
organization is the following hierarchy from top to bottom: Graphic Processing Clusters (GPCs),
Texture Processing Clusters (TPCs), Streaming Multiprocessors (SMs), and finally CUDA cores.
We focus on the architecture around the CUDA cores as they are most relevant to this dissertation.
Within each CUDA core, there is a floating-point and an arithmetic logic unit that performs the
computations. The CUDA core is abstractly associated with a thread or small set of independent
instructions, and threads are organized into thread blocks. At the hardware level, the threads are
organized into warps of 32 threads because there are some multiple of 32 CUDA cores within each
SM, which plays an important part in scheduling tasks. In a few instances, we organize tasks in
multiples of 32 to maximize the efficiencies of synchronization in a warp.
Synchronization is important because the NVIDIA GPUs implement a single instruction,
multiple thread (SIMT) model. In a parallelized program, every thread executes the same set of
instructions. At the warp level, instructions are executed in lockstep. For example, an instruction
could be: add the numbers in the first two registers or grab a number in a memory location plus
an offset. Machine commands are executed on the exact same clock cycle in the GPU in all 32
threads of the warp. Outside of the warps, the same code might be running a little off from one
another. Therefore, the timing of memory writes and reads become an important consideration in
this dissertation.
We consider a simple hardware setup of a single CPU and GPU. The programmer considers
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two locations: the host (CPU) and the device (GPU). Programming instructions must be sent to
each location. In addition, data must be sent from the host to the device and vice versa. These
data transfers between host and device are potential choke points. The data transfers can be either
efficiently dispatched or separated from the computation by concurrent operations. Data transfers
can be done asynchronously through the use of streams while other computations proceed.
The next important part of the architecture is the memory model. Reading and writing data
takes time or clock cycles as there are different steps and pathways to complete the task. Memory
can have multiple hardware layers from the fastest registers in the processor through multiple levels
of cache to the system random access memory. Since we focus on the device, we assume the host
only has global memory and the compiler and run time systems takes care of the rest. The device
has memory on three different levels; global, local and shared that must be managed by the user.
The easiest to use is global memory, every thread has read and write access to global memory. It
must be managed such that read and write operations are not interleaved to create an unknown
memory state. In contrast, local memory is only available to the thread and does not need as much
care for scope and timing as it is isolated from being touched by other threads. Moreover accessing
and fetching local memory is either similar to global memory or it is similar to a register on the
chip. Local memory could be stored in registers, the fastest type of memory, but is usually isolated
in the global memory of the device, the slowest type of memory. The compiler will try to optimize
memory management based on the size of the data being retrieved and its usage. The guaranteed
fastest memory is shared memory which trades accessibility and complexity for speed. Finally shared
memory’s scope is between global and local memory. It is available to all the threads in the same
block and is comparable to registers and faster than global memory.
In the programmer’s model, we think from the point of view of the host as the host orchestrates the work. We create variables and do computations all within host memory. To use the GPU,
we send data and commands to the GPU to do work. There is a cost to copying the information over
to the GPU and back to the CPU, so any GPU computation must outweigh the cost of transmission.
To marginalize the overhead cost of sending data, we use data streams. We sequence the data to
send it in chunks so that the GPU starts computing a chunk while the next is transferred. There
are additional speed-ups from pinning host memory as it usually is automatically done to start a
transfer. However we choose not to do this as our data transfers are usually at the beginning and
end of the computation and the time savings do not scale with the models we implement. Once
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data is in the device, on occasion, we transfer to local or shared memory, which is data accessible
only to a core or to the block. Shared data can be allocated statically or dynamically through the
kernel function. We can move data once locally and then transfer it back at the end of a computation instead of repeatedly accessing global memory in a thread. This is because global data access
is slower than local/shared data. Another memory issue that we come across is race conditions.
The order in which each thread reads and writes to memory may not be deterministic in the code.
For example, two threads, A and B, write to memory a value in the same place in memory at the
same time. The unknown condition of the memory, either the value from thread A or thread B or
a mangled combination of the two, is called a race condition. There are concepts such as atomic
operations, semaphores, mutex, and other ways to deal with this concurrency issue.
Once the data is transferred to the GPU, it is in the device’s global memory. There are
thousands of cores on the GPU that have access to global memory. The simple cores are directed
by a kernel program that is executed in parallel. Multiple kernels can be written for each part of
the task. The threads that execute the kernels are able to self identify, which means they know
their thread index, and block index, which in turn allows us to direct their tasks and which part
of memory to use. For example, in Chapter 5, we have every thread compute a complex random
number then the first thread selects which random number to use. In Section 3.4, we use the thread
index to choose what numbers to add in memory.

3.2

Setup
The following setup is for the Palmetto Cluster at Clemson University, a high performance

computing (HPC) cluster; however, the concepts are still applicable in other settings. The cluster
is a set of computers called nodes. The nodes are networked with high speed connections. When
we connect to the cluster via SSH, the terminal is at the login node. The login node runs on Red
Had Enterprise Linux as well as the rest of the cluster. In the login node, we may read and write
files and use other basic Linux utilities, but we cannot run our code. Past the login node, the rest
of the cluster has several thousand nodes with different interconnections and hardware availability.
The output of the whatsfree command shows there are NVIDIA K20, K40, P100, and V100 GPUs
associated with various other hardware configurations. The exact hardware we use depends on the
availability, the features, and the tools we need for our work.
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The Palmetto Cluster uses the Portable Batch System (PBS) to request the resources and
job scheduling. The qsub command submits a request to run a script or run an interactive session.
Options of the command allow one to request the number of cores, amount of memory, the number
and type of GPUs as well as the length of the request. Once the command is entered, the scheduler
adds our request to the queue, and once available, the terminal switches to the available node. In
the interactive environment, the terminal prompt changes indicated one is in the node.
After we login into a node, we can load modules. Modules are easy to install software
resources The command module avail contains a condensed list of modules. In our case, we use
the command to find the correct version of CUDA, gcc and R. Even though the toolkit comes
with NVIDIA CUDA Compiler (NVCC), it requires a C++ compiler. The latest compilers do not
always work with NVCC. On Windows, Visual C++ 14.1 in Visual Studio 2017 did not work with
NVCC but Visual C++ 14.0 in Visual Studio 2015 did work at the time of the setup. Sometimes
unexpected behavior or limited features can be from the wrong toolkit and compiler versions. To
check support, go to the Installation Guides for CUDA linked on the landing page [78] or directly
to the Linux guide [79].

3.3

Compiling
The NVCC compiles in two stages for the GPU. The two stages let the programmer choose

between targeting the program to run on a specific hardware architecture or allowing the final stage
to be completed by a yet to be determined architecture at the cost of a slower startup. The first
stage is the virtual architecture which compiles a PTX file. The virtual architecture is designated
by the compute xx designation. The final stage generates the binaries and compiles to a Cubin for
the machine code to be ran by the GPU. The second stage can be left to run-time compilation when
the target architecture is unknown.
When compiling a GPU program to use in R, many flags are required during compilation.
The goal of each flag is to appropriately produce a binary to be run by R with additional libraries
included.
1. nvcc is the program to be called. Its location is found in the PATH variable in the linux
environment and placed by the previous module add calls.
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2. −O3 is the code optimization level. The compiler will make several passes at the code to search
for ways to optimize it. This automatic process is not a guarantee that it will be different from
previous levels, run faster, will be more efficient or error free. There are three levels with the
second level the most commonly used, and the third level is the riskiest.
3. −arch=compute 35 is the virtual architecture for 3.5 which is for Kepler, K40. compute 60
is the 6.0 compute architecture for Pascal, P100, compute 70 and compute 72 is the compute
architecture for Volta, V100. It is recommended to target the lowest architecture for the
features we want.
4. −code=sm 35 targets the 3.5 architecture binaries for Kepler, K40. Similarly, the sm 60 is the
for 6.0 compute architecture for Pascal, P100, sm 70 and sm 72 is the compute architecture
for Volta, V100. If we want to use run-time compilation swap out sm xx for compute xx.
5. −G indicates debug mode.
6. −lcublas −lcurand −lcusolver links the CUDA cublas, curand and cusolver libraries in the
toolkit. The modules include the paths to the libraries and are automatically looked up,
otherwise a direct path is required.
7. −−shared −Xcompiler −fPIC is the set of commands to get a binary file that R can use. The
first part, −−shared, builds a shareable library. The second part, −Xcompiler − fPIC, sets
a flag for position independent code where memory locations are offset rather than absolute
addresses so that the library can be loaded anywhere in program memory.
8. −o cuHorse.so tells the compiler what the output filename should be.
9. cuHorse.cu is the file or files to be compiled.
Further information can be found in the NVCC documentation [80].

3.4

A Simple Program
We now show a simple program for R that uses a GPU to demonstrate using CUDA SDK.

Appendix C.1 contains links to the R code and CUDA code. The goal of the code is to add two
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vectors. Parallelization occurs when we return the componentwise sum where each core adds their
respective component together.
The R script loads the binary gpu program.so for the GPU, creates a wrapper function
to call the GPU code, creates inputs, then calls the function and unloads the GPU code. Note
the .C function call ensures that copies of all the data, not references, are sent to the external
function. While copies of the data are created, only pointers or memory locations will be passed
to our function. In C/C++, a pointer is a memory location declared with an int ∗a. The address
in memory of the variable a is &a and to get the actual value at the memory location it can be
dereferenced by ∗ operator or a [0] .
The next part is the CUDA code that we saved as add vector.cu. In the program we include
all the necessary libraries, in this case the CUDA runtime library, we declare the kernel for the device
and write the host program. One of the ways kernels are declared is by the

global

declaration

specifier. When writing a kernel, the point of view of the device should be taken. The kernel should
first identify itself by thread id, block id, and block dimension. Distinguishing the kernel’s identity
allows the kernel to use different data or compute different tasks. The kernel from the first example
uses the thread index to add the values at the corresponding indices in the vectors. That means for
a vector of size 10, 10 threads will be launched to add two numbers.
Following the simple kernel function, we return to the point of view of the host. The first
part Extern ‘‘C’’ is a directive for the functions that can be called by the library. Next is the
function, called in R. The variable cudaError t is usually returned for every basic CUDA function.
We check the error after each device function call or we wrap them in another function to check
them. Since we are not running critical computations, they can be ignored as they usually indicate
a catastrophic failure.
The basic way to allocate global memory on the device is by using cudaMalloc. We give a
double pointer address so that the function can return a new location for the pointer in addition
to the number of bits we want to allocate. Next we have the data on the host and move it to the
device using cudaMemcpy. It requires the device and host pointers, the size of the memory, and the
direction of the transfer.
Finally we execute the kernel. We launch with n blocks and 1 thread per block by the
<<<...>>> operator which is the execution configuration syntax. Either we call a double in this
example or a quad-tuple that has the stream and memory management in it. After the kernel is
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called and all threads executed, we still have our results on the device. We then send the results
back to the host and free all the device and host memory that was dynamically allocated.

3.5

A Second Program
In this section the code is similar to the code in the previous section with the exception of

using an outside library. A link to the program is in Appendix C.2. The wrapper and initialization
from R remain nearly identical except for the function name. The library, cuBLAS, contains reusable
code for basic linear algebra subroutines (BLAS) for NVIDIA GPUs. For this program, there is no
need to write a kernel function for adding two vectors, the function is part of the library. Instead,
the program needs to be made aware of the library and where to find the code to run it.
To use the library, we introduce a handler. The handler stores the location of resources to
using the library. There is a price for using the library, most of which is paid for in resources and
time when the handler is initialized. We let cuBLAS manage all the threads, blocks, etc. by calling
the function from the host. Later we must destroy the handler to free system resources back to the
host. Additionally, cublasSetVector and cublasGetVector are are just wrappers for cudaMemcpy.
However they have a nice increment function that allows us to grab the diagonal out of a matrix or
any other subset.
The most subtle part of the function call is how alpha, incx, iny are set. They are all set to
be 1 in the BLAS <t>axpy call. Note there is a mix of variables from the host cublas handle, n [0], 1
and device, d x, d y. In the documentation, if a variable says host or device, the default setting is
host. To toggle between where a variable exists, use cublasSetPointerMode, which is documented in
the cuBLAS helper functions. For more information, we refer to the cuBLAS documentation [81].
We use these methods over the next chapters applied to more complex programs.

3.6

Performance
We run two different simulations to demonstrate the effectiveness of our two simple pro-

grams. In each simulation, we compare running R code (CPU only) versus the simple kernel (CUDA
kernel) and the built-in library (CUDA library) programs. We repeat the simulations for numerical
vectors of size 10i for i = 1, . . . , 9 and compute six summary statistics after running each program
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100 times. We chose to scale up to vectors of size 109 because it was the last increment that fits
within our GPU’s memory. The first simulation demonstrates the overhead costs of running a GPU
program. The data found in Table C.1 and Figure C.1 shows the cost of starting a GPU program
and transferring data to and from the GPU outweighs the computation time by an order of magnitude. Moreover, the data demonstrates that the GPU libraries, while convenient, incur additional
overhead costs. The second simulation demonstrates the acceleration of running a GPU program
when we increase the numerical load by adding two vectors not once but 100 times. The results in
Table C.2 and Figure C.2 show the CUDA kernel and CUDA library programs accelerate the computations as the vector size increases. When adding larger vectors, the CUDA kernel and CUDA
library programs are over an order of magnitude faster and the CUDA library is optimized better
than our custom kernel. The simulations demonstrate that we can see acceleration benefits from
large computational tasks that stay on the GPU and using built-in libraries.
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Chapter 4

GPU Acceleration for Logistic
Regression with Penalty
In this chapter, we are interested in measuring the benefits of GPU acceleration. Applications for GPU acceleration are numerous but we focus on optimization, a common machine learning
task. Optimization is a hard problem because many problems do not have closed form analytic solutions. In linear regression, the ordinary least squares solution is an example of an analytic solution.
In particular, we demonstrate GPU acceleration on the logistic regression with `1 regularization
as our objective function. We choose logistic regression as it has no analytic solution and it is a
common link for binary data. For example, McMahan et. al. [41] use logistic regression to relate
disease status to covariates in a group testing application.
The goal of our optimization is to find the regression coefficients that maximize the likelihood
function or, with a simple negation, the equivalent problem of minimizing the objective function
with the penalty term. A descent method is a common way to find the minimum of the objective
function. We employ two types of descent methods: stochastic gradient descent and stochastic
coordinate descent in different programming languages to see the performance improvements. A
survey by Yuan et al. [82] includes other methods that we do not explore here.
We compare the formulation of Newton’s method to stochastic descent methods to understand the origins of the descent methods and trade-offs. Newton’s method is an iterative method
for root finding with quadratic convergence. It has applications in optimization problems because
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finding critical values or potential extrema is a root finding problem. We wish to minimize the
scalar function F (x) ∈ R where x ∈ Rd and F (x) typically convex. We then wish to find critical
points of the gradient ∇F (x) = 0 as potential solutions. Newton’s method gives a sequence of points
that converge to the solution, xt+1 = xt − ∇2 f (xt )−1 ∇f (xt ). Each iteration of Newton’s method
moves closer to the critical point. In particular, it moves in the general direction of ∇f (xt ) where
∇2 f (xt )−1 is a linear transformation that optimally scales and rotates the direction. One downside
of Newton’s method is that it can be expensive to compute ∇2 f (xt )−1 on each iteration.
Gradient descent is an iterative method where each iteration moves in the direction of the
gradient similar to Newton’s method. Gradient descent is represented by the iterations xt+1 =
xt − γt ∇f (xt ) for some γt called the step size. There are two methods we explore similar to gradient
descent; stochastic gradient descent and coordinate descent. Both these methods stem from ideas of
Robbins and Monro [83] who first presented the idea to solve optimization problems stochastically.
For gradient descent, the step size is called the learning rate ηt and for coordinate descent, the step
size is denoted αt .
In stochastic gradient descent, we rewrite F (x) as

Pn

i=1

Fi (x) where Fi (x) is the ith record

in the data set. The problem is formulated such that each update needs a single observation from
the data. Thus with each observation in the data, we update the sequence until convergence with
xt+1 = xt −ηt ∇Fi (xt ) where ηt is called the learning rate. The stochastic gradient descent algorithm
randomizes Fi then updates x for each i. However, there are two issue with this methodology. First,
allowing the gradient to be evaluated with one data point creates instability in the direction and
magnitude of the update. Second, an incorrectly selected learning rate can cause the algorithm to
converge slowly. We solve the the first issue with batching, that is we take the average update of
several data points. The second issue is solved using an adaptive learning rate. We use AdaGrad [84]
because of its ease of implementation. AdaGrad tracks the diagonal of the outer product of the
subgradient sequence to change the learning rate per parameter. It is a specialization of the standard
gradient descent that gives frequent features lower learning rates.
In stochastic coordinate descent, we take vertical slices of data to update our solution
instead of horizontal slices of data in stochastic gradient descent. We update for each coordinate in
x ∈ Rd . With each iteration, we create a sequence that updates only one coordinate with xj,t+1 =
xj,t − αt (∇F (xt ))j where αt is the step size. The algorithm randomly updates the coordinates of
the solution until convergence.
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In Section 4.1, we derive the algorithms that implement stochastic coordinate descent and
gradient descent to fit logistic regression models. In Section 4.2, we look at the performance of
the algorithm with a comparison to GPU acceleration. For in-depth linear regression examples, see
Appendix D.

4.1

Logistic Regression Derivation

In this section, our focus is on the algorithms for logistic regression. In particular, the model
Pn
assumes that we have data, X, and response, Y. The data is normalized such that i=1 xij = 0 and
Pn
1
2
−xT
i β )−1 and the probability
i=1 xij = 1, so the probability of success is P (Yi = 1|xi ) = (1 + e
n
T

of failure is P (Yi = 0|xi ) = (1 + exi β )−1 . We have the following likelihood function that we wish to
maximize as well as the scaled log likelihood function which is equivalent because the log function
is monotonic:

argmax L(β|X) = argmax
β

β

pyi i (1 − pi )1−yi

i=1

= argmax
β

N
Y

N
1 X
log(pyi i (1 − pi )1−yi ).
N i=1

(4.1)

We frame the problem as a minimization problem by taking the negative of the scaled log likelihood
and adding the penalty, we have the following:

argmin H(β) = argmin F (β) + λ kβkL1
β

β

= argmin −
β



N
d
X
1 X
pi
yi log
+ log(1 − pi ) + λ
|βj | .
N i=1
1 − pi
j=1

N
d
X
1 X
= argmin −
yi µi + log(1 − pi ) + λ
|βj | ,
N i=1
β
j=1

(4.2)

where pi = P (Yi = 1|xi ) and µi = xTi β. Moreover we have the following useful terms:
∂p
eµ xk
=
= p(1 − p)xk
∂βk
(1 + eµ )2
∂(1 − p)
= −p(1 − p)xk .
∂βk

43

(4.3)

With these terms, we find the gradient and Hessian of the likelihood function. For the gradient, we
use the definition of the subdifferential for the penalty term whereas the Hessian does not need a
special case.
∂
kβkL1
∂βk



N
sign(βk )
1 X
=−
xik (yi − pi ) + λ

N i=1

[−1, 1]

(∇H(β))k = (∇F (β))k + λ

if βk 6= 0
if βk = 0

(∇2 H(β))ij = (∇2 F (β))ij
=

N
1 X
−xki xkj pk (1 − pk )
N

(4.4)

k=1

Our goal is to ensure that for each iteration we decrease the function F (β) in search of the minimum.
In order to ensure this, we optimally use the step size in the stochastic coordinate descent iteration. That is, we use the condition of Shalev-Shwartz and Tewari [85] that F (β + δβj ej ) ≤ F (β) +
δβj (∇F (β))j + 21 α(δβj )2 . This condition ensures that on the T th iteration β (T ) is close to the minimizer, β ∗ , E[F (β (T ) )] − F (β ∗ ) < C/T for some C. Following Taylor’s Theorem, we need to select
PN
α such that δβj e0j ∇2 F (β)δβj ej ≤ α(δβj )2 . When we find the max ∇2 F (β)jj = N1 i=1 x2ij pi (1−pi ).
PN
We have pi (1 − pi ) has a maximum of 1/4 at pi = 1/2. Therefore α = 41 N1 i=1 x2ij = 14 from the
regularization.
After dealing with the likelihood part of the function we address the penalty. The `1
penalty or LASSO term is carefully handled. The derivative of |βj | changes with the sign of βj and
includes all subderivatives when βj = 0. When updating β t , we have to consider the sign changes
of the components, βj,t and βj,t+1 . Suppose that βj,t > 0, then βj,t+1 = βj,t − γt (∇H(β t )) > 0 is
correct so long as βj,t+1 remains positive. Thus we have the condition that βj,t − γt ∇F (β t ) > γt λ.
Similarly βj,t < 0 gives rise to the condition that βj,t − γt ∇F (β t ) < −γt λ. Thus we are left with
βj,t − γt ∇F (β t ) ∈ [−γt λ, γt λ] when βj,t+1 = 0. These three cases can be exactly represented by the
soft-thresholding function:

sτ (w) = sign(w) max(0, |w| − τ ).

(4.5)

For stochastic gradient descent, we have ∇Fi (β t ) = −(yi −pi )xi and ηt is the learning rate. Hence our
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naive update step is β t+1 = sηt λ (β t + ηt (yi − pi )xi ). We use the algorithm AdaGrad introduced
by Duchi, Hazan, and Singer [84] to provide and adaptive learning rate. While AdaGrad has
been improved upon by algorithms such as AdaDelta [86] and Adam [87], AdaGrad is simpler to
implement. In addition, we batch our update to add stability. This means that we take a random
subset of indices of size B and average the gradient. For the largest batch size, B = N , we have
gradient descent which is slow. For the smallest batch size B = 1 is too sensitive to outliers. A large
batch size approximates the gradient for a fast update. Furthermore we choose a common learning
rate, ηt = 1 · t−1/2 . Algorithm 4.1 represents our version of stochastic gradient descent.
Result: argminβ H(β)
Set β = 0 ∈ Rd
while not converged do
Choose It ⊂ [N ] uniformly
Pat random with |It | = B.
Let Gt+1,ii ← Gt,ii + ( B1 i∈It ((yi − pi )xi ))2i .
p
Let ηt ← t−1/2 /  + Gt+1,ii .

P
Let β t+1 ← sηt λ β t + ηt B1 i∈It ((yi − pi )xi ) .
end
Algorithm 4.1: AdaGrad Stochastic gradient descent with batching for logistic regression with
`1 penalty.
For coordinate descent, we have (∇F (β t ))k = − N1

PN

is sufficient. The update step is β k,t+1 = sαt λ β k,t + αt N1

xik (yi −pi ) and the step size αt = 14

Pn
i=1 xik (yi − pi ) . Shalev-Shwartz and
i=1

Tewari [85] introduce a stochastic coordinate descent with convergence results. Algorithm 4.2 is our
implementation.
Result: argminβ H(β)
Set β = 0 ∈ Rd
while not converged do
Chose k ∈ {1, . . . , d}
random.
 uniformly at

PN
1
Let βk,t+1 ← sαt λ β k,t + αt ( N i=1 xik (yi − pi )) .
end
Algorithm 4.2: Stochastic coordinate descent for logistic regression with `1 penalty.
In order to implement these methods in parallel, we made several attempts using existing
literature. For SGD, we attempted the Hogwild approach of Recht, etc. [88] for asynchronous updates
to the solution for coordinate descent. The asynchronous updates means that every time a thread
starts an update it uses the latest version of β. However, this implementation failed to converge.
Instead we exploit parallel structures in Algorithm 4.3. For each processor, we compute the gradient
of a random row and accumulate the gradients. In this algorithm, the number of threads equals the
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batch size. After we synchronize the threads with a wall, for the d components of β we update the
outer product of the gradients, the step size, and combine it to update the parameter.
Result: argminβ H(β)
Set β = 0 ∈ Rd
while not converged do
do in parallel
Choose i ∈ {1, . . . , N } uniformly at random.
Compute pi .
Atomically update Wj ← Wj + (yi − pi )xij for all j.
end
Synchronize.
do in parallel
Choose j ∈ {1, . . . , d}.
2
Let Gt+1,jj ← Gt,jj + B1 Wj .
p
Let ηt ← t−1/2 /  + Gt+1,ii .

Let β j,t+1 ← sηt λ β j,t + ηt B1 Wj ) .
end
end
Algorithm 4.3: Parallel stochastic gradient descent with batching for logistic regression with
`1 penalty.

We had similar problems with SCD. The shotgun, a parallelized shooting approach, by
Bradley et al. [89] was difficult to implement due to the duplicate features. Algorithm 4.4 instead
uses the same parallel structure but does not use the same update or duplicate features. We update
µt using a parallelized matrix vector multiplication. Using µt , we perform several updates for random
column vectors.
Result: argminβ H(β)
Set β = 0 ∈ Rd
while not converged do
do in parallel
µt ← Xβ t .
end
do in parallel
Choose k ∈ {1, . . . 
, d} uniformly at random.

PN
Let βk,t+1 ← sαt λ β k,t + αt ( N1 i=1 xik (yi − pi )) .
end
end
Algorithm 4.4: Parallel stochastic coordinate descent with batching for logistic regression with
`1 penalty.

Both methods that we implemented, while effective, are general purpose algorithms. In
contrast, the glmnet algorithm of Friedman et al.
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[90] is designed for logistic regression with

penalty. The algorithm uses the Taylor expansion to find a weighted least squares approximation.
Moreover, we need to solve for several λ with nearby solutions. Therefore each solution for λ can
warm start the algorithm. We provide the derivation of the glmnet update from the following Taylor
expansion:
1
F (β) = F (β̃) + (β − β̃)T ∇F (β̃) + (β − β̃)T ∇2 F (β̃)(β − β̃) + Remainder.
2

(4.6)

1
argmin F (β̃) + (β − β̃)T ∇F (β̃) + (β − β̃)T ∇2 F (β̃)(β − β̃)
2
β
N
1 X
1
yi µ̃i + log(1 − p̃i ) − (yi − p̃i )(µi − µ̃i ) − p̃i (1 − p̃i )(µi − µ̃i )2
argmin
N
2
β
i=1
"

2

2 #
N
−1 X
yi − p̃i
−2yi µ̃i − 2 log(1 − p̃i )
y − p̃i
argmin
p̃i (1 − p̃i ) µi − µ̃i −
+
−
2N i=1
p̃i (1 − p̃i )
p̃i (1 − p̃i )
p̃i (1 − p̃i )
β

(4.7)
The first term is a quadratic and the remainder we will ignore. We can then obtain a form for the
weighted least squares problem

2
N
yi − p̃i
−1 X
p̃i (1 − p̃i ) µi − µ̃i −
2N i=1
p̃i (1 − p̃i )
β


N
yi − p̃i
∂`Q (β)
1 X
p̃i (1 − p̃i ) µi − µ̃i −
xij
=−
∂βj
N i=1
p̃i (1 − p̃i )

argmin `Q (β) = argmin
β

(4.8)

Thus we have

βj =

sλ ( N1

PN

i=1

P
p̃i (1 − p̃i )xij ( k6=j xik βk − µ̃i −
PN
1
2
i=1 p̃i (1 − p̃i )xij
N

yi −p̃i
p̃i (1−p̃i ) ))

(4.9)

Friedman et al. [90] proceed to describe the glmnet algorithm as the following:
To add parallelism, we split the algorithm into two parts similar to SCD. The first part is to
update the mean in parallel, and the second part is to use the common update for each coordinate
in parallel. We have the following parallel glmnet Algorithm 4.6.
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Result: argminβ H(β)
Set β = 0 ∈ Rd .
while not converged do
Let µ̃i = xTi β.
for j = 1 . . . d do
βj ←

1
sλ ( N

PN

i=1

p̃i (1−p̃i )xij (
PN
1
N

P

k6=j

xik βk −µ̃i − p̃

yi −p̃i
))
i (1−p̃i )

2
i=1 p̃i (1−p̃i )xij

end
end
Algorithm 4.5: glmnet for logistic regression with `1 penalty.
Result: argminβ H(β)
Set β = 0 ∈ Rd .
while not converged do
do in parallel
µ̃i ← Xβ.
end
do in parallel
βj ←

1
sλ ( N

PN

i=1

p̃i (1−p̃i )xij (
PN
1
N

P

k6=j

xik βk −µ̃i − p̃

yi −p̃i
))
i (1−p̃i )

2
i=1 p̃i (1−p̃i )xij

end
end
Algorithm 4.6: Parallel glmnet for logistic regression with `1 penalty.

4.2

Performance
In order to test the performance of the algorithms for logistic regression, we create synthetic

simulations. Synthetic simulations allow us to create a test data set for a logistic regression. The
test data set is limited by allowable matrix allocation sizes in R. We create a matrix, X, of size n × p
from the standard normal distribution. We create covariates, β, of size p from the Beta distribution
and set m of the coefficients as zero. We choose five testing scenarios found in Tables 4.1, 4.2, and
4.3. Note that from Section 3, we could not use vectors over size 109 thus our design matrix does
not exceed that size as well.
A key consideration is the convergence condition for the algorithms as we do not have the
Case
1
2
3
4
5

n
104
5 ∗ 104
105
5 ∗ 105
106

p
10
50
100
500
1000

m
2
10
20
100
200

Table 4.1: Parameters for gradient descent algorithms.
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Case
1
2
3
4
5

n
4 · 103
2 · 104
4 · 104
2 · 104
2 · 105

p
100
500
1000
5000
104

m
20
100
200
1000
2000

Table 4.2: Parameters for coordinate descent algorithms.
Case
1
2
3
4
5

n
103
5 ∗ 103
104
5 ∗ 104
105

p
100
500
1000
5000
104

m
20
100
200
1000
2000

Table 4.3: Parameters for glmnet algorithms.
true solution in general. We chose a stopping condition such that the max coordinate wise update
is less than an error tolerance or β t+1 − β t

∞

< 10−4 . However, when one coordinate at a time

is updated this condition is too aggressive as all but one coordinate is the same value. For SCD
and glmnet, we track the last update to β j for each coordinate and stop when all are less than our
tolerance. For example, set wj = 1 for all j, when j is updated set wj = |βj,t+1 − βj,t |. Therefore
our stopping condition is kwj k∞ < 10−4 . We check this condition before the common mean µ is
computed.
We ran the algorithms on a single core CPU with a NVIDIA V100 GPU. We set the batch
size and the number of processors to be B = P = 4096. Furthermore, we use 8 blocks of 512
threads to achieve our 4096 parallel processors. For each case, we simulated the data, selected a λ,
and ran the relevant algorithms 5 times. For SGD, we chose a simulation that emphasizes a larger
n than p as the parallelism is row wise. We wrote Algorithm 4.1 in R and C and implemented
Algorith 4.3 in CUDA. Our results are in Figure 4.1. The results show for all problem sizes that
parallelism improves the time to convergence. However, the performance improvement is not the
same order of magnitude of P . This is caused by the simplicity of the gradient update relative to
the synchronization and other overhead. A more complex update would yield better results. This
issue carries over the SCD and glmnet algorithms. We select design matrix sizes that take advantage
of the column wise parallelism. For SCD, we implement Algorithm 4.2 in R and C and Algorithm
4.4 in CUDA. When we used single threads, the largest runs failed to complete in the maximum
server time. This means the stopping condition requires every column index to be iterated which
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takes more time when randomly selecting columns. We replaced the single core SCD that computes
the mean and iterates over all columns. Figure 4.2, shows that the R implementation is still slow
and we had to drop the largest case. We see the parallelism shows improvement after accounting for
overhead. For glmnet, we implement Algorithm 4.5 in R and C and Algorithm 4.6 in CUDA. Figure
4.3, shows the overhead of parallelism slowing down the algorithm for smaller sizes. The uneven
scaling with the design matrix size is indicative of the randomness of our convergence criteria with
the smaller ratio of n : p in the design matrix.

Figure 4.1: The graph shows the timings of three implementations of stochastic gradient descent for
logistic regression with `1 penalty. The R and C implementations are written for a single processor
and the CUDA implementation is written using a parallel algorithm.
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Figure 4.2: The graph shows the timings of three implementations of stochastic coordinate descent
for logistic regression with `1 penalty. The R and C implementations are written for a single processor
and the CUDA implementation is written using a parallel algorithm.
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Figure 4.3: The graph shows the timings of three implementations of glmnet for logistic regression
with `1 penalty. The R and C implementations are written for a single processor and the CUDA
implementation is written using a parallel algorithm.
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Chapter 5

Horseshoe Probit
In this chapter, we explore the benefits of GPU acceleration using Clemson’s High Performance Cluster in a Bayesian statistical model. In particular, we benchmark the case study by
Terenin, Dong, and Draper [67]. The case study revolves around a Bayesian probit regression with
a horseshoe prior. The horseshoe prior was introduced by Carvalho, Polson, and Scott [91]. The
binary response from Albert and Chib [55] and the horseshoe prior was used for a GPU-accelerated
case study by Terenin, Dong, and Draper [67]. In Section 5.1, we establish the model and derive the
posterior sampling algorithm. In Section 5.2, we build probability distributions from basic functions
because the CUDA SDK has limit random number generating functionality. In Section 5.4, we discuss two programming features: randomness and streaming. These features have been used in other
sections but a thorough discussion is necessary in this example. A portion of the definitions and
theorems used in this chapter can be found in Appendix E. The code used in this chapter is found
in Appendix F.

5.1

Model
This section will introduce the probit model with the horseshoe prior. We will further

decompose the horseshoe prior into inverse gamma distributions to simplify our conversion to GPU
acceleration. Lastly, we present the likelihood function. The probit model proposed by Terenin,
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Dong and Draper [67] is

yi |zi = round[Φ(zi )],
zi |xi , β ∼ N (xi β, 1),
zi ⊥ z−i |β

(5.1)

where the priors from Carvalho, Polson and Scott [91] are

βj |λj , τ ∼ N (0, λ2j τ 2 ),
λj ∼ C + (0, 1),
τ ∼ C + (0, 1).

(5.2)

The parameter estimation for this problem is easier than our earlier work in Chapter 2,
but not trivial.

In order to make a Gibbs sampler GPU ready, we augment the prior distri-

butions. The Cauchy distribution is difficult to directly sample from so we further decompose
λ2j |νj ∼ IG(1/2, 1/νj ) and νj ∼ IG(1/2, 1) and τ 2 | ∼ IG(1/2, 1/) and  ∼ IG(1/2, 1). The
decomposition is outlined using the theorems in Appendix E.

5.1.1

Posterior Computation
Now that we have established our model along with the prior, we write the likelihood then

the posterior and conditional posterior distributions. We are able to compute conditional posterior
distributions for every parameter. We use a Gibbs sampler and avoid any Metropolis-Hasting steps
since we have conditional posterior distributions for every parameter.
First we have the following augmented likelihood function for probit regression from Albert
and Chib [55]:

π(y|Z, β) =

N
Y

{1(Zi > 0)1(yi = 1) + 1(Zi ≤ 0)1(yi = 0)}φ(Zi |xi β, 1).

i=1

We combine the likelihood function and the priors to get the full the posterior as follows:

π(Z, β|y) ∝ π(β)

N
Y

{1(Zi > 0)1(yi = 1) + 1(Zi ≤ 0)1(yi = 0)}φ(Zi |xi β, 1)

i=1
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(5.3)

=

p
Y

N (βj |0, λ2j τ 2 )IG(λ2j |1/2, νj−1 )IG(νj |1/2, 1)IG(τ 2 |1/2, −1 )IG(|1/2, 1)

j=1

×

N
Y

{1(Zi > 0)1(yi = 1) + 1(Zi ≤ 0)1(yi = 0)}N (zi |xi β, 1, yi )

(5.4)

i=1

From the full posterior, we derive the full conditional posteriors as follows:

zi ∼ T N (xi β, 1, yi )
τ

−2

∼ IG

p + 1 1 1 X βj2
, +
2

2
λ2j

!

1
+ 1)
τ2
βj2
1
λ2j ∼ IG(1, 2 + )
2τ
νi
1
νj ∼ IG(1, 2 + 1)
λj

 ∼ IG(1,

β ∼ N (ΣX T z, Σ)

(5.5)


−2 −1
.
where Σ = X T X + τ −2 diag(λ−2
1 , . . . , λp )
For inference, we create a Gibbs sampler with full conditional posteriors. From the above
list of conditional posterior distributions, we see that we need to sample from a normal distribution,
truncated normal distribution, exponential and inverse gamma distribution. Notice that many of
the posterior distributions are listed as inverse gamma. When the shape is one for an inverse gamma
distribution, it is equivalent to an exponential distribution. In the next section, we review sampling
methods for those distributions to complete the Markov chain Monte Carlo method.

5.2

Distributions
From the previous section, we need to sample from a normal distribution, truncated normal

distribution, and inverse gamma distribution. The CUDA toolkit offers a library for random number generation but not all of the aforementioned distributions. In exchange for performance and
parallelism, there are several of the usual trade-offs. The programmer is responsible for a litany of
tasks with respect to random number generation. These tasks include: selecting the random number
generator, initializing and tracking the starting states for each thread, and transforming the basic
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distributions. The basic distributions available are: the standard uniform, standard normal, log
normal and Poisson distributions. Therefore we spend some time building the distributions we need.
We choose methods that extend the available distributions to our desired distributions utilizing the
built-in sampling methods. When we sample from an exponential distribution, a gamma distribution, or a truncated normal distribution, they all must be derived from a sampling method based
on a uniform or normal distribution.

5.2.1

Exponential
We begin with the exponential distribution. The following Lemma 5.2.1 gives us that the

exponential distribution is a simple transformation of the uniform distribution:
Lemma 5.2.1. If U ∼ U (0, 1), then − log U/λ ∼ Exp(λ).
Proof. We have that P (− log U/λ ≤ u) = P (U ≥ e−λu ) = 1 − FU (e−λu ) = 1 − e−λu .

5.2.2

Truncated Normal
In this subsection, we discuss how to build the truncated normal distribution for (−∞, 0]

and [0, ∞). In order to do this, we use part of the efficient sampler from Li and Ghosh [92]. To
efficiently sample the truncated normal, we combine three samplers: a normal rejection sampler, a
half-normal rejection sampler and a one-sided translated-exponential.
Li and Ghosh [92] method for a truncated normal distribution uses the accept reject algorithm that is outlined in Algorithm 5.1. With the accept reject algorithm, the expected number
Result: Sample from distribution X with density f using accept-reject algorithm
repeat
1) Sample y from Y with density g
2) Sample u from U nif (0, 1)
until u < f (y)/M g(y);
return x=y
Algorithm 5.1: Accept reject algorithm.

of iterations is M . Thus we wish to minimize M whenever possible, or else we waste too much
time rejecting samples. Minimizing M is the reason there are three components to sampling the
truncated normal distribution.
We are interested in sampling from the truncated normal distribution with mean xβ and
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standard deviation 1 on [0, ∞). When we negate the mean, we get the distribution for the support
(−∞, 0]. Hence we focus only on the problem for positive support.
The accept reject algorithm needs four components: a target distribution, a sample distribution, a uniform sampler and M . We begin by writing the target distribution for the truncated
normal as follows:
Definition 1 (Truncated Normal Distribution). Let the mean and variance be µ and σ 2 respectively.
Let x ∈ (a, b). The density is
(x−µ)2

2

T N (x|µ, σ , a, b) =

√ 1
e− 2σ2
2πσ 2
a−µ
Φ( b−µ
σ ) − Φ( σ )

=

φ( x−µ
σ )
σ(Φ( b−µ
σ )

− Φ( a−µ
σ ))

and the distribution is
FX (x|µ, σ 2 , a, b) =

a−µ
Φ( x−µ
σ ) − Φ( σ )
a−µ
Φ( b−µ
σ ) − Φ( σ )

.

Furthermore, we simplify our target distribution under a linear transform to align our target
distribution with the sample distribution. In our case the sample distribution is a standard normal
distribution. We have the following lemma to transform the truncated normal:
Lemma 5.2.2. If X is from T N (µ, σ 2 , 0, ∞) then

X−µ
σ

is from T N (0, 1, − σµ , ∞).

Proof. We have that the density for X is

fX (x) = R
b

√ 1
e−
2πσ 2

√ 1
e−
a
2πσ 2

(x−µ)2
2σ 2
(x−µ)2
2σ 2

.

(5.6)

dx

Then the density of (X − µ)/σ is fX (xσ + µ)σ or
2

f(X−µ)/σ (x) =

x
√1 e− 2
2π
0−µ
Φ( ∞−µ
σ ) − Φ( σ )

2

=
1

x
√1 e− 2
2π
.
− µ −0
− Φ( σ1 )

(5.7)

Let −µ/σ = a. Then we optimize T N (0, 1, a, ∞) for three cases which gives the three
sampling distributions that combine to the truncated normal.
1. If a < 0, then let x ∼ N (0, 1) and let the accept reject sampler reject if x ∈ (−∞, a). We have
that T N (0, 1, a, ∞) ≤

1
1−Φ(a) N (0, 1).

Thus the probability of acceptance is 1/M = 1 − Φ(a).
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2. If 0 ≤ a < a∗ , then let x ∼ N (0, 1) and take |x| and let the accept reject sampler reject
if |x| < a. The density of the half normal is 2φ(x)1(x > 0). We have T N (0, 1, a, ∞) ≤
1
2(1−Φ(a)) 2φ(x)1(x

> 0). Thus the probability of acceptance is 1/M = 2(1 − Φ(a)). Hence

when a > 0 we use the half normal sampler as it is twice as efficient.
3. If a∗ < a, then we sample from the translated exponential density gY (y). The accept reject
2

sampler condition rejects if u > e−(y−λ) /2 . The density for the translated exponential is
√
2
λ2
1
λe−λ(y−a) 1(y > a). We can choose M
= 2πλe− 2 +λa (1−Φ(a)), giving f /M g = e−(x−λ) /2 ≤
1. Hence for x > a we may maximize 1/M with a choice of λ =

√
a+ a2 +4
.
2

We choose a∗ for when the acceptance probability of the half√normal
and the translated
!
exponential are equal. Thus we have 2(1 − Φ(a)) =

√

√
2
2π a+ 2a +4 e−

a+

a2 +4
2
2

2

√

+a

a+

a2 +4
2

(1 − Φ(a))

or a∗ ≈ 0.2570. With our choice of a∗ , it is the optimal value of a∗ that minimizes M or the mean
number of iterations needed to accept a value. Finally we have the truncated normal distribution
in terms of the standard normal and exponential density.

5.2.3

Inverse-Gamma
Finally, we discuss how to build the inverse-gamma distribution. We will use Cheng’s

algorithm for sampling the gamma distribution from G(α, 1) [2]. We then divide by the rate
parameter to get G(α, β).
Result: Sample from Gamma(α, 1) distribution
repeat
1) Generate a pair of uniform random numbers, U1 and U2 .
2) Set V = a log U1 (1 − U1 ) and X = αeV
until b + cV − X < log(U12 U2 );
return X
Algorithm 5.2: Sample from the Gamma distribution by an algorithm introduced by Cheng
[2].
To generate τ −2 , we do not have a high acceptance rate for the method from Cheng [2].
Terenin, Dong and Draper [67] suggests to generate blocks of 32 candidates, check them and use the
first available one. This requires local memory between the 32 threads that is faster then the global
memory.
Each thread proceeds to generate a candidate, checks if it works, and sets a local flag if true.
Once every thread is done producing a candidate, the first thread sees if any of the other threads
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found a candidate. If an acceptable candidate is found, it exits the process and if not, it restarts
the process. We include a wall to block all threads until the threads are finished each iteration. The
wall is not necessary if all the threads are on a warp. Hence we generate 32 candidates in the time
it takes for one candidate to be produced with a little overhead to sync and to find the correct one.

5.3

Algorithm
The parallel algorithm for the horseshoe probit E.1 is quite complicated because we add

parallelism to all matrix operations as well as generate distributions in a parallel manner. For
example, we use 8 CUDA functions to sample β. The operations to copy a matrix, add matrices,
multiply a matrix and a vector, dot product, solve dense linear systems, and solve upper triangular
systems are built in functions that have been optimized for parallelism. Additionally, we wrote
several custom CUDA kernels to independently sample all other distributions.

5.4

Implementation
The previous sections introduced the algorithms to sample from several distributions that

are not built by the CUDA SDK. In this section, we learn how to implement them in the CUDA
programming environment while taking advantage of the hardware whenever possible. In Subsection
5.4.1, we focus on setting up random number generation and the built in random distributions. In
Subsection 5.4.2, we delve deeper into optimally streaming data in and out of the GPU device.

5.4.1

cuRand
Part of the CUDA SDK is the cuRand library. The cuRand functions allow the GPU to

generate random numbers. There are a few lines to setup a random number generator. First we must
select the type or method of random number generation and the seed. Since the GPU uses SIMD,
we have to be careful that when there are multiple threads running that each thread is generating
a different random numbers. To do this, we use a state of the random generator which is composed
of the seed, the sequence, and the offset in the sequence. This way we are guaranteed that each
state will generate a different random sequence. Moreover the states will remain where they are in
the sequence and multiple subsequent calls to the state will produce different parts of the random
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sequence. This allows for it to be initialized once and not repeat itself. We choose to assign each
thread a different sequence with no offset.
In the following code, we create the device states, choose our generator, select the random
seed and destroy our generator.
c u r a n d G e n e r a t o r t gen ;
curandState t ∗ d states ;
c u r a n d C r e a t e G e n e r a t o r (&gen , CURAND RNG PSEUDO PHILOX4 32 10) ;
curandSetPseudoRandomGeneratorSeed ( gen , 1234ULL) ; // s e t t o time
...
c u r a n d D e s t r o y G e n e r a t o r ( gen ) ;
Once the generator, and seed are selected, we can initialize a unique random number state
for every thread. The state is used to generate random numbers from the builtin functions that will
be unique for every thread.
/∗ I n i t i a l i z e random number g e n e r a t o r ∗/
global

void i n i t ( unsigned int seed , c u r a n d S t a t e t ∗ d s t a t e s ) {

int i d x = t h r e a d I d x . x +blockDim . x ∗ b l o c k I d x . x ;
c u r a n d i n i t ( seed , idx , 0 , &d s t a t e s [ i d x ] ) ;
}
Later on in the main loop, we generate random samples two different ways. Either we
generate random numbers using function calls in custom kernels or using function calls from the
host device. When we use function calls in kernels, every kernel must be given a pointer to the state
of the random sequence. We use the thread identifier to recall the state with the proper sequence.
In the following code snippet, we used the states and thread index to sample z in the kernel. To
sample a random number, each thread feeds its thread index into the appropriate state and then
that state is used to draw the next random number.
/∗ Sample normals ∗/
global

void s a m p l e z ( c u r a n d S t a t e t ∗ d s t a t e s , int ∗d Y , double ∗d mu

,→ , double ∗ d z ) {
int i d x = t h r e a d I d x . x + blockDim . x ∗ b l o c k I d x . x ;
...
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d s = c u r a n d n o r m a l d o u b l e (& d s t a t e s [ i d x ] ) ;
...
}
Alternatively, from the host we can ask for a set of n random samples to be generated on
the device. After the random samples are generated we can simply use a pointer to determine where
they are in memory to read them later.
/∗ Sample 2p + 1 uniform random v a r i a b l e s ∗/
curandGenerateUniformDouble ( gen , d uniform , p + p + 1 ) ;

5.4.2

Streaming
For the NVIDIA GPU, transferring data from device and host and floating point calculations

in the core are not dependent operations. Therefore we can transfer memory data while other nonblocking processes can be done simultaneously. This process is called streaming.
We set up two streaming handles for this application. The following code sets up and
destroys the streams:
cudaStream t stream1 ;
cudaStream t stream2 ;
cudaStreamCreate (& stream1 ) ;
cudaStreamCreate (& stream2 ) ;
...
cudaStreamDestroy ( stream1 ) ;
cudaStreamDestroy ( stream2 ) ;
We interleave the streams for several operations. For example allocating memory and copying into memory are separate operations. We move several variables onto the device. While we
allocate up the memory for one variable, we begin queuing up memory copies.
/∗ A l l o c a t e s p a c e f o r t a u s q u a r e i n v e r s e ∗/
cudaMalloc ( ( void ∗ ∗ )&d t a u s q u a r e i n v e r s e , s i z e o f ( double ) ) ;
cudaMemcpyAsync ( d t a u s q u a r e i n v e r s e , &t a u s q u a r e i n v e r s e , s i z e o f ( double
,→ ) , cudaMemcpyHostToDevice , stream1 ) ;
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/∗ A l l o c a t e s p a c e f o r v i n v e r s e ∗/
cudaMalloc ( ( void ∗ ∗ )&d v i n v e r s e , p ∗ s i z e o f ( double ) ) ;
c u b l a s S e t V e c t o r A s y n c ( p , s i z e o f ( double ) , v i n v e r s e , 1 , d v i n v e r s e , 1 ,
,→ stream2 ) ;
Another instance when streaming improves performance is when retrieving results from the
device back to the host. After every update of β (t) , the results are sent back to the host while
one can proceed with another computation. This reduces the memory needed on the device side
as one does not have to store every iteration of β (t) . Additionally, it saves time at the end of the
computation to move the entire chunk of memory back to the host.
/∗ S t e p v i i i : Compute Beta = Rs + mu ∗/
cublasDaxpy ( handle , p , d one , d s , 1 , d XTz , 1 ) ;
cublasGetVectorAsync ( p , s i z e o f ( double ) , d XTz , 1 , s t o r e + t ∗ p , 1 ,
,→ stream1 ) ;

5.5

Performance
We use the following probit population model to evaluate our estimation methodology:

Yi ∼ Bernoulli(Φ(x0i β))

(5.8)

where with xi is a vector of size d generated from the standard normal, that is xij ∼ N (0, 1), and β
is a vector of size d with mostly zeros. We generate the data {(Yi , Xi )} for i = 1, . . . , N . We choose
n = 104 and d = 103 . We set β = (1.3, 4, −1, 1.6, 5, −2, 0, . . . , 0)0 .
We perform and retain 100,000 posterior draws. Even with a small example such as this we
see significant differences in the languages. See Table 5.1. Although almost ever step uses parallelism,
the most significant speed ups are from the Cholesky decomposition, inverting the correlation matrix,
and sampling the truncated normal. Both the Cholesky decomposition and the solve are for matrices
of size d×d. Since we use a large d = 103 ), we can expect parallelism to gain an advantage. Moreover,
a significant amount of time in the R solve method is used to check inputs and choose the solve
method for every iteration. Whereas we choose the solve method without checks. Lastly, we sample
n = (104 ) independent truncated normal distributions. Independence allows us to divide n by the
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Language
R
CUDA

Min
1569.2530
147.7432

1-Quartile
1597.0731
148.2983

Mean
1619.3852
148.5039

Median
1607.5422
148.2989

3-Quartile
1624.1556
148.7514

Max
1698.9023
149.4278

Table 5.1: The table shows the timings for five runs of the horseshoe probit MCMC in two implementations. The R implementation is written for a single processor and the CUDA implementation
is written using a parallel algorithm. Timings are for 1,000 iterations, 10,000 observations with 100
covariates. All timings are displayed in seconds.
number of threads to perform the work instead of computing them sequentially. In Appendix F, we
have the link to the code for our tests.
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Chapter 6

Future Directions
There are a couple areas to improve upon for group testing. First, while our estimations
are fast, they can be improved upon with GPU acceleration. The measurement for group testing
can be switched to included dilution effects. The correlation of the disease can include risk factors.
Lastly, there are several opportunities to improve variable selection and estimation.
Our methodology for group testing is a computationally intensive process and takes time to
run. Our next steps are to increase its performance using GPU acceleration. In order to use GPU
acceleration, we have to identify areas for parallelization. In general there are three areas that we
can improve. If sections are independent, we can use threads to compute them in parallel. If we use
matrix operations, we can use built in matrix libraries to accelerate the computation. If there is an
aggregation function, we have opportunities to parallelize the aggregation.
For Markov chain Monte Carlo methods, every iteration depends on the state of the last
iteration. This dependence prevents us from parallelizing the iterations. In addition there are global
parameters that need to be estimated at every iteration such as R and β that must be sampled
before continuing. Hence we focus on parallelization opportunities on a parameter by parameter
basis.
We have three sets of global parameters R, β and to a lesser extent the sensitivities and specificities. All global parameters have different opportunities for GPU acceleration. The MetropolisHastings steps in sampling R depend on a sequential process for each ρrs to be computed. We could
simultaneously sample ρrs for all rs, but we would risk bad mixing and failing to converge to our
target distribution. Hence in the case of R we do not have independent pieces that have paralleliza64

tion opportunities at a high level. One can only benefit from GPU accelerated matrix operations
and computing expensive aggregation functions. For the case of sampling the β distribution we
simultaneously sample. Therefore, we can only take advantage of matrix operations and aggregation
functions required to sample β. When computing sensitivity and specificity there is an opportunity
to compute the disease index and specimen type independently. Moreover if the ordering of the
group size does not affect other sensitivities and specificities, that is we do not use a truncated beta
distribution with upper and lower bounds, then we can independently compute the specificities and
sensitivies by group size. Each instance were we have independence, we can use separate threads to
compute in parallel.
At the individual levels, sampling can sometimes offer more opportunities because they are
independent along the patient or disease dimension. When sampling γ, we can independently sample
each patient. The most complicated sampling occurs when computing the true disease status. To
parallelize this step, we have to identify disjoint sets of pools. A disjoint set of pools is where there
is a patient can only be present in the pool set. This ensures that when a patients status is updated
then it will be available to the other patients in the pool set when their status is updated. In
our simulation and case study, we had many disjoint pools sets. Small disjoint sets of pools are a
characteristic for our testing schemas. For instance in Dorfman group testing the group pool and
the dependent individual pools would be set of pools disjoint from all other sets of pools. Hence
we can parallellize easily. In a general setting, a simple computation can be performed before the
MCMC to determine the number of threads. We assign pools that have common patients a counting
index. For every available thread, we assign the next counting index. Beyond the independence
within pools, we can add parallelism on the disease index. For each disease. we can independently
compute the true disease status of the patients. This is because we only need to know the mean for
the disease to compute the true disease status.
When performing group testing, one has to set a threshold for the classification specimen.
Since we are interested in parameter estimation instead of classification, we can capture biomarker
levels such as nucleic acid concentrations. This will allow us to use richer information as well
as directly address the dilution effect and to prevent any issues with the threshold choice for the
pool. The correlation between diseases is assumed to be universal, however there may be additional
correlations in sub populations. We could explore was to add a dependence for every patient on the
correlations.
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Finally, there are several ways to improve estimation performance. During the exploration
of this paper we experimented with variable selection. As more information is collected in medical
records, more predictors are available to the model. Variable selection can bring forward and help
isolate the most important risk factors. Spike and slab variable selection shows some promise but
was computationally too expensive during early stages of this work. Additionally, we did not explore
interactions or other higher order effects.
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Appendix A

Group Testing Algorithms

Finally, we write the Metropolis-Hastings algorithms for both the probit and logistic distributions. Most of our parameters are updated once per iteration in the Monte Carlo Markov Chain.
(t)

For each iteration, we use the superscript (t) as in yeid to indicate the tth iteration of yeid . The
complications of indexing our data structures mean parameters such as zejd be updated |Pj | times
every iteration. Thus the superscript (t∗ ) indicates an intermediate iteration between t and t + 1.
Additionally, R is updated D(D−1)/2 times; therefore, we use the (tk ) notation for the intermediate
iteration k ∈ [D(D − 1)/2] . We use (?) (star) to indicate the proposal on the (tk ) iteration. We
sample ρrs on a uniform random walk with reflective boundaries −1 and 1 with step size δ = 0.05.
We write the probit model algorithm as follows:
(0)

= 0 and β (0) = 0 for the ith patient and set R(0) = I2 .
(
)
(t∗ )
(t∗ )

1(x+P ye(−i)d
1−1(x+P ye(−i)d
)
)
Q
Zjd 1−Zjd
1−Zjd Zjd
x
2. Let gid (x) =
Spj :d S pj :d
p1−x
j∈Ai Sej :d S ej :d
id0 (1−pid0 )

1. Initialize Ti

for x ∈ {0, 1}.
For all d = 1, . . . , D and for all i = 1, . . . , N :
(t+1)

(a) Sample Tid

(t)

(t)

(t+1)

∼ N (µ̃id , Σ̃id )I(Tid

(t)

(t+1)

> 0)yeid I(Ti1

(t)

≤ 0)1−eyid .

(t+1)
(b) Sample Yeid
∼ Bernoulli [gid (1)/ {gid (0) + gid (1)}].

n
o−1
PN
0
(t) −1
3. Sample β (t+1) ∼ NQ (µ̃(t) , Σ̃(t) ) where Σ̃(t) = Σ−1
+
X
(R
)
X
and
i
0
i
i=1
nP
o
N
0
(t) −1 (t+1)
µ̃(t+1) = Σ̃(t)
Ti
.
i=1 Xi (R )
(t)

(t+1)

(t)

4. Sample ρ?rs from [ρrs − δ, ρrs + δ]. Set ρrs
(
min 1,

(t+1)

Otherwise ρrs

= ρ?rs with probability

(t+1)
, R? )
i=1 N (µi
QN
(t+1)
, R(tk ) )
i=1 N (µi

QN

)
.

(t)

= ρrs .

5. Go to step 2.
The logit algorithm is similar to the probit algorithm but with extra steps for φ and the
importance sampling weights. Moreover the importance weights produce not a number results in R.
This is caused by an infinite return value from the student-t quantile function. When we encounter
an infinite return value we substitute a large positive number.
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(0)

(0)

= 0 and β (0) = 0, φi

1. Initialize Ti

(t+1)

2. Sample φi

h
n
o i
(t+1)
(t)
(t+1)
(t)
∼ Γ (ν̃ + 2)/2, ν̃ + σ̃ −2 (Ti
− µi )0 (R(t) )−1 (Ti
− µi ) /2 for all i.

(



Q

3. Let gid (x) =

∼ Γ(ν̃/2, ν̃/2) for the ith patient and set R(0) = I2 .

j∈Ai

1−Zjd
Z
Sejjd
:d S ej :d

(t∗ )
1(x+P ye(−i)d
)

)
(t∗ )
1−1(x+P ye(−i)d
)
1−Zjd Zjd
x
Spj :d S pj :d
p1−x
id0 (1−pid0 )

for x ∈ {0, 1}.
For all d = 1, . . . , D and for all i = 1, . . . , N :
(t+1)

(a) Sample Tid

≈ (t)

≈

(t)

(t+1)

∼ N (µid , Σid )I(Tid

(t)

(t+1)

> 0)yeid I(Ti1

(t)

≤ 0)1−eyid .

(t+1)
(b) Sample Yeid
∼ Bernoulli [gid (1)/ {gid (0) + gid (1)}].

n
≈
≈
PN (t+1) 0 (t) −1 o−1
≈
−2
Xi (R ) Xi
4. Sample β (t+1) ∼ NQ (µ(t) , Σ(t) ) where Σ0(t) = Σ−1
and
0 + σ̃
i=1 φi
n
o
≈
P
≈ (t+1)
(t+1)
(t+1)
N
µ
= Σ(t) σ̃ −2 i=1 φi
X0i (R(t) )−1 Ti
.
(t+1)

(t)

(t)

5. Sample ρ?rs from [ρrs − δ, ρrs + δ]. Set ρrs
(
min 1,

(t+1)

Otherwise ρrs

= ρ?rs with probability

(t+1)
(t+1) ?
, σ̃ 2 φi
R )
i=1 N (µi
QN
(t+1)
(t+1) (tk )
2
, σ̃ φi
R )
i=1 N (µi

QN

)
.

(t)

= ρrs .

6. Compute w(t+1) ∝

QN

i=1

(t+1)

L2,ν̃ (Ti

(t+1)

; µi , R(t+1) )/T2,ν̃ (Ti

; µi , σ̃ 2 R(t+1) ).

7. Go to step 2.
To add the sampling for testing accuracies, we add the following steps for independent test
configurations.
1. Compute 

 X

X
(t+1)
(t+1)
(t+1)
Se(l):d ∼ f
Zjd zejd + T Pl,d ,
(1 − Zjd )e
zjd + F Nl,d , 0, 1 for all d and l.


j∈M(l)

j∈M(l)

2. Compute
(t+1)

Sp(l):d ∼ f


 X


(t+1)

(1 − Zjd )(1 − zejd

) + T Nl,d ,

j∈M(l)

X
j∈M(l)



(t+1)
Zjd (1 − zejd ) + F Pl,d , 0, 1 for all


d and l.
If we want to include a dilution effect, we instead add the following:
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1. Compute 

 X

X
(t+1)
(t+1)
(t+1)
Se(l):d ∼ f
Zjd zejd + T Pl,d ,
(1 − Zjd )e
zjd + F Nl,d , Ae(l):d , Be(l):d for all d


j∈M(l)

j∈M(l)

and l.
2. Compute 

 X

X
(t+1)
(t+1)
(t+1)
Sp(l):d ∼ f
(1 − Zjd )(1 − zejd ) + T Nl,d ,
Zjd (1 − zejd ) + F Pl,d , Ap(l):d , Bp(l):d


j∈M(l)

j∈M(l)

for all d and l.
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Appendix B
Scenario

1

Test Rows and Columns

Re-Test Positive Column

NN

PP

NN

NN

NN

NN

◦

◦

◦

◦

◦

NN

◦

◦

◦

◦

NN

◦

◦

◦

NN

◦

◦

NN

◦

◦

Scenario

2

Simulation Data

NN

PP

NN

NN

NN

NN

◦

NN

◦

◦

◦

◦

NN

◦

NN

◦

◦

◦

◦

◦

NN

◦

NP

◦

◦

◦

◦

◦

◦

NN

◦

PN

◦

◦

◦

◦

◦

◦

NN

◦

NN

◦

◦

◦

Test Rows and Columns

Re-Test Intersections

NN

PP

NN

NN

NN

NN

PP

NN

NN

NN

NN

◦

◦

◦

◦

◦

NN

◦

◦

◦

◦

◦

PN

◦

◦

◦

◦

◦

PN

◦

NN

◦

◦

◦

NP

◦

◦

◦

◦

◦

NP

◦

NP

◦

◦

◦

NN

◦

◦

◦

◦

◦

NN

◦

◦

◦

◦

◦

NN

◦

◦

◦

◦

◦

NN

◦

◦

◦

◦

◦

Figure B.1: Each table represents a part of the process for testing a square five by five array. Each
row represents the different scenarios for the last stage. The first table in each row is the result
of testing rows and columns. The results of the row and column are labeled as row and column
headers with N and P for negative and positive for each of the two diseases. The second table in
each row represents which individuals are tested and their test results are labeled on the interior
of the table. In the first scenario, only a column test positive, then the testing procedure dictates
that every individual is tested in the column. In the second scenario, a column and two rows test
positive, then the testing procedure dictates that every individual in the intersection is tested. In
both cases, we classify the remaining individuals as negative for both diseases.

The following tables contain the data for the synthetic calibration and Iowa clinical results.
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Parameter

IT
Prevalence
Average number of tests

β 10 = −2.1

β 11 = 0.5

β 12 = 0.5

β 20 = −1.7

β 21 = 0.5

β 22 = 0.5

ρ = 0.3

MPT

DT

AT

d1 = 0.05 d2 = 0.10
5008

1252

3573.4

3863.6

Bias (CP95)

-0.0529 (0.94)

0.0844 (0.87)

-0.0166 (0.96)

-0.0138 (0.95)

SSD (ESE)

0.1301 (0.1276)

0.1404 (0.1275)

0.0787 (0.0778)

0.0670 (0.0696)

Bias (CP95)

0.0184 (0.93)

-0.0191 (0.92)

0.0061 (0.96)

0.0069 (0.96)

SSD (ESE)

0.0637 (0.0619)

0.0721 (0.0703)

0.0435 (0.0445)

0.0396 (0.0404)

Bias (CP95)

0.0289 (0.96)

-0.0044 (0.95)

0.0130 (0.95)

0.0103 (0.95)

SSD (ESE)

0.1209 (0.1195)

0.1728 (0.1568)

0.0866 (0.0839)

0.0777 (0.0768)

Bias (CP95)

-0.0120 (0.94)

0.0158 (0.94)

-0.0072 (0.94)

-0.0067 (0.92)

SSD (ESE)

0.0630 (0.0597)

0.0875 (0.0845)

0.0521 (0.0497)

0.0504 (0.0477)

Bias (CP95)

0.0035 (0.95)

0.0018 (0.95)

0.0014 (0.96)

0.0010 (0.95)

SSD (ESE)

0.0347 (0.0357)

0.0563 (0.0549)

0.0306 (0.0313)

0.0296 (0.0301)

Bias (CP95)

0.0054 (0.93)

0.0095 (0.95)

0.0040 (0.94)

0.0043 (0.92)

SSD (ESE)

0.0696 (0.0651)

0.1147 (0.1117)

0.0621 (0.0582)

0.0602 (0.0564)

Bias (CP95)

-0.0045 (0.94)

-0.0256 (0.94)

-0.0042 (0.94)

-0.0035 (0.95)

SSD (ESE)

0.0676 (0.0647)

0.0837 (0.0852)

0.0526 (0.0516)

0.0483 (0.0477)

Table B.1: Known assay accuracy probabilities Se(1):1 = 0.94, Se(2):1 = 0.90, Se(1):2 = 0.98, Se(2):2 =
0.96 and Sp(1):1 = 0.93, Sp(2):1 = 0.95, Sp(1):2 = 0.97, Sp(2):2 = 0.98 (imperfect testing) and unknown
ρ = 0.3. Average bias of 500 posterior mean estimates (Bias), sample standard deviation of 500
posterior mean estimates (SSD), average of 500 estimates of the posterior standard deviation (ESE),
and empirical coverage probability (CP95) of 95% equal-tail credible intervals are given for each
estimated parameter when possible. The total number of individuals is N = 5008 with disease
status generated by probit population model. Prevalence of each disease in the population are
given. For Dorfman testing (DT) and array testing (AT) the average number of tests are shown.
Master pool testing (MPT), DT and AT uses master pools of size 4.
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Parameter

IT
Prevalence
Average number of tests

MPT

DT

AT

d1 = 0.05 d2 = 0.10
5008

1252

3578.2

3864.1

β 10 = −2.1

Bias (CP95)

-0.1548 (0.91)

-1.0792 (0.73)

0.0062 (0.96)

-0.0059 (0.96)

SSD (ESE)

0.8121 (0.3567)

2.2442 (0.7457)

0.0874 (0.0947)

0.0700 (0.0744)

β 11 = 0.5

Bias (CP95)

0.3086 (0.76)

0.4721 (0.58)

0.0053 (0.95)

0.0024 (0.95)

SSD (ESE)

0.4574 (0.2237)

0.7977 (0.3271)

0.0454 (0.0458)

0.0407 (0.0406)

β 12 = 0.5

β 20 = −1.7

β 21 = 0.5

β 22 = 0.5

ρ = 0.3

Se(1):1 = 0.94

Se(2):1 = 0.90

Se(1):2 = 0.98

Se(2):2 = 0.96

Sp(1):1 = 0.93

Sp(2):1 = 0.95

Sp(1):2 = 0.97

Sp(2):2 = 0.98

Bias (CP95)

0.3704 (0.83)

1.0090 (0.69)

0.0079 (0.97)

0.0040 (0.96)

SSD (ESE)

0.7437 (0.2949)

1.9803 (0.6553)

0.0827 (0.0851)

0.0766 (0.0769)

Bias (CP95)

0.0580 (0.94)

-0.2887 (0.91)

0.0080 (0.97)

-0.0013 (0.96)

SSD (ESE)

0.1555 (0.1597)

0.4013 (0.3138)

0.0533 (0.0561)

0.0482 (0.0490)

Bias (CP95)

0.1356 (0.79)

0.2536 (0.65)

0.0020 (0.95)

0.0003 (0.93)

SSD (ESE)

0.0909 (0.1101)

0.2321 (0.1787)

0.0323 (0.0318)

0.0322 (0.0302)

Bias (CP95)

0.1343 (0.88)

0.2946 (0.78)

0.0018 (0.96)

-0.0004 (0.95)

SSD (ESE)

0.1145 (0.1296)

0.3244 (0.2623)

0.0570 (0.0586)

0.0549 (0.0564)

Bias (CP95)

0.2173 (0.70)

0.1689 (0.69)

-0.0106 (0.95)

-0.0071 (0.95)

SSD (ESE)

0.1369 (0.1463)

0.3227 (0.2008)

0.0543 (0.0526)

0.0500 (0.0483)

Bias (CP95)

-0.3728 (0.72)

-0.0218 (0.97)

-0.0051 (0.95)

SSD (ESE)

0.1135 (0.1734)

0.0345 (0.0442)

0.0233 (0.0240)

Bias (CP95)

-0.3165 (0.76)

-0.0142 (0.96)

-0.0040 (0.94)

SSD (ESE)

0.1596 (0.1393)

0.0454 (0.0523)

0.0233 (0.0233)

Bias (CP95)

-0.2685 (0.55)

-0.0101 (0.99)

-0.0028 (0.97)

SSD (ESE)

0.0863 (0.1382)

0.0113 (0.0172)

0.0089 (0.0097)

Bias (CP95)

-0.1850 (0.81)

-0.0114 (0.97)

-0.0021 (0.95)

SSD (ESE)

0.0933 (0.1029)

0.0219 (0.0265)

0.0104 (0.0107)

Bias (CP95)

-0.0053 (0.87)

-0.0002 (0.95)

-0.0003 (0.93)

SSD (ESE)

0.0090 (0.0089)

0.0074 (0.0077)

0.0093 (0.0089)

Bias (CP95)

-0.0994 (0.59)

0.0031 (0.97)

0.0002 (0.95)

SSD (ESE)

0.1595 (0.0380)

0.0113 (0.0125)

0.0070 (0.0071)

Bias (CP95)

-0.0059 (0.90)

0.0002 (0.97)

-0.0010 (0.95)

SSD (ESE)

0.0091 (0.0096)

0.0059 (0.0064)

0.0073 (0.0075)

Bias (CP95)

-0.0874 (0.78)

0.0019 (0.98)

-0.0003 (0.97)

SSD (ESE)

0.0834 (0.0474)

0.0065 (0.0084)

0.0051 (0.0053)

Table B.2: Unknown assay accuracy probabilities Se(1):1 = 0.94, Se(2):1 = 0.90, Se(1):2 = 0.98,
Se(2):2 = 0.96 and Sp(1):1 = 0.93, Sp(2):1 = 0.95, Sp(1):2 = 0.97, Sp(2):2 = 0.98 (imperfect testing) and
unknown ρ = 0.3. Average bias of 500 posterior mean estimates (Bias), sample standard deviation
of 500 posterior mean estimates (SSD), average of 500 estimates of the posterior standard deviation
(ESE), and empirical coverage probability (CP95) of 95% equal-tail credible intervals are given for
each estimated parameter when possible. The total number of individuals is N = 5008 with disease
status generated by probit population model. Prevalence of each disease in the population are given.
For Dorfman testing (DT) and array testing (AT) the average number of tests are shown. Master
pool testing (MPT), DT and AT uses master pools of size 4.
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Parameter

DT no order
Prevalence
Average number of tests

DT order

AT no order

AT order

d1 = 0.05 d2 = 0.10
3573.3

3573.3

3864.4

3864.4

β 10 = −2.1

Bias (CP95)

0.0069 (0.96)

0.0135 (0.96)

-0.0053 (0.95)

-0.0028 (0.95)

SSD (ESE)

0.0922 (0.0950)

0.0920 (0.0952)

0.0735 (0.0742)

0.0735 (0.0743)

β 11 = 0.5

Bias (CP95)

0.0041 (0.95)

0.0035 (0.94)

0.0017 (0.95)

0.0017 (0.95)

SSD (ESE)

0.0462 (0.0457)

0.0463 (0.0456)

0.0398 (0.0405)

0.0398 (0.0405)

β 12 = 0.5

β 20 = −1.7

β 21 = 0.5

β 22 = 0.5

ρ = 0.3

Se(1):1 = 0.94

Se(2):1 = 0.90

Se(1):2 = 0.98

Se(2):2 = 0.96

Sp(1):1 = 0.93

Sp(2):1 = 0.95

Sp(1):2 = 0.97

Sp(2):2 = 0.98

Bias (CP95)

0.0102 (0.95)

0.0095 (0.95)

0.0033 (0.95)

0.0032 (0.95)

SSD (ESE)

0.0861 (0.0851)

0.0856 (0.0849)

0.0762 (0.0767)

0.0762 (0.0769)

Bias (CP95)

0.0025 (0.97)

0.0058 (0.97)

-0.0046 (0.96)

-0.0037 (0.97)

SSD (ESE)

0.0533 (0.0562)

0.0529 (0.0565)

0.0479 (0.0491)

0.0477 (0.0492)

Bias (CP95)

0.0026 (0.96)

0.0033 (0.96)

0.0013 (0.95)

0.0017 (0.95)

SSD (ESE)

0.0313 (0.0319)

0.0313 (0.0319)

0.0295 (0.0303)

0.0296 (0.0303)

Bias (CP95)

0.0071 (0.96)

0.0076 (0.96)

0.0041 (0.96)

0.0044 (0.96)

SSD (ESE)

0.0583 (0.0587)

0.0584 (0.0588)

0.0565 (0.0565)

0.0566 (0.0566)

Bias (CP95)

-0.0064 (0.95)

-0.0090 (0.95)

-0.0045 (0.95)

-0.0068 (0.94)

SSD (ESE)

0.0518 (0.0525)

0.0518 (0.0525)

0.0485 (0.0482)

0.0487 (0.0482)

Bias (CP95)

-0.0213 (0.99)

-0.0075 (0.99)

-0.0050 (0.96)

0.0008 (0.97)

SSD (ESE)

0.0331 (0.0446)

0.0267 (0.0374)

0.0225 (0.0240)

0.0181 (0.0206)

Bias (CP95)

-0.0180 (0.97)

-0.0376 (0.93)

-0.0024 (0.94)

-0.0073 (0.95)

SSD (ESE)

0.0469 (0.0526)

0.0399 (0.0485)

0.0232 (0.0232)

0.0208 (0.0222)

Bias (CP95)

-0.0091 (0.99)

-0.0065 (0.99)

-0.0033 (0.96)

-0.0015 (0.96)

SSD (ESE)

0.0111 (0.0169)

0.0103 (0.0146)

0.0090 (0.0098)

0.0075 (0.0083)

Bias (CP95)

-0.0115 (0.96)

-0.0199 (0.95)

-0.0025 (0.93)

-0.0048 (0.94)

SSD (ESE)

0.0226 (0.0264)

0.0184 (0.0246)

0.0109 (0.0107)

0.0098 (0.0103)

Bias (CP95)

0.0006 (0.95)

0.0014 (0.95)

-0.0011 (0.96)

-0.0013 (0.97)

SSD (ESE)

0.0079 (0.0077)

0.0074 (0.0074)

0.0088 (0.0089)

0.0080 (0.0085)

Bias (CP95)

0.0029 (0.98)

0.0018 (0.99)

-0.0004 (0.95)

0.0001 (0.95)

SSD (ESE)

0.0107 (0.0126)

0.0088 (0.0107)

0.0069 (0.0071)

0.0065 (0.0069)

Bias (CP95)

-0.0003 (0.95)

-0.0004 (0.96)

-0.0009 (0.95)

-0.0022 (0.97)

SSD (ESE)

0.0064 (0.0064)

0.0058 (0.0061)

0.0076 (0.0075)

0.0064 (0.0070)

Bias (CP95)

0.0017 (0.99)

0.0026 (0.98)

-0.0001 (0.97)

0.0009 (0.97)

SSD (ESE)

0.0064 (0.0084)

0.0052 (0.0069)

0.0050 (0.0053)

0.0046 (0.0049)

Table B.3: Unknown assay accuracy probabilities Se(1):1 = 0.94, Se(2):1 = 0.90, Se(1):2 = 0.98,
Se(2):2 = 0.96 and Sp(1):1 = 0.93, Sp(2):1 = 0.95, Sp(1):2 = 0.97, Sp(2):2 = 0.98 (imperfect testing)
and unknown ρ = 0.3. Assumes ordering for assay accuracies. Average bias of 500 posterior mean
estimates (Bias), sample standard deviation of 500 posterior mean estimates (SSD), average of 500
estimates of the posterior standard deviation (ESE), and empirical coverage probability (CP95)
of 95% equal-tail credible intervals are given for each estimated parameter when possible. The
total number of individuals is N = 5008 with disease status generated by probit population model.
Prevalence of each disease in the population are given. For Dorfman testing (DT) and array testing
(AT) the average number of tests are shown. DT and AT uses master pools of size 4.
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Parameter

IT
Prevalence
Average number of tests

β 10 = −3.3

β 11 = 0.5

β 12 = 0.5

β 20 = −2.55

β 21 = 0.5

β 22 = 0.5

ρ = 0.3

MPT

DT

AT

d1 = 0.05 d2 = 0.10
5008

1252

3566.3

3860.8

Bias (CP95)

-0.0845 (0.94)

0.1335 (0.82)

-0.0261 (0.94)

-0.0172 (0.91)

SSD (ESE)

0.2131 (0.2048)

0.2433 (0.2175)

0.1340 (0.1291)

0.1286 (0.1197)

Bias (CP95)

0.0184 (0.93)

-0.0512 (0.91)

0.0033 (0.94)

0.0047 (0.95)

SSD (ESE)

0.1092 (0.1076)

0.1436 (0.1378)

0.0799 (0.0779)

0.0739 (0.0725)

Bias (CP95)

0.0366 (0.94)

0.0106 (0.93)

0.0148 (0.94)

0.0094 (0.92)

SSD (ESE)

0.2355 (0.2272)

0.3420 (0.3144)

0.1623 (0.1581)

0.1569 (0.1473)

Bias (CP95)

-0.0142 (0.93)

0.0322 (0.90)

-0.0065 (0.93)

-0.0057 (0.92)

SSD (ESE)

0.0970 (0.0934)

0.1488 (0.1431)

0.0834 (0.0819)

0.0811 (0.0793)

Bias (CP95)

0.0049 (0.95)

-0.0095 (0.92)

0.0029 (0.95)

0.0031 (0.94)

SSD (ESE)

0.0552 (0.0571)

0.0985 (0.0985)

0.0508 (0.0516)

0.0511 (0.0502)

Bias (CP95)

0.0048 (0.94)

0.0085 (0.92)

0.0000 (0.95)

-0.0019 (0.95)

SSD (ESE)

0.1140 (0.1129)

0.2256 (0.2111)

0.1032 (0.1024)

0.0997 (0.0996)

Bias (CP95)

0.0023 (0.92)

-0.0301 (0.92)

-0.0009 (0.94)

-0.0023 (0.95)

SSD (ESE)

0.0706 (0.0680)

0.0907 (0.0887)

0.0546 (0.0529)

0.0494 (0.0488)

Table B.4: Known assay accuracy probabilities Se(1):1 = 0.94, Se(2):1 = 0.90, Se(1):2 = 0.98, Se(2):2 =
0.96 and Sp(1):1 = 0.93, Sp(2):1 = 0.95, Sp(1):2 = 0.97, Sp(2):2 = 0.98 (imperfect testing) and unknown
ρ = 0.3. Average bias of 500 posterior mean estimates (Bias), sample standard deviation of 500
posterior mean estimates (SSD), average of 500 estimates of the posterior standard deviation (ESE),
and empirical coverage probability (CP95) of 95% equal-tail credible intervals are given for each
estimated parameter when possible. The total number of individuals is N = 5008 with disease
status generated by logistic population model. Prevalence of each disease in the population are
given. For Dorfman testing (DT) and array testing (AT) the average number of tests are shown.
Master pool testing (MPT), DT and AT uses master pools of size 4.
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Parameter

IT
Prevalence
Average number of tests

MPT

DT

AT

d1 = 0.05 d2 = 0.10
5008

1252

3566.5

3856.4

β 10 = −3.3

Bias (CP95)

0.1087 (0.88)

-0.2441 (0.58)

0.0588 (0.93)

-0.0088 (0.94)

SSD (ESE)

1.5659 (0.8944)

6.1371 (1.7864)

0.1626 (0.1849)

0.1360 (0.1321)

β 11 = 0.5

Bias (CP95)

0.3321 (0.89)

-0.2027 (0.55)

-0.0036 (0.93)

-0.0013 (0.93)

SSD (ESE)

0.9085 (0.3071)

3.9308 (1.0766)

0.0754 (0.0793)

0.0730 (0.0719)

β 12 = 0.5

β 20 = −2.55

β 21 = 0.5

β 22 = 0.5

ρ = 0.3

Se(1):1 = 0.94

Se(2):1 = 0.90

Se(1):2 = 0.98

Se(2):2 = 0.96

Sp(1):1 = 0.93

Sp(2):1 = 0.95

Sp(1):2 = 0.97

Sp(2):2 = 0.98

Bias (CP95)

0.4684 (0.91)

1.2416 (0.60)

0.0167 (0.95)

0.0080 (0.94)

SSD (ESE)

1.3174 (0.5461)

6.5378 (2.0586)

0.1640 (0.1601)

0.1545 (0.1463)

Bias (CP95)

0.1405 (0.93)

-2.3682 (0.67)

0.0276 (0.90)

-0.0063 (0.94)

SSD (ESE)

0.4766 (0.4876)

4.8239 (1.4378)

0.0998 (0.0997)

0.0798 (0.0830)

Bias (CP95)

0.2451 (0.85)

0.9965 (0.44)

-0.0038 (0.94)

-0.0020 (0.92)

SSD (ESE)

0.1919 (0.2057)

3.0176 (0.7572)

0.0543 (0.0521)

0.0536 (0.0503)

Bias (CP95)

0.2638 (0.85)

2.1825 (0.62)

0.0028 (0.94)

0.0041 (0.95)

SSD (ESE)

0.2717 (0.2732)

4.7859 (1.4853)

0.1061 (0.1028)

0.0977 (0.0996)

Bias (CP95)

0.3739 (0.36)

0.0335 (0.57)

-0.0033 (0.95)

-0.0047 (0.93)

SSD (ESE)

0.1323 (0.1536)

0.5005 (0.2745)

0.0531 (0.0537)

0.0510 (0.0490)

Bias (CP95)

-0.3958 (0.73)

-0.0371 (0.98)

-0.0054 (0.97)

SSD (ESE)

0.1217 (0.1994)

0.0375 (0.0552)

0.0233 (0.0262)

Bias (CP95)

-0.4526 (0.53)

-0.0261 (0.97)

-0.0025 (0.93)

SSD (ESE)

0.2145 (0.1198)

0.0514 (0.0641)

0.0268 (0.0255)

Bias (CP95)

-0.3536 (0.33)

-0.0119 (0.99)

-0.0031 (0.96)

SSD (ESE)

0.1093 (0.1730)

0.0104 (0.0189)

0.0094 (0.0102)

Bias (CP95)

-0.3228 (0.60)

-0.0180 (0.95)

-0.0018 (0.95)

SSD (ESE)

0.1817 (0.1112)

0.0268 (0.0315)

0.0108 (0.0112)

Bias (CP95)

-0.0039 (0.88)

0.0010 (0.96)

-0.0000 (0.95)

SSD (ESE)

0.0147 (0.0162)

0.0079 (0.0085)

0.0088 (0.0090)

Bias (CP95)

-0.1945 (0.47)

0.0065 (0.98)

0.0001 (0.92)

SSD (ESE)

0.1891 (0.0806)

0.0115 (0.0148)

0.0081 (0.0076)

Bias (CP95)

-0.0179 (0.83)

0.0014 (0.95)

-0.0017 (0.94)

SSD (ESE)

0.0147 (0.0172)

0.0069 (0.0072)

0.0076 (0.0077)

Bias (CP95)

-0.2084 (0.37)

0.0026 (0.99)

-0.0003 (0.97)

SSD (ESE)

0.1518 (0.0639)

0.0057 (0.0090)

0.0051 (0.0056)

Table B.5: Unknown assay accuracy probabilities Se(1):1 = 0.94, Se(2):1 = 0.90, Se(1):2 = 0.98,
Se(2):2 = 0.96 and Sp(1):1 = 0.93, Sp(2):1 = 0.95, Sp(1):2 = 0.97, Sp(2):2 = 0.98 (imperfect testing) and
unknown ρ = 0.3. Average bias of 500 posterior mean estimates (Bias), sample standard deviation
of 500 posterior mean estimates (SSD), average of 500 estimates of the posterior standard deviation
(ESE), and empirical coverage probability (CP95) of 95% equal-tail credible intervals are given for
each estimated parameter when possible. The total number of individuals is N = 5008 with disease
status generated by logistic population model. Prevalence of each disease in the population are
given. For Dorfman testing (DT) and array testing (AT) the average number of tests are shown.
Master pool testing (MPT), DT and AT uses master pools of size 4.
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Parameter

DT no order
Prevalence
Average number of tests

DT order

AT no order

AT order

d1 = 0.05 d2 = 0.10
3570.5

3570.5

3861.6

3861.6

β 10 = −3.3

Bias (CP95)

0.0665 (0.92)

0.0828 (0.92)

-0.0084 (0.94)

-0.0019 (0.94)

SSD (ESE)

0.1667 (0.1848)

0.1670 (0.1882)

0.1377 (0.1330)

0.1388 (0.1324)

β 11 = 0.5

Bias (CP95)

0.0035 (0.93)

0.0013 (0.93)

0.0019 (0.92)

0.0024 (0.94)

SSD (ESE)

0.0846 (0.0793)

0.0834 (0.0784)

0.0731 (0.0724)

0.0726 (0.0726)

β 12 = 0.5

β 20 = −2.55

β 21 = 0.5

β 22 = 0.5

ρ = 0.3

Se(1):1 = 0.94

Se(2):1 = 0.90

Se(1):2 = 0.98

Se(2):2 = 0.96

Sp(1):1 = 0.93

Sp(2):1 = 0.95

Sp(1):2 = 0.97

Sp(2):2 = 0.98

Bias (CP95)

0.0020 (0.93)

-0.0014 (0.93)

-0.0049 (0.94)

-0.0039 (0.94)

SSD (ESE)

0.1655 (0.1582)

0.1641 (0.1575)

0.1521 (0.1472)

0.1524 (0.1470)

Bias (CP95)

0.0259 (0.91)

0.0343 (0.90)

-0.0060 (0.91)

-0.0041 (0.91)

SSD (ESE)

0.0959 (0.1003)

0.0949 (0.1008)

0.0910 (0.0830)

0.0903 (0.0833)

Bias (CP95)

0.0042 (0.92)

0.0044 (0.91)

0.0030 (0.92)

0.0034 (0.94)

SSD (ESE)

0.0553 (0.0515)

0.0548 (0.0519)

0.0531 (0.0505)

0.0539 (0.0504)

Bias (CP95)

0.0066 (0.93)

0.0067 (0.91)

0.0067 (0.92)

0.0080 (0.92)

SSD (ESE)

0.1068 (0.1034)

0.1068 (0.1025)

0.1077 (0.1004)

0.1071 (0.0999)

Bias (CP95)

-0.0095 (0.92)

-0.0117 (0.92)

-0.0079 (0.91)

-0.0098 (0.91)

SSD (ESE)

0.0554 (0.0535)

0.0554 (0.0536)

0.0534 (0.0494)

0.0546 (0.0497)

Bias (CP95)

-0.0377 (0.98)

-0.0173 (1.00)

-0.0040 (0.95)

0.0027 (0.98)

SSD (ESE)

0.0368 (0.0558)

0.0299 (0.0454)

0.0250 (0.0261)

0.0201 (0.0222)

Bias (CP95)

-0.0278 (0.98)

-0.0547 (0.92)

-0.0017 (0.94)

-0.0080 (0.94)

SSD (ESE)

0.0528 (0.0652)

0.0454 (0.0590)

0.0265 (0.0256)

0.0238 (0.0245)

Bias (CP95)

-0.0108 (1.00)

-0.0092 (0.98)

-0.0035 (0.94)

-0.0015 (0.96)

SSD (ESE)

0.0092 (0.0186)

0.0104 (0.0163)

0.0094 (0.0102)

0.0076 (0.0085)

Bias (CP95)

-0.0174 (0.97)

-0.0263 (0.93)

-0.0012 (0.94)

-0.0039 (0.96)

SSD (ESE)

0.0269 (0.0314)

0.0212 (0.0287)

0.0111 (0.0111)

0.0098 (0.0106)

Bias (CP95)

0.0017 (0.96)

0.0032 (0.96)

-0.0010 (0.95)

-0.0009 (0.96)

SSD (ESE)

0.0078 (0.0086)

0.0074 (0.0081)

0.0089 (0.0091)

0.0082 (0.0086)

Bias (CP95)

0.0074 (0.97)

0.0048 (0.98)

-0.0006 (0.94)

0.0001 (0.96)

SSD (ESE)

0.0111 (0.0149)

0.0092 (0.0123)

0.0077 (0.0076)

0.0073 (0.0074)

Bias (CP95)

0.0014 (0.95)

0.0013 (0.97)

-0.0014 (0.94)

-0.0026 (0.96)

SSD (ESE)

0.0066 (0.0072)

0.0060 (0.0067)

0.0079 (0.0077)

0.0068 (0.0072)

Bias (CP95)

0.0026 (0.99)

0.0039 (0.98)

-0.0004 (0.93)

0.0008 (0.93)

SSD (ESE)

0.0054 (0.0090)

0.0047 (0.0074)

0.0057 (0.0056)

0.0052 (0.0052)

Table B.6: Unknown assay accuracy probabilities Se(1):1 = 0.94, Se(2):1 = 0.90, Se(1):2 = 0.98,
Se(2):2 = 0.96 and Sp(1):1 = 0.93, Sp(2):1 = 0.95, Sp(1):2 = 0.97, Sp(2):2 = 0.98 (imperfect testing) and
unknown ρ = 0.3. Average bias of 500 posterior mean estimates (Bias), sample standard deviation
of 500 posterior mean estimates (SSD), average of 500 estimates of the posterior standard deviation
(ESE), and empirical coverage probability (CP95) of 95% equal-tail credible intervals are given for
each estimated parameter when possible. The total number of individuals is N = 5008 with disease
status generated by logistic population model. Prevalence of each disease in the population are
given. For Dorfman testing (DT) and array testing (AT) the average number of tests are shown.
DT and AT uses master pools of size 4.
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Figure B.2: The patient age distribution for the 2014 Female Iowa SHL data.

Parameter
Count

# of Patients

Race W

Race B

RNP

RMP

RC

S

ST

SC

SP

13,862

11,205

1,506

6,215

1,769

703

3,873

9,546

731

120

Table B.7: Patient categorical covariates for 2014 Female Iowa SHL with positive encoding counts.
Race has three categories white (W), black (B) and other and is one-hot encoded. A positive
indicator or yes response to other risk factors are counted for each encoding.

Disease Specimen

CT Swab

CT Urine

NG Swab

NG Urine

Seα (TP)

192

197

126

116

Seβ (FN)

12

11

1

11

Spα (TN)

1154

1170

1335

1347

Spβ (FP)

28

13

17

10

Table B.8: The informed prior parameters for the beta distribution for sensitivity and specificity for
each disease and specimen type. The data counts are from the female urine and swab performance
tables for CT and NG found in the data sheet for the Aptima Combo 2 Assay [1].
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Probit

Probit

No Se, Sp ordering

β 1,0 ( Intercept )

β 1,1 ( Age )

β 1,2 ( Race W )

β 1,3 ( Race B )

β 1,4 ( RNP )

β 1,5 ( RMP )

β 1,6 ( RC )

β 1,7 ( S )

β 1,8 ( ST )

β 1,9 ( SC )

β 1,10 ( SP )

β 2,0 ( Intercept )

β 2,1 ( Age )

β 2,2 ( Race W )

β 2,3 ( Race B )

β 2,4 ( RNP )

β 2,5 ( RMP )

β 2,6 ( RC )

β 2,7 ( S )

β 2,8 ( ST )

β 2,9 ( SC )

β 2,10 ( SP )

Logistic

Se, Sp ordering

Logistic

No Se, Sp ordering

Se, Sp ordering

Mean (ETI95)

−0.744

(−0.931, −0.560)

−0.736

(−0.922, −0.546)

−1.089

(−1.324, −0.740)

−1.077

(−1.296, −0.768 )

ESE (HPD95)

0.093

(−0.935, −0.566)

0.095

(−0.927, −0.554)

0.236

(−1.386, −0.897)

0.167

(−1.296, −0.768 )

Mean (ETI95)

−0.034

(−0.040, −0.028)

−0.034

(−0.040, −0.028)

−0.070

(−0.078, −0.058)

−0.071

(−0.079, −0.061 )

ESE (HPD95)

0.003

(−0.040, −0.028)

0.003

(−0.040, −0.028)

0.005

(−0.081, −0.063)

0.006

(−0.079, −0.061 )

Mean (ETI95)

−0.162

(−0.274, −0.049)

−0.164

(−0.275, −0.056)

−0.328

(−0.476, −0.134)

−0.283

(−0.486, −0.171 )

ESE (HPD95)

0.057

(−0.271, −0.047)

0.057

(−0.279, −0.061)

0.082

(−0.514, −0.227)

0.090

(−0.486, −0.171 )

Mean (ETI95)

0.014

(−0.131, 0.155)

0.015

(−0.125, 0.155)

−0.010

(−0.197, 0.228)

0.011

(−0.197, 0.188 )

ESE (HPD95)

0.072

(−0.130, 0.156)

0.072

(−0.133, 0.146)

0.104

(−0.244, 0.120)

0.119

(−0.197, 0.188 )

Mean (ETI95)

0.140

( 0.074, 0.206)

0.140

( 0.074, 0.204)

0.311

( 0.174, 0.384)

0.251

( 0.176, 0.372 )

ESE (HPD95)

0.034

( 0.073, 0.204)

0.034

( 0.074, 0.203)

0.076

( 0.152, 0.328)

0.063

( 0.176, 0.372 )

Mean (ETI95)

0.164

( 0.072, 0.256)

0.164

( 0.073, 0.257)

0.231

( 0.163, 0.449)

0.321

( 0.165, 0.426 )

ESE (HPD95)

0.047

( 0.073, 0.256)

0.047

( 0.075, 0.258)

0.077

( 0.133, 0.376)

0.062

( 0.165, 0.426 )

Mean (ETI95)

0.732

( 0.616, 0.846)

0.737

( 0.622, 0.857)

1.349

( 1.191, 1.518)

1.405

( 1.204, 1.502 )

ESE (HPD95)

0.059

( 0.615, 0.844)

0.059

( 0.622, 0.857)

0.093

( 1.150, 1.437)

0.087

( 1.204, 1.502 )

Mean (ETI95)

0.132

( 0.055, 0.207)

0.134

( 0.055, 0.211)

0.261

( 0.145, 0.380)

0.290

( 0.150, 0.365 )

ESE (HPD95)

0.039

( 0.057, 0.209)

0.039

( 0.058, 0.213)

0.074

( 0.114, 0.318)

0.063

( 0.150, 0.365 )

Mean (ETI95)

0.097

( 0.005, 0.194)

0.091

(−0.004, 0.191)

0.265

( 0.050, 0.353)

0.178

( 0.050, 0.323 )

ESE (HPD95)

0.049

( 0.004, 0.192)

0.050

(−0.007, 0.186)

0.149

( 0.022, 0.270)

0.087

( 0.050, 0.323 )

Mean (ETI95)

0.087

(−0.054, 0.223)

0.086

(−0.049, 0.223)

0.130

(−0.036, 0.390)

0.249

(−0.020, 0.359 )

ESE (HPD95)

0.071

(−0.056, 0.219)

0.070

(−0.051, 0.219)

0.159

(−0.086, 0.283)

0.148

(−0.020, 0.359 )

Mean (ETI95)

0.103

(−0.243, 0.426)

0.100

(−0.246, 0.419)

0.113

(−0.362, 0.678)

0.320

(−0.383, 0.602 )

ESE (HPD95)

0.171

(−0.216, 0.449)

0.173

(−0.238, 0.427)

0.257

(−0.479, 0.438)

0.301

(−0.383, 0.602 )

Mean (ETI95)

−2.501

(−2.903, −2.133)

−2.511

(−2.919, −2.140)

−4.786

(−5.841, −4.127)

−4.900

(−5.768, −4.311 )

ESE (HPD95)

0.195

(−2.881, −2.120)

0.197

(−2.907, −2.131)

0.432

(−6.069, −4.535)

0.356

(−5.768, −4.311 )

Mean (ETI95)

−0.007

(−0.018, 0.003)

−0.007

(−0.018, 0.003)

−0.025

(−0.046, 0.001)

−0.025

(−0.042, −0.002 )

ESE (HPD95)

0.005

(−0.018, 0.003)

0.005

(−0.018, 0.003)

0.010

(−0.051, −0.011)

0.017

(−0.042, −0.002 )

Mean (ETI95)

−0.132

(−0.375, 0.126)

−0.133

(−0.362, 0.119)

−0.395

(−0.784, 0.221)

−0.305

(−0.794, 0.148 )

ESE (HPD95)

0.128

(−0.380, 0.117)

0.123

(−0.369, 0.105)

0.232

(−0.880, −0.059)

0.313

(−0.794, 0.148 )

Mean (ETI95)

0.296

( 0.020, 0.581)

0.298

( 0.021, 0.587)

0.609

( 0.119, 1.281)

0.592

( 0.122, 1.191 )

ESE (HPD95)

0.145

( 0.026, 0.585)

0.143

( 0.009, 0.571)

0.321

( 0.004, 0.971)

0.365

( 0.122, 1.191 )

Mean (ETI95)

0.061

(−0.082, 0.206)

0.058

(−0.081, 0.203)

0.098

(−0.142, 0.482)

0.095

(−0.139, 0.450 )

ESE (HPD95)

0.074

(−0.090, 0.198)

0.073

(−0.079, 0.206)

0.194

(−0.224, 0.319)

0.288

(−0.100, 0.486 )

Mean (ETI95)

0.196

( 0.002, 0.376)

0.185

(−0.020, 0.371)

0.310

( 0.095, 0.877)

0.502

( 0.062, 0.749 )

ESE (HPD95)

0.096

( 0.004, 0.376)

0.099

(−0.016, 0.375)

0.338

( 0.014, 0.678)

0.169

( 0.062, 0.749 )

Mean (ETI95)

0.923

( 0.742, 1.103)

0.924

( 0.743, 1.107)

2.163

( 1.877, 2.561)

2.154

( 1.864, 2.506 )

ESE (HPD95)

0.092

( 0.737, 1.098)

0.092

( 0.747, 1.109)

0.185

( 1.799, 2.390)

0.122

( 1.864, 2.506 )

Mean (ETI95)

0.137

(−0.024, 0.291)

0.146

(−0.012, 0.303)

0.203

(−0.030, 0.654)

0.503

( 0.005, 0.641 )

ESE (HPD95)

0.081

(−0.030, 0.284)

0.081

(−0.006, 0.310)

0.186

(−0.105, 0.486)

0.178

( 0.005, 0.641 )

Mean (ETI95)

0.158

(−0.040, 0.380)

0.162

(−0.033, 0.386)

0.461

( 0.031, 1.072)

0.358

( 0.080, 0.937 )

ESE (HPD95)

0.106

(−0.049, 0.363)

0.107

(−0.037, 0.380)

0.240

(−0.052, 0.753)

0.187

( 0.080, 0.937 )

Mean (ETI95)

0.162

(−0.077, 0.388)

0.165

(−0.075, 0.395)

0.420

(−0.010, 0.878)

0.611

( 0.008, 0.826 )

ESE (HPD95)

0.121

(−0.075, 0.390)

0.121

(−0.071, 0.397)

0.219

(−0.118, 0.661)

0.314

( 0.008, 0.826 )

Mean (ETI95)

0.185

(−0.409, 0.701)

0.183

(−0.406, 0.688)

0.265

(−0.809, 1.463)

0.448

(−0.684, 1.332 )

ESE (HPD95)

0.283

(−0.361, 0.743)

0.278

(−0.344, 0.743)

0.566

(−1.139, 0.991)

0.681

(−0.532, 1.433 )

Table B.9: The regression parameter estimates for all stratum of the Iowa test set using the Bayesian
probit and logistic model. The sensitivity and specificity used the Hologic data to inform beta
distributed priors. Ordering was optionally enforced with regards to the size of the pool. The β
parameters had a normal prior with zero mean and a diffuse covariance matrix. The parameter ρ
had a uniform prior. The posterior mean estimate, estimated posterior standard deviation, 95%
highest posterior density interval and 95% equal-tailed interval are given for each predictor for each
posterior distribution. The diseases are chlamydia (d = 1) and gonorrhea (d = 2).
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Probit

Probit

No Se, Sp ordering

ρ

Se(1),1 (Swab, 1)

Se(2),1 (Swab, 2)

Se(3),1 (Swab, 3)

Se(4),1 (Swab, 4)

Se(5),1 (Urine, 1)

Se(1),2 (Swab, 1)

Se(2),2 (Swab, 2)

Se(3),2 (Swab, 3)

Se(4),2 (Swab, 4)

Se(5),2 (Urine, 1)

Sp(1),1 (Swab, 1)

Sp(2),1 (Swab, 2)

Sp(3),1 (Swab, 3)

Sp(4),1 (Swab, 4)

Sp(5,1 (Urine, 1)

Sp(1),2 (Swab, 1)

Sp(2),2 (Swab, 2)

Sp(3),2 (Swab, 3)

Sp(4),2 (Swab, 4)

Sp(5,2 (Urine, 1)

Logistic

Se, Sp ordering

Logistic

No Se, Sp ordering

Se, Sp ordering

Mean (ETI95)

0.484

( 0.390, 0.566)

0.487

( 0.406, 0.561)

0.399

( 0.321, 0.480)

0.384

( 0.321, 0.473 )

ESE (HPD95)

0.043

( 0.400, 0.571)

0.040

( 0.411, 0.565)

0.032

( 0.303, 0.436)

0.040

( 0.321, 0.473 )

Mean (ETI95)

0.985

( 0.975, 0.992)

0.985

( 0.977, 0.992)

0.985

( 0.979, 0.992)

0.986

( 0.980, 0.991 )

ESE (HPD95)

0.004

( 0.977, 0.993)

0.004

( 0.978, 0.993)

0.002

( 0.977, 0.989)

0.004

( 0.980, 0.991 )

Mean (ETI95)

0.943

( 0.908, 0.970)

0.975

( 0.965, 0.983)

0.949

( 0.917, 0.966)

0.977

( 0.968, 0.981 )

ESE (HPD95)

0.016

( 0.911, 0.972)

0.005

( 0.965, 0.984)

0.013

( 0.917, 0.964)

0.004

( 0.968, 0.981 )

Mean (ETI95)

0.943

( 0.908, 0.970)

0.972

( 0.962, 0.980)

0.949

( 0.919, 0.968)

0.974

( 0.965, 0.978 )

ESE (HPD95)

0.016

( 0.911, 0.971)

0.005

( 0.963, 0.981)

0.015

( 0.912, 0.958)

0.004

( 0.966, 0.979 )

Mean (ETI95)

0.986

( 0.977, 0.993)

0.970

( 0.959, 0.978)

0.986

( 0.979, 0.992)

0.971

( 0.962, 0.977 )

ESE (HPD95)

0.004

( 0.978, 0.993)

0.005

( 0.960, 0.979)

0.003

( 0.979, 0.991)

0.004

( 0.963, 0.977 )

Mean (ETI95)

0.940

( 0.904, 0.968)

0.940

( 0.905, 0.967)

0.936

( 0.914, 0.964)

0.944

( 0.916, 0.961 )

ESE (HPD95)

0.016

( 0.908, 0.970)

0.016

( 0.908, 0.968)

0.013

( 0.914, 0.962)

0.014

( 0.919, 0.964 )

Mean (ETI95)

0.944

( 0.910, 0.971)

0.951

( 0.927, 0.971)

0.941

( 0.920, 0.968)

0.956

( 0.934, 0.967 )

ESE (HPD95)

0.015

( 0.912, 0.972)

0.011

( 0.927, 0.971)

0.023

( 0.920, 0.965)

0.009

( 0.934, 0.967 )

Mean (ETI95)

0.907

( 0.852, 0.951)

0.933

( 0.908, 0.955)

0.912

( 0.868, 0.945)

0.931

( 0.915, 0.949 )

ESE (HPD95)

0.025

( 0.857, 0.953)

0.012

( 0.911, 0.957)

0.017

( 0.858, 0.930)

0.010

( 0.915, 0.949 )

Mean (ETI95)

0.907

( 0.851, 0.951)

0.922

( 0.895, 0.944)

0.913

( 0.866, 0.946)

0.925

( 0.903, 0.939 )

ESE (HPD95)

0.026

( 0.854, 0.953)

0.013

( 0.896, 0.945)

0.029

( 0.855, 0.929)

0.011

( 0.903, 0.939 )

Mean (ETI95)

0.945

( 0.910, 0.971)

0.912

( 0.882, 0.937)

0.949

( 0.920, 0.968)

0.916

( 0.891, 0.932 )

ESE (HPD95)

0.016

( 0.913, 0.972)

0.014

( 0.885, 0.938)

0.015

( 0.913, 0.958)

0.010

( 0.894, 0.934 )

Mean (ETI95)

0.985

( 0.957, 0.998)

0.985

( 0.957, 0.998)

0.987

( 0.968, 0.997)

0.984

( 0.968, 0.996 )

ESE (HPD95)

0.011

( 0.963, 1.000)

0.011

( 0.963, 1.000)

0.010

( 0.968, 0.996)

0.012

( 0.975, 0.999 )

Mean (ETI95)

0.998

( 0.997, 0.999)

0.995

( 0.993, 0.996)

0.998

( 0.997, 0.999)

0.995

( 0.994, 0.996 )

ESE (HPD95)

0.001

( 0.997, 0.999)

0.001

( 0.993, 0.996)

0.000

( 0.997, 0.999)

0.000

( 0.994, 0.996 )

Mean (ETI95)

0.988

( 0.982, 0.994)

0.995

( 0.994, 0.996)

0.990

( 0.983, 0.993)

0.995

( 0.994, 0.996 )

ESE (HPD95)

0.003

( 0.982, 0.994)

0.001

( 0.994, 0.996)

0.002

( 0.982, 0.991)

0.001

( 0.994, 0.996 )

Mean (ETI95)

0.988

( 0.981, 0.994)

0.995

( 0.994, 0.997)

0.988

( 0.983, 0.993)

0.995

( 0.994, 0.996 )

ESE (HPD95)

0.003

( 0.982, 0.994)

0.001

( 0.994, 0.997)

0.003

( 0.982, 0.991)

0.001

( 0.994, 0.996 )

Mean (ETI95)

0.995

( 0.992, 0.997)

0.996

( 0.995, 0.998)

0.995

( 0.993, 0.997)

0.996

( 0.995, 0.997 )

ESE (HPD95)

0.001

( 0.992, 0.997)

0.001

( 0.995, 0.998)

0.002

( 0.992, 0.996)

0.001

( 0.995, 0.997 )

Mean (ETI95)

0.979

( 0.972, 0.986)

0.979

( 0.972, 0.986)

0.978

( 0.974, 0.985)

0.979

( 0.974, 0.984 )

ESE (HPD95)

0.004

( 0.972, 0.987)

0.004

( 0.972, 0.986)

0.004

( 0.973, 0.983)

0.004

( 0.974, 0.984 )

Mean (ETI95)

0.999

( 0.998, 0.999)

0.997

( 0.996, 0.998)

0.999

( 0.998, 0.999)

0.997

( 0.996, 0.998 )

ESE (HPD95)

0.000

( 0.998, 0.999)

0.000

( 0.996, 0.998)

0.000

( 0.998, 0.999)

0.000

( 0.996, 0.998 )

Mean (ETI95)

0.992

( 0.987, 0.996)

0.997

( 0.996, 0.998)

0.990

( 0.988, 0.996)

0.997

( 0.997, 0.998 )

ESE (HPD95)

0.002

( 0.987, 0.996)

0.000

( 0.996, 0.998)

0.002

( 0.988, 0.995)

0.000

( 0.997, 0.998 )

Mean (ETI95)

0.992

( 0.986, 0.996)

0.997

( 0.997, 0.998)

0.992

( 0.988, 0.995)

0.998

( 0.997, 0.998 )

ESE (HPD95)

0.002

( 0.987, 0.996)

0.000

( 0.997, 0.998)

0.001

( 0.988, 0.995)

0.000

( 0.997, 0.998 )

Mean (ETI95)

0.997

( 0.995, 0.998)

0.998

( 0.997, 0.999)

0.997

( 0.995, 0.998)

0.998

( 0.997, 0.999 )

ESE (HPD95)

0.001

( 0.995, 0.998)

0.000

( 0.997, 0.999)

0.001

( 0.995, 0.998)

0.000

( 0.997, 0.999 )

Mean (ETI95)

0.994

( 0.991, 0.996)

0.994

( 0.991, 0.996)

0.993

( 0.992, 0.996)

0.993

( 0.992, 0.995 )

ESE (HPD95)

0.001

( 0.991, 0.996)

0.001

( 0.991, 0.996)

0.001

( 0.991, 0.995)

0.001

( 0.992, 0.996 )

Table B.10: The scale, sensitivity and specificity parameter estimates for all stratum of the Iowa
test set using the Bayesian probit and logistic model. The sensitivity and specificity used the
Hologic data to inform beta distributed priors. Ordering was optionally enforced with regards to
the size of the pool. With ordering, we used the following partial ordering corresponding to pool
size Se(1),d ≥ Se(2),d ≥ Se(3),d ≥ Se(4),d , and Sp(1),d ≤ Sp(2),d ≤ Sp(3),d ≤ Sp(4),d for d = 1, 2. The
β parameters had a normal prior with zero mean and a diffuse covariance matrix. The parameter
ρ had a uniform prior. The posterior mean estimate, estimated posterior standard deviation, 95%
highest posterior density interval and 95% equal-tailed interval are given for each predictor for each
posterior distribution. The diseases are chlamydia (d = 1) and gonorrhea (d = 2).
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Appendix C
C.1

Introductory CUDA Code Repositories

Simple Program
The R script is found in the cuda examples github repository of pcubre with the file name

add vector.R. is the framework to interact between R and C/C++. We dynamically load the library,
provide a function signature to the library, and unload the library.
The CUDA program is found in the cuda examples github repository of pcubre under the
name add vector.cu. It has three parts: load headers, a device kernel, and a host program. The
device kernel finds its own index and then performs the appropriate addition based on the index.
The host program allocates memory on the device, copies data to the device, launches the kernel,
moves data back to the host and frees device memory.

C.2

Second Program
The CUDA program found cuda examples github repository of pcubre under the name

add vector 2.cu. is a small program using additional libraries. It has two parts: load headers, and
a host program. The host program is different from the earlier program as uses a handler to set up
the library and moves memory between the device and host via matrix and vector functions.

81

C.3

Simulations
Vector Size

Language

Min

1-Quartile

Mean

Median

3-Quartile

Max

Evaluations

101

R

0.0003

0.0013

0.0022

0.0018

0.0033

0.0096

100

101

CUDA kernel

0.2494

0.2607

0.2946

0.2798

0.2884

1.5244

100

101

CUDA library

0.6227

0.6353

0.6499

0.6412

0.6465

1.3791

100

102

R

0.0005

0.0008

0.0033

0.0023

0.0061

0.0069

100

102

CUDA kernel

0.2464

0.2574

0.2729

0.2755

0.2849

0.3086

100

102

CUDA library

0.6274

0.6427

0.6660

0.6512

0.6570

1.7869

100

103

R

0.0027

0.0041

0.0057

0.0048

0.0071

0.0163

100

103

CUDA kernel

0.2632

0.2780

0.2912

0.2899

0.2995

0.5122

100

103

CUDA library

0.6441

0.6632

0.6770

0.6744

0.6868

0.8135

100

104

R

0.0233

0.0274

0.0378

0.0411

0.0466

0.0535

100

104

CUDA kernel

0.4018

0.5473

0.5387

0.5554

0.5673

0.6479

100

104

CUDA library

0.7702

0.9403

0.9504

0.9616

0.9690

2.2898

100

105

R

0.2279

0.2309

0.2599

0.2326

0.2364

1.4865

100

105

CUDA kernel

1.6316

1.6719

1.7667

1.6797

1.6879

3.0429

100

105

CUDA library

1.8702

1.8967

2.0438

1.9076

1.9263

4.1852

100

106

R

2.2768

2.3026

3.0070

2.3203

2.3871

25.8529

100

106

CUDA kernel

13.3620

13.7002

16.3052

14.5700

15.5582

44.3450

100

106

CUDA library

12.5322

12.9081

16.0420

13.8855

15.1548

44.3460

100

107

R

27.4952

28.2571

29.9086

29.3003

30.8850

54.2894

100

107

CUDA kernel

183.8623

187.8381

195.1081

190.4356

198.7771

239.1906

100

107

CUDA library

167.3054

171.2911

177.7724

175.2761

182.1034

211.5703

100

108

R

298.7344

299.1144

306.8947

299.7457

307.9471

539.6474

100

108

CUDA kernel

1846.0654

1871.2546

1898.4229

1894.1307

1913.5316

1986.4911

100

108

CUDA library

1690.8641

1719.6367

1748.3970

1744.5908

1773.2190

1842.2082

100

109

R

2989.5161

3395.3064

3935.1477

4158.1613

4428.6801

5648.8770

100

109

CUDA kernel

18425.2621

18504.2436

19187.3646

18687.5881

19391.7940

27757.4831

100

109

CUDA library

16905.1594

16985.2045

17439.2973

17152.4995

17788.5568

22584.4471

100

Table C.1: Microsecond timings for 100 evaluations of functions that add two vectors. The both
vectors have dimension 10i for i = 1, . . . , 9. The three functions where called from R and utilized
either R vector addition, the Nvidia cuBLAS library or a custom kernel implementation. They were
added on a Palmetto HPC node with a V100 and 64gb of memory.
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Vector Size

Language

Min

1-Quartile

Mean

Median

3-Quartile

Max

101

R

11.4250

13.0565

16.7017

15.5190

16.6115

59.8930

Evaluations
100

101

CUDA kernel

298.5260

308.6900

362.8955

329.5865

337.0180

3164.5810

100

101

CUDA library

784.3160

793.5230

834.7403

797.2535

803.4535

1800.4250

100

102

R

32.2200

36.2460

41.4432

41.8470

45.4565

64.0570

100

102

CUDA kernel

300.4320

310.9335

344.7658

329.2185

339.1205

1321.0960

100

102

CUDA library

759.4510

815.6710

862.9754

822.5620

832.9065

2050.0010

100

103

R

214.0760

376.3590

369.5524

387.1125

395.1855

411.3300

100

103

CUDA kernel

313.4450

336.1470

373.6682

346.4940

361.3675

1562.3670

100

103

CUDA library

814.8790

845.6790

910.5580

867.9925

889.1225

2259.6360

100

104

R

1936.4810

1946.0275

2091.2105

1950.0345

1953.5680

4431.4660

100

104

CUDA kernel

664.2980

686.7515

714.5434

698.6620

707.5625

1741.4890

100

104

CUDA library

927.5570

944.4415

996.3053

959.2785

976.0510

2134.8460

100

105

R

19197.7830

20373.8270

20649.0109

20391.0320

20425.0085

44907.5530

100

105

CUDA kernel

4579.0040

4612.6085

4768.5866

4655.5365

4793.0140

6053.4960

100

105

CUDA library

1997.4180

2196.2820

2430.7635

2327.2155

2512.5320

3996.6350

100

106

R

196482.0950

199265.1430

206804.1463

202277.2085

209849.7790

244242.4630

100

106

CUDA kernel

38997.2570

39674.5730

41981.3113

40738.0560

42383.2545

65577.7560

100

106

CUDA library

14832.3970

15278.4140

17632.3712

16187.4545

17009.1640

42120.4920

100

107

R

2534010.7790

2587059.1425

2601346.4783

2600044.5515

2613744.6295

2691286.0410

100

107

CUDA kernel

444139.5800

447063.4960

457329.8523

450491.4200

467333.3240

490134.9900

100

107

CUDA library

193418.9970

195866.3945

206724.4619

201731.5470

216095.8375

237053.7630

100

108

R

22992094.6780

23023521.5920

23479118.8865

23042662.8500

23075528.4960

33431615.0600

100

108

CUDA kernel

4431228.8120

4451962.2615

4478375.7105

4468270.3020

4472830.3840

5029489.3510

100

108

CUDA library

1907584.4630

1926139.1810

1963621.5519

1939344.4990

1947535.3540

2861840.3780

100

109

R

206015005.4990

209943465.9835

220938231.9035

215718359.0965

233421430.0020

273024560.9830

100

109

CUDA kernel

45252926.2350

47733750.0645

48583731.8736

48116913.2375

49526135.6595

53804125.3580

100

109

CUDA library

20002668.8770

22343227.2525

22643012.1014

22483137.1600

22928511.6130

26978105.7540

100

Table C.2: Microsecond timings for 100 evaluations of functions that sequentially adds two vectors
100 times. The both vectors have dimension 10i for i = 1, . . . , 9. The three functions where
called from R and utilized either R vector addition, the Nvidia cuBLAS library or a custom kernel
implementation. They were added on a Palmetto HPC node with a V100 and 64gb of memory.
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Figure C.1: Average times for 100 evaluations of functions that add two vectors in microseconds.
The axes scale is log10 . The both vectors have dimension 10i for i = 1, . . . , 9. The three functions
where called from R and utilized either R vector addition, the Nvidia cuBLAS library or a custom
kernel implementation. They were added on a Palmetto HPC node with a V100 and 64gb of memory.
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Figure C.2: Average times for 100 evaluations of functions that sequentially add two vectors 100
times in microseconds. The axes scale is log10 . The both vectors have dimension 10i for i = 1, . . . , 9.
The three functions where called from R and utilized either R vector addition, the Nvidia cuBLAS
library or a custom kernel implementation. They were added on a Palmetto HPC node with a V100
and 64gb of memory.
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Appendix D

Descent Algorithms

In this section, we review the concepts of stochastic gradient descent and stochastic coordinate descent for linear regression. The objective is to apply the concepts to simple and familiar
problems in order to grasp the methodology.

D.1

Linear Regression
Linear regression acts as a baseline for most modeling. It can be written as the following

forms:

argmin
β

1
2
kY − Xβk2
2N

= argmin
β

p
N
X
1 X
(yi −
xij βj )2 ,
2N i=1
j=1

(1)

where N is the number of observations, p is the number of variables and yi is ith observation and
xij is the jth co-variate of the ith observation.
We can find the exact solution by taking partial derivatives with respect to β.


p
N
X
∂  1 X
(yi −
xij βj )2 
∂βk 2N i=1
j=1
=−

p
N
X
1 X
(yi −
xij βj )xik
N i=1
j=1

=−

1 T
X (Y − Xβ)
N k

(2)

or

∇(β) = −

1 T
X (Y − Xβ)
N

Thus we have a critical point β ols for the solution to 0 = ∇(β).

0 = ∇(β) = −

1 T
X (Y − Xβ)
N

XT Xβ = XT Y (the normal equation)
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(3)

β ols = (XT X)−1 XT Y when XT X is invertible

D.2

(4)

Stochastic Descent
Even though there can be an exact solution to linear regression, we can use other methods

to compare. One method that we present in two variations are stochastic methods. It was Robbins
and Monro [83] who first presented the idea to solve optimization problems stochastically. Their
methodology was to iterate to find the solution by xn+1 − xn = an (α − yn ) where an is in `2 , yn
is a random variable, α is a constant, and xn is a sequence heading to the solution. This method
essentially is a contraction that finds a solution, similar to other methods such as Newton’s method,
xn+1 − xn = ∇2 F (xn )−1 ∇F (xn ).
1
To distinguish between the two methods, we set the notation F (β) = 2N
Pp
Pp
PN
1
1
2
2
i=1 Fi (β).
j=1 xij β j ) and Fi (β) = 2 (yi −
j=1 xij β j ) . Thus we have F (β) = N

PN

i=1 (yi

−

For Stochastic Gradient Descent (SGD) we have the equation

β t+1 = β t − ηt ∇Fi (β t )
= β t − ηt (−xi (yi − xTi β t ))

(5)

where ηt is called the learning rate. The learning rate is usually of the form ηt = Ct−c for some
constants C and c. Then we have the algorithm:
Result: argminβ F (β)
Set β = 0 ∈ Rp
while not converged do
Chose i ∈ {1, . . . , N } uniformly at random.
Let β t+1 ← β t − ηt (−xi (yi − xTi β t ).
end

Moreover to add stability one can use the implicit SGD

β t+1 = β t − ηt ∇Fi (β t+1 )
= β t − ηt (−xi (yi − xTi β t+1 ))
= βt −

ηt

2 (−xi (yi

1 + ηt kxi k2

− xTi β t )).

(6)

Additionally, an intermediate method uses mini-batch where one takes a subset of [N ],
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St ⊂ [N ], of size B = |St | such that

β t+1 = β t − ηt

1 X
∇Fi (β t )
B
i∈St

1 X
(−xi (yi − xTi β t ))
= β t − ηt
B

(7)

i∈St

where B = N recovers the gradient descent.
For Stochastic Coordinate Descent (SCD) we have the equation

βk,t+1 = βk,t − αt (∇F (β t ))k
= βk,t − αt (−

1 T
X (Y − Xβ))
N k

(8)

where αt is the step size. In the case of linear regression, a step size of 1 is sufficient. Then we have
the algorithm:
Result: argminβ F (β)
Set β = 0 ∈ Rp
while not converged do
Chose k ∈ {1, . . . , p} uniformly at random.
Let βk,t+1 ← βk,t − αt (− N1 XTk (Y − Xβ)).
end

D.3

LASSO
Popularized by Tibshirani [93] the least absolute shrinkage and selection operator (lasso)

helps automate variable selection. This section we will apply the lasso techniques on both SGD and
SCD in linear regression. First we have the new problem form:

argmin
β

1
2
kY − Xβk2 + λ kβk1
2N

p
p
N
X
X
1 X
2
= argmin
(yi −
xij βj ) + λ
|βj | ,
2N i=1
β
j=1
i=1

for any λ. Let F (β) =

1
2N

2

kY − Xβk2 , G(β) = λ kβk1 and H(β) = F (β) + G(β).
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(9)

We can find the solution by taking partial derivatives with respect to β.



p
p
N
X
X
X
∂  1
(yi −
xij βj )2 + λ
|βj |
∂βk 2N i=1
j=1
j=1
=−

p
N
X
1 X
(yi −
xij βj )xik + λ sign(βk )
N i=1
j=1

=−

1 T
X (Y − Xβ) + λ sign(βk )
N k

(10)

or

∇H(β) = −

1 T
X (Y − Xβ) + sign(β)
N

(11)

where sign(·) ∈ {−1, 0, 1}p is a vector version of the sign function for inputs in Rp .
When solving our gradient descent problems β can change sign component wise and we
must allow for the possibility that a component is zero. Therefore we want to track the sign changes
at each iteration of β t+1 = β t − γt ∇H(β t ).
Solving for critical points,
p
N
X
1 X
0=−
(yi −
xij βj )xik + λ sign(βk )
N i=1
j=1
Pn
Pp
1
i=1 xik (yi −
j6=k xij βj ) − sign(βk )λ
N
βk =
.
P
N
1
2
i=1 xik
N

However there are issues. Let ck =

1
N

Pn

i=1

xik (yi −

Pp

j6=k

(12)

xij βj ). Then we have the following

conditions:

βk > 0 if and only if ck > λ, βk < 0

if and only if ck < −λ, βk = 0 if and only if ck ∈ [−λ, λ].

Thus we have the operator
Definition 2 (Soft Threshold Operator). Let ω ∈ Rd and τ be a vector where each component is
the same, sign(·) be the vector sign function, and (·)+ = max(·, 0). Then sτ (ω) = sign(ω)(|ω| − τ )+
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is the soft threshold operator with

sτ (ω) = sign(ω)(|ω| − τ )+ =





ω−τ




ω+τ






0

ω>τ
ω < −τ
ω ∈ [−τ, τ ]

Then
sλ
βk =

D.4



1
N

Pn


Pp
xik (yi − j6=k xij βj )
.
PN 2
1
i=1 xik
N

i=1

(13)

LASSO with Stochastic Descent
Incorporating stochastic descent in the SGD and SCD cases with lasso is a small modifica-

tion. In the case of SGD, we have the following conditions:

βk,t+1 > 0 if and only if βk,t − ηt ∇Hi (β t ) > 0
if and only if βk,t − ηt (−(yi −
if and only if βk,t − ηt (−(yi −

p
X
j=1
p
X

xij βj,t )xik + λ) > 0

xij βj,t )xik ) > ηt λ,

j=1

βk,t+1 < 0 if and only if βk,t − ηt ∇Hi (β t ) < 0
if and only if βk,t − ηt (−(yi −
if and only if βk,t − ηt (−(yi −
βk,t+1 = 0 if and only if βk,t − ηt (−(yi −

p
X
j=1
p
X
j=1
p
X

xij βj,t )xik − λ) < 0
xij βj,t )xik ) < −ηt λ,
xij βj,t )xik ∈ [−ηt λ, ηt λ].

(14)

j=1

The above equations can be rewritten as


β t+1 = sηt λ β t − ηt (−(yi − xTi β t )xi ) .

Thus we have the modified SGD algorithm:
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(15)

Result: argminβ H(β)
Set β = 0 ∈ Rp
while not converged do
Chose i ∈ {1, . . . , N } uniformly at random.
Let β t+1 ← sηt λ β t − ηt (−(yi − xTi β t )xi ) .
end

In the case of SCD, we have the following conditions:

βk,t+1 > 0 if and only if βk,t − αt ∇H(β t )j > 0
1 T
X (Y − Xβ t ) + λ) > 0
N k
1
if and only if βk,t − αt (− XTk (Y − Xβ t )) > ηt λ,
N
if and only if βk,t − αt (−

βk,t+1 < 0 if and only if βk,t − αt ∇Hi (β t ) < 0
1 T
X (Y − Xβ t ) − λ) < 0
N k
1
if and only if βk,t − αt (− XTk (Y − Xβ t )) < −ηt λ,
N
1
= 0 if and only if βk,t − αt (− XTk (Y − Xβ t )) ∈ [−ηt λ, ηt λ].
N
if and only if βk,t − αt (−

βk,t+1

(16)

The above equations can be rewritten as


1
β k,t+1 = sηt λ β k,t − αt (− XTk (Y − Xβ t )) .
N

(17)

Thus we have the modified SCD algorithm
Result: argminβ H(β)
Set β = 0 ∈ Rp
while not converged do
Chose k ∈ {1, . . . , p} uniformly at random.

Let βk,t+1 ← sαt λ β k,t − αt (− N1 XTk (Y − Xβ t )) .
end

In the R script found at github.com/pcubre/cuda_examples/blob/master/thesis_linear_
regression_sgd_scd_lasso.R, we have the simple program to compare the methods. The algorithms stop when there is approximate convergence to the solution. For these examples convergence
is measured relative L2 error of 5% to the true solution or the solution from the R package glmnet.
The following violin plots exams the speed of evaluating 100 iterations
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Figure D.1: Timings for 100 iterations for stochastic descent methods for linear regression.
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Appendix E

Horseeshoe Probit

In this Appendix, we provide supplemental proofs and lemmas used to in the derivation of
the Horseshoe probit model.
Definition 3 (Gamma Density). Let the shape and rate be α > 0 and β > 0 respectively. Let
x ∈ (0, ∞). Then the density is

G(x|α, β) =

β α α−1 −βx
x
e
.
Γ(α)

Definition 4 (Inverse Gamma Density). Let the shape and scale be α > 0 and β > 0 respectively.
Let x ∈ (0, ∞). Then the density is

IG(x|α, β) =

β α −α−1 − β
x
e x.
Γ(α)

Lemma E.1. If X is generated by a random variable with distribution FX (x) and density fX (x),
then 1/X has distribution F X1 (x) = 1 − FX ( x1 ) and density f X1 (x) = fX ( x1 ) x12 .
1
Proof. We have that F X1 (x) = P ( X
< x) = P ( x1 < X) = 1 − FX ( x1 ). Therefore f X1 (x) = F 01 (x) =
X

0 1 1
( x ) x2 = fX ( x1 ) x12
FX

Lemma E.2. If X ∼ G(α, β), then

1
X

is IG(α, β).

Proof. Let X be generated by G(x|α, β) =
generated by G( x1 |α, β) x12 =

α

β
−α−1
e
Γ(α) x

−β
x

βα
α−1 −βx
e
.
Γ(α) x

Then by the previous lemma 1/X is

= IG(α, β).

Lemma E.3. G(α, β) is G(α, 1)/β.
Proof. Let g(x) = x/β and X ∼ G(α, 1). Then g −1 (x) = xβ and (g −1 )0 (x) = β. Thus fX/β (y) =
fX (xβ)β = G(α, β).
Definition 5 (Exponential Density). Let the rate be λ > 0 and x ∈ [0, ∞). Then the density is

Exp(x|λ)λe−λx

and the distribution is
1 − e−λx .
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Lemma E.4. G(α = 1, β = λ) is Exp(λ).
Proof. We have that G(x|α = 1, β = λ) = λ1 x1−1 e−λx = Exp(x|λ).
Definition 6 (Cauchy Density). Let the location and scale be x0 and γ > 0 respectively. Let
x ∈ (−∞, ∞). Then the density is

f (x|x0 , γ) =

1
.
0 2
πγ [1+( x−x
) ]
γ

Lemma E.5. Let C + (0, 1) be the truncated Cauchy distribution on R+ . Then the density is

f (x|0, 1) =

2
.
π(1 + x2 )

Proof. We find the integrating constant for the standard Cauchy distribution over the positive reals
R∞

is

0

dx
1+x2

=tan−1 (x)|∞
0 =π
2

.

Lemma E.6. If X has distribution FX (x) and density fX (x), then

√

X has distribution F√X (x) =

FX (x2 ) and density f√X (x) = fX (x2 )2x.
√
Proof. The proof is strait forward as F√X (x) = P ( X < x) = P (X < x2 ) = FX (x2 ) and f√X (x) =
0
0
F√
(x2 )2x = fX (x2 )2x.
(x) = FX
X

Theorem E.7. Let

√

x ∼ C + (0, 1) be a truncated Cauchy distribution on R+ . Then x|a ∼ IG( ν2 , νa ),

a ∼ IG( 12 , A12 ).
Proof.
Z
f (x) =

f (x|a)f (a)da
ν
a

Z
=
=

Γ
ν
Γ

ν
2

 ν2
ν
a
− ν2 −1 − x

e
x
ν
2

ν
2

ν

 √ x− 2 −1
π



1
A2

 21
1
2
− 21 −1 − Aa

e
da
a
1

Γ 2
 12 Z

1
A2

a−

ν+1
2 −1

e− a ( x + A2 ) da
1

 Z
  12
ν
Γ ν+1
ν
ν2
1
−
−1
2
√ x 2
=
 ν+1
A2
Γ ν2
π
ν
1
2
x + A2

ν
Γ ν+1
ν2
1
1
2
=
√
ν
ν+1
Γ ν2
πA x− 2 −1 ν + 1  2
x

A2
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ν

1

ν
x

+
Γ

 ν+1

1
2
A2 
ν+1
2

a−

ν+1
2 −1

e− a ( x + A2 ) da
1

ν

1

=

Γ
Γ

ν+1

 2
ν √
2



πνA



1
1 + Ax2 ν

 ν+1
2

1
1

x2

Thus we let ν = 1 and A = 1. Then we have the density is f (x) =
√
have that X ∼ C + (0, 1).

1
1
π(1+x)2 x 12

. With the lemma we

The below is Horseshoe Probit algorithm where we indication a parallel operation.
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Result: β (t)
for t iterations do
do in parallel
A ← XT X.
end
do in parallel

A ← A + diag 1/λ21 , . . . , 1/λ2p /τ 2 .
end
do in parallel
Σ−1 ← DenseLinearSolver(Ax = I).
end
do in parallel
s ∼ N (0, 1) of size n.
end
do in parallel
Rs ← T riangleSolver(Σ−1 x = s)
end
do in parallel
B ← XT z(t−1)
end
do in parallel
µ(t) ← DenseLinearSolver(Σ−1 µ = B)
end
do in parallel
β (t) ← Rs + µ
end
do in parallel
Yi∗ ← (2Yi − 1).
(t)
Ti ∼ T N (0, 1, µi Yi∗ , ∞) by Li and Ghosh sampler.
(t)
zi ← Yi∗ (Ti + µi Yi∗ )
end
do in parallel
U ∼ U nif orm(0, 1) of size 2p + 1.
(t)
λ−2
← − log(Ui )/(νi−1 + τ −2 β i /2).
i
−2
ν−1 ← − log(Ui+p )/(1 + λi ).
 ← − log(U2p+1 )/(1 + τ −2 ).
end
do in parallel
P (t)
C ← (β i )2 /λ2i .
τ 2 ∼ Gamma((p + 1)/2, 1) by Cheng sampler.
τ −2 ← (−1 + C/2)/τ 2 .
end
end
Algorithm E.1: Parallel Horseshoe Probit.
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Appendix F

Horseshoe Probit Code Repositories

In this Appendix, we provide the implementation of the Horseshoe Probit in two forms:
R and R/Cuda. The code for the Horseshoe Probit in R at https://github.com/pcubre/cuda_
examples/blob/master/cuHo.R.
We then have the code for the Horseshoe Probit in Cuda and R First, we have the R
code to launch the CUDA at https://github.com/pcubre/cuda_examples/blob/master/cuH.R.
The CUDA code that launches the main process at https://github.com/pcubre/cuda_examples/
blob/master/cuHorse1.cu
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[15] Paula Saá, Melanie Proctor, Gregory Foster, David Krysztof, Colleen Winton, Jeffrey M Linnen,
Kui Gao, Jaye P Brodsky, Ronald J Limberger, Roger Y Dodd, et al. Investigational testing
for zika virus among us blood donors. New England Journal of Medicine, 378(19):1778–1788,
2018.
[16] Joseph L Gastwirth. The efficiency of pooling in the detection of rare mutations. American
Journal of Human Genetics, 67(4):1036, 2000.
[17] Charles P Woodbury, John F Fitzloff, and Stacy S Vincent. Sample multiplexing for greater
throughput in hplc and related methods. Analytical chemistry, 67(5):885–890, 1995.
[18] Keith H. Thompson. Estimation of the proportion of vectors in a natural population of insects.
Biometrics, 18(4):568–578, 1962.
[19] Emmanuel Barillot, Bruno Lacroix, and Daniel Cohen. Theoretical analysis of library screening
using a n-dimensional pooling strategy. Nucleic acids research, 19(22):6241–6247, 1991.
[20] Steven F Arnold et al.
5(6):1170–1182, 1977.

Generalized group testing procedures.

The Annals of Statistics,

[21] Navneet K Dhand, Wesley O Johnson, and Jenny-Ann LML Toribio. A bayesian approach to
estimate ojd prevalence from pooled fecal samples of variable pool size. Journal of Agricultural,
Biological and Environmental Statistics, 15(4):452–473, 2010.
[22] CP Farrington. Estimating prevalence by group testing using generalized linear models. Statistics in medicine, 11(12):1591–1597, 1992.
[23] Christopher R. Bilder. Group Testing for Estimation, pages 1–11. American Cancer Society,
2019.
[24] RM Phatarfod and Aidan Sudbury. The use of a square array scheme in blood testing. Statistics
in Medicine, 13(22):2337–2343, 1994.
[25] Hae-Young Kim, Michael G Hudgens, Jonathan M Dreyfuss, Daniel J Westreich, and Christopher D Pilcher. Comparison of group testing algorithms for case identification in the presence
of test error. Biometrics, 63(4):1152–1163, 2007.
[26] Andrew Sterrett. On the detection of defective members of large populations. Ann. Math.
Statist., 28(4):1033–1036, 12 1957.
[27] M. Sobel and P. A. Groll. Group testing to eliminate efficiently all defectives in a binomial
sample. The Bell System Technical Journal, 38(5):1179–1252, Sept 1959.
[28] FK Hwang. A generalized binomial group testing problem. Journal of the American Statistical
Association, 70(352):923–926, 1975.
[29] Joanna Lynn Lewis, Vivian Marie Lockary, and Sadika Kobic. Cost savings and increased
efficiency using a stratified specimen pooling strategy for chlamydia trachomatis and neisseria
gonorrhoeae. Sexually Transmitted Diseases, 39(1):46–48, 2012.
99

[30] Christopher R Bilder, Joshua M Tebbs, and Peng Chen. Informative retesting. Journal of the
American Statistical Association, 105(491):942–955, 2010.
[31] Christopher S McMahan, Joshua M Tebbs, and Christopher R Bilder. Informative dorfman
screening. Biometrics, 68(1):287–296, 2012.
[32] Jacqueline M Hughes-Oliver and William H Swallow. A two-stage adaptive group-testing
procedure for estimating small proportions. Journal of the American Statistical Association,
89(427):982–993, 1994.
[33] Milton Sobel and RM Elashoff. Group testing with a new goal, estimation. Biometrika,
62(1):181–193, 1975.
[34] Chao L Chen and William H Swallow. Using group testing to estimate a proportion, and to
test the binomial model. Biometrics, pages 1035–1046, 1990.
[35] Christopher R Bilder and Joshua M Tebbs. Empirical bayesian estimation of the disease transmission probability in multiple-vector-transfer designs. Biometrical Journal: Journal of Mathematical Methods in Biosciences, 47(4):502–516, 2005.
[36] Stijn Vansteelandt, Els Goetghebeur, and Thomas Verstraeten. Regression models for disease
prevalence with diagnostic tests on pools of serum samples. Biometrics, 56(4):1126–1133, 2000.
[37] Aurore Delaigle and Alexander Meister. Nonparametric regression analysis for group testing
data. Journal of the American Statistical Association, 106(494):640–650, 2011.
[38] Aurore Delaigle, Peter Hall, and JR Wishart. New approaches to nonparametric and semiparametric regression for univariate and multivariate group testing data. Biometrika, 101(3):567–
585, 2014.
[39] Minge Xie. Regression analysis of group testing samples. Statistics in medicine, 20(13):1957–
1969, 2001.
[40] Boan Zhang, Christopher R Bilder, and Joshua M Tebbs. Group testing regression model
estimation when case identification is a goal. Biometrical Journal, 55(2):173–189, 2013.
[41] Christopher S McMahan, Joshua M Tebbs, Timothy E Hanson, and Christopher R Bilder.
Bayesian regression for group testing data. Biometrics, 73(4):1443–1452, 2017.
[42] Yan Liu, Christopher S McMahan, Joshua M Tebbs, Colin M Gallagher, and Christopher R
Bilder. Generalized additive regression for group testing data. Biostatistics, 2020.
[43] Chase N Joyner, Christopher S McMahan, Joshua M Tebbs, and Christopher R Bilder. From
mixed effects modeling to spike and slab variable selection: A bayesian regression model for
group testing data. Biometrics, 76(3):913–923, 2020.
[44] Boan Zhang, Christopher R Bilder, and Joshua M Tebbs. Regression analysis for multipledisease group testing data. Statistics in medicine, 32(28):4954–4966, 2013.
[45] Roche. cobas® taqscreen mpx test, 2009.
[46] Roche. cobas® taqscreen mpx test, version 2.0, 2019.
[47] Joshua M Tebbs, Christopher S McMahan, and Christopher R Bilder. Two-stage hierarchical group testing for multiple infections with application to the infertility prevention project.
Biometrics, 69(4):1064–1073, 2013.

100

[48] Peijie Hou, Joshua M Tebbs, Christopher R Bilder, and Christopher S McMahan. Hierarchical
group testing for multiple infections. Biometrics, 73(2):656–665, 2017.
[49] Peijie Hou, Joshua M Tebbs, Dewei Wang, Christopher S McMahan, and Christopher R Bilder.
Array testing for multiplex assays. Biostatistics, 21(3):417–431, 2020.
[50] Jacqueline M Hughes-Oliver and William F Rosenberger. Efficient estimation of the prevalence
of multiple rare traits. Biometrika, 87(2):315–327, 2000.
[51] T Verstraeten, B Farah, Luc Duchateau, and R Matu. Pooling sera to reduce the cost of hiv
surveillance: a feasibility study in a rural kenyan district. Tropical Medicine & International
Health, 3(9):747–750, 1998.
[52] Juexin Lin, Dewei Wang, and Qi Zheng. Regression analysis and variable selection for two-stage
multiple-infection group testing data. Statistics in medicine, 38(23):4519–4533, 2019.
[53] Christopher R Bilder, Joshua M Tebbs, and Christopher S McMahan. Informative group testing
for multiplex assays. Biometrics, 75(1):278–288, 2019.
[54] Christopher R Bilder, Joshua M Tebbs, and Christopher S McMahan. Informative array testing
with multiplex assays. Statistics in medicine, 2021.
[55] James H. Albert and Siddhartha Chib. Bayesian analysis of binary and polychotomous response
data. Journal of the American Statistical Association, 88(422):669–679, 1993.
[56] Sean M O’Brien and David B Dunson. Bayesian multivariate logistic regression. Biometrics,
60(3):739–746, 2004.
[57] Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2019,
2021.
[58] E Scott Larsen and David McAllister. Fast matrix multiplies using graphics hardware. In
Proceedings of the 2001 ACM/IEEE Conference on Supercomputing, pages 55–55, 2001.
[59] Martin Rumpf and Robert Strzodka. Level set segmentation in graphics hardware. In Proceedings 2001 International Conference on Image Processing (Cat. No. 01CH37205), volume 3,
pages 1103–1106. IEEE, 2001.
[60] Mark J Harris, Greg Coombe, Thorsten Scheuermann, and Anselmo Lastra. Physically-based
visual simulation on graphics hardware. In Graphics Hardware, volume 2002, pages 1–10, 2002.
[61] Theodore Kim and Ming C Lin. Visual simulation of ice crystal growth. In Proceedings of
the 2003 ACM SIGGRAPH/Eurographics symposium on Computer animation, pages 86–97.
Citeseer, 2003.
[62] Kyoung-Su Oh and Keechul Jung. Gpu implementation of neural networks. Pattern Recognition,
37(6):1311–1314, 2004.
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